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Abstract
PtIV-diazidodihydroxido complexes are inert in the dark, but can be selectively
activated by irradiation with light and become potently cytotoxic towards cancer
cells. By site-specific irradiation to tumour tissue, the side-effects to healthy tissue
associated with conventional chemotherapeutics, such as cisplatin, can be
circumvented. This thesis aims to develop design photoactivatable platinum(IV)
diazidodihydroxido complexes to achieve higher photocytotoxicity, lower cross-
resistance and longer wavelength of activation.
A series of PtIV diazidodihydroxido complexes with trans azido, trans hydryxido
groups and mixed trans aliphatic/aromatic amines, was designed, synthesized and
characterized. Trans, trans, trans-[Pt(N3)2(OH)2(MA)(Py)] (5) and trans, trans,
trans-[Pt(N3)2(OH)2(MA)(Tz)] (8) are potently cytotoxic towards A2780, OE19 and
HaCaT cell lines upon irradiation with UVA. Remarkably, they also showed potent
cytotoxic effects towards A2780cis (cisplatin-resistant ovarian cancer cell subline).
Also, the photocytotoxicity towards the A2780, A2780cis, OE19 and HaCaT cell
lines upon irradiation with blue light (λmax = 420 nm) is still potent compared to that
upon irradiation with UVA. These complexes are highly inert in the absence of light
and have almost no dark toxicity.
Upon irradiation with UVA/blue light, the complex 5 was observed to release free
azide anions N3−, azidyl radicals N3•, nitrogen gas N2 and form nitrene intermediates.
It was of importance to discover that singlet oxygen (1O2) is generated from
photoreactions in the absence of an exogenous source of oxygen, whereas hydrogen
peroxide (H2O2) and hydroxyl radical intermediates did not appear to be formed.
Mono-functional and bi-functional Pt adducts were captured from the photoinduced
binding of complexes 5 and 8 to 5'-GMP and a DNA oligonucleotide. It was
discovered for the first time that the oxidation of 5'-GMP can occur during the
photoreaction of complex 5 upon irradiation with UVA. Singlet oxygen and nitrene
intermediate generated from this photoreaction are likely to be the cause of the
oxidative damage to guanine.
4-Nitropyridine, 2,2'-bipyridine, and terpyridines were used as ligands in novel
photoactivable PtIV (di)azido complexes and two were activated by green light. A
new two-photon-activatable PtII complex, cis-[PtCl2(MOPEP)2](42), was also
designed, synthesized and characterized. It was observed that this complex was
sensitive to one-photon excitation below 500 nm and the ligand MOPEP underwent
rapid solvent (acetonitrile) substitution upon irradiation. The same photoreaction was
also triggered by two-photon excitation with fs-pulses laser light between 600 – 700
nm.
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This thesis is concerned with photoactivatable platinum(IV) diazidodihydroxido
complexes as potential anticancer agents. An introduction to the coordination
chemistry of platinum, platinum based anticancer drugs and the photochemistry of
metal complexes are given in this Chapter.
1.1 Platinum
1.1.1 General properties
Platinum is a Group 10 element with an atomic number of 78, which is a very rare
metal, occurring as only 5 ppb in the Earth's crust. Its atomic and physical properties
are listed in Table 1.1.
Table 1.1 Atomic and physical properties of platinum.1-4
Atomic Number 78
Atomic Weight (relative to 12C = 12) 195.084
Density (g/cm3, at 293 K) 21.45
Melting Point (K) 2045
Boiling Point (K) 4098
Electronic Configuration
[Xe] 4f14 5d9 6s1 Pt0
[Xe] 4f14 5d8 PtII
[Xe] 4f14 5d6 PtIV
Pauling Electronegativity 2.28
Electron Affinity (kJ/mol) 205.3
Ionization Energies (kJ/mol)
1st: 870
2nd: 1791
Atomic (crystal) radii (Å)
1.375 (0) (in metal)
0.74 (II) (square-planar)
0.765 (IV) (octahedral)
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Platinum has six naturally occurring isotopes: 190Pt, 192Pt, 194Pt, 195Pt, 196Pt, and 198Pt.
The most abundant is 195Pt, comprising 33.83% of all platinum. Moreover, 195Pt has
a nuclear spin quantum number I = ½, which is the only isotope with NMR activity
(Table 1.2). As all the other isotopes have zero nuclear spin, 195Pt NMR
spectroscopy has found great use both by direct observation of the 195Pt resonance
and by observation of 195Pt “satellites”. The term “Pt satellites” is used to describe
the NMR resonance of a nucleus coupled to 195Pt (ca. 1/3 natural abundance of all Pt)
which will split into a doublet symmetrically placed beside the central resonance
arising from those species containing all the other Pt isotopes. The relative intensity
of the three resonances is close to 1:4:1 (Figure 1.1).2, 5 Further discussions on the
shape of Pt satellites and Pt NMR can be found in Chapters 2 and 3.
Table 1.2 Platinum isotopes and nuclear spin quantum numbers.
Isotopes Natural Abundance Nuclear Spin Quantum Number (I)
190Pt 0.01% I = 0
192Pt 0.078 % I = 0
194Pt 32.9 % I = 0
195Pt 33.8 % I = ½
196Pt 25.3 % I = 0
198Pt 7.21 % I = 0
Figure 1.1 Platinum satellites, e.g., for a 1H NMR resonance.
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1.1.2 Oxidation states and coordination chemistry
Although platinum can exist in the 0, +1, +2, +3, +4, +5 and +6 oxidation states,2, 6
the most common oxidation states are +2 and +4. The +1 and +3 states exist
generally in molecules that have M–M bonds. PtII has a strong preference for square-
planar geometry and a coordination number of four, and most PtIV species have
octahedral structure and coordination number of six. The splitting of the d-orbitals
and electronic configurations with strong field ligands are depicted in Figure 1.2
The relatively slow substitution rates of PtII complexes (e.g., the hydrolysis of cis-
[Pt(NH3)2Cl2] has a first order rate constant of 2.5×10-5 s-1)7 facilitates mechanistic
studies and has found wide applications in research of geometrical isomerism and
reaction mechanisms.1
Figure 1.2 Splitting of the d-orbitals in crystal fields of square-planar (PtII, d8) and
octahedral (PtIV, d6) symmetries. The electrons are configured in a strong ligand field.
In Pearson’s “soft/hard” acid/base theory, PtII is classified in the group of “soft”
acids, which means that PtII is easy to polarize and prefers to form complexes with
“soft” bases.8, 9 Many stable PtII complexes are formed with “soft” ligands such as S
dxy dxz dyz
dz2 dx2 - y2
dxz dyz
dx2 - y2
dxy
dz2
PtII (d8) PtIV (d6)
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or P donors and ligands that can π-bond, such as CN−, NO2−, alkenes and alkynes. In
aqueous solution, the stability of halide complexes with PtII increases in the order F−
<< Cl− < Br− < I−. Although PtII generally shows low affinity for “hard” (F and O)
ligands, in the latter case there are some notable exceptions, such as μ-OH, acetates, 
diketonates, carboxylates and phenoxides.3, 10
Platinum in the +4 oxidation state has a d6 electronic configuration and the
coordination number is invariably 6 with octahedral geometry.10 PtIV complexes are
almost always low spin due to the large splitting of the d-orbitals and therefore have
a large crystal field stabilisation energy. In “hard/soft” acid/base theory, PtIV is also
classified as a “soft” acid, but much harder than PtII. PtIV complexes are generally
more thermally stable and kinetically inert than PtII complexes.2 The substitution
reactions of PtIV complexes can be greatly accelerated by the presence of PtII
species.10
1.1.3 Trans effect
The trans effect is an important kinetic effect first systematized by Chernyaev in the
1920s in the coordination chemistry of metals, particularly platinum(II) and (IV). In
short, the trans effect is defined as the effect of a given ligand upon the rate of
substitution of a leaving group opposite to it in a metal complex.3 This influence to
the opposite, or trans groups, is greater than the influence of adjacent, or cis groups.
The trans effect is exclusively a kinetic effect in the substitution reaction, related
presumably to the transition state, as well as the ground state. In square-planar
substitution reactions, the thermodynamically preferred isomer is not always
produced. After comparing the kinetics of a range of ligand substitution reactions,
the following empirical series of decreasing trans effect was produced: 3, 11, 12
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CO, CN−, C2H4 > PR3, H− > CH3− > R2S > C6H5− , NO2− , I− > SCN− > Br− > Cl− >
pyridine > NH3 > OH− > H2O
Theoretical explanation of the trans effect is based on the combination of σ-bonding 
and π-bonding.12 Strong σ-donors, such as PR3 and H−, contribute high electron
density to metal ion, weakening the bond trans to it. Some ligands, e.g., CO and CN−,
possess empty orbitals that can act as π-acceptors to remove electron density from 
the metal ion, making the region trans to the ligand electron-deficient and vulnerable
to the nucleophile in the transition state. The application of the trans effect will be
further discussed when describing the synthesis of cisplatin and various analogues in
Chapter 3.
The trans-influence is a concept related to trans effect but is a ground-state effect.
The trans-influence of a ligand is a measure of its effect on the strength of the bond
opposite to it in a complex, which can be the lengthening of bonds determined by X-
ray diffraction, vibrational strength by IR spectroscopy and coupling constants by
NMR spectroscopy. 3, 12
1.2 Platinum based anticancer drugs
1.2.1 Cisplatin
The anticancer activity of cisplatin (cis-[PtCl2(NH3)2], also known as CDDP) was
discovered accidently by Dr B. Rosenberg in ca. 1968 13, 14. The promptly followed
clinical trials demonstrated its efficacy towards a variety of solid tumors. Cisplatin
was approved by the FDA in 1978 for clinic use in metastatic testicular cancer and
ovarian cancer,15 and later for transitional bladder cancer, lung cancer, lymphomas,
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myelomas and melanoma. Today it is routinely used in 32 of 78 clinic treatment
regimes listed in Martindale in combination with a wide range of other drugs.16, 17
1.2.1.1 Mechanism of action
It is generally accepted that platinum complexes exert their cytotoxicity by entering
the cell and binding to DNA.18, 19 Cisplatin is administered via intravenous injection
to the bloodstream of patient, where the relatively high Cl− concentration in the
blood plasma (ca. 100 mM) supresses the hydrolysis of chlorido ligands on cisplatin.
The complex maintains neutral charge to facilitate the penetration through cell
membranes. Much evidence suggests that cisplatin can be attacked by cytoplasmic
thiol-containing species such as the tripeptide glutathione and metallothioneins, and
this leads to deactivation because platinum is highly affinitive to sulphur.20, 21 This
process is believed as one of the causes of side effects of and resistance to cisplatin
(vide infra).
The mechanism of cellular uptake of the high polar molecule, cisplatin, is generally
believed to be passive diffusion;22 however, recent research has suggested that the
copper transporter (CRT1) is also involved in its cellular influx.23 Once the complex
has entered the cell, the relatively lower concentration of cellular chloride (4 – 20
mM) allows for aquation of cisplatin. Figure 1.3 describes the hydrolysis reaction,
including half reaction times of hydrolysis and pKa values of the aqua adducts. The
highly activated species cis-[PtCl(NH3)2(OH2)]+ and cis-[Pt(NH3)2(OH2)2]2+ are
formed24 and the former is believed to be responsible for the majority of DNA
binding (> 98%).25, 26
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Figure 1.3 Hydrolysis reaction pathways of cisplatin, and the hydrolysis half-
reaction times26 (310 K) and pKa values27 (300 K) of aqua species are given.
DNA binding of the mono-aqua species cis-[PtCl(NH3)2(OH2)]+ is kinetically
controlled, as aquation of cisplatin is the rate-determining step.28 The preferential
binding sites for platinum on DNA are guanine-N7 (Figure 1.4), as this is the most
nucleophilic site.19, 29 Other N-donors, such as adenine-N7, can also bind to Pt.
Figure 1.4 DNA bases: adenine, thymine, guanine and cytosine.
Once the mono-aqua species cis-[PtCl(NH3)2(OH2)]+ binds to DNA, bifunctional
adducts or crosslinks are rapidly formed by ring closure, accompanied by the loss of
Chapter 1 — Introduction
9
the other chloride. Most crosslinks are GpG 1,2 intrastrand (60 – 65% of all adducts)
and ApG 1,2 intrastrand (20 – 25%). Other less frequent products include GpXpG
1,3 intrastrand crosslinks (ca. 2%) and G-G interstrand crosslinks (ca. 2%), and ca. 2%
adducts on guanines remains monofunctional.15, 30 In all cases, the two ammine
groups (also called “carrier ligands”) remain bound to platinum. In 1995, the first
crystal structure by X-ray crystallography of GpG intrastrand adduct in a DNA
duplex31 and the solution structure by NMR of a G–G interstrand crosslink32 were
reported.
The binding of PtII to DNA bases is strong and appears to be essentially
irreversible.10 The formation of the bifunctional adduct causes significant distortion
of the DNA, which can be recognized by certain cellular housekeeping proteins.33
These proteins can either trigger DNA repair or release signal for apoptotic cell
death.19, 34, 35 Nevertheless, it is noted that a number of alternative cellular targets and
protein recognition processes have also been discovered.36
1.2.1.2 Resistance and side-effects
Cisplatin is indeed very effective and has had a major clinical impact, particularly for
testicular or ovarian cancers. However, severe side effects such as nausea and
vomiting, nephrotoxicity, ototoxicity, neuropathy and myelo-suppression accompany
the treatment, which limits the dose of administration.37 Cisplatin modifies DNA
non-selectively in all actively dividing cells, regardless of whether they are
cancerous or not. In addition, cisplatin attacks proteins or peptides in cells and in
blood plasma, particularly those with histidine, cysteine and methionine,15 namely,
human serum albumin,38 metallothioneins39 and tripeptide glutathione.40 Very
recently, the interaction of cisplatin with a wide range of proteins was studied,
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including calmodulin,41, 42 ubiquitin,43 copper chaperone proteins,44 and copper
transport proteins.45 In fact, studies have shown that 24 h after cisplatin
administration, 65 – 98% of the platinum in blood plasma is bound to proteins.46, 47
This protein binding has been blamed for deactivation of the drug and some of the
severe side effects of cisplatin treatment.20, 48-51
Another important factor that limits the efficacy of cisplatin against a number of
malignancies is cellular resistance. The resistance to cisplatin is largely attributed to
reduced accumulation, increased cytoplasmic detoxification by cellular thiols and
increased DNA repair/tolerance of platinum-DNA adducts.15, 52 After administration
of the platinum complex by intravenous injection, a large proportion of PtII drugs are
lost in the bloodstream before arriving at their ultimate target (vide supra). Also, Pt
drugs enter cells by passive diffusion or using either transporters, a significant one
being the copper transporter CTR1. Loss of CTR1 results in less platinum entering
cells and, consequently, drug resistance.23, 53 In addition, the large volume of
damaged cells further causes altered cellular transport, enhanced overexpression of
DNA-damage recognition proteins and repair of distorted DNA, and decreased
apoptosis contributing to tumour resistance to Pt drugs.33
There are several strategies to overcome the resistance to cisplatin,15
 Increase the levels of platinum that reach tumours with e.g., liposomal
enclosed platinum drugs;
 Combine existing platinum drugs with molecularly targeting moieties;
 Develop new platinum drugs such as oxaliplatin with novel mechanisms that
are capable of circumventing cisplatin-mediated resistance;
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 Use other drugs either alone or in combination to exploit particular cisplatin-
mediated resistance mechanisms.
1.2.2 Development of new platinum anticancer drugs
The discovery of cisplatin stimulated the synthesis and screening of over 2000
different types of Pt complexes with different amines and anionic ligands. Much
effort has been devoted to the design of novel Pt anticancer drugs to make
chemotherapy safer for patients, in particular, lessening severe side effects, 54, 55
increasing oral bioavailability, 52, 56 and overcoming drug resistance. 22, 23, 40, 57-59 An
additional approach involves the use of a photosensitizing agent in combination with
light which provides a promising avenue to achieve accurate targeting.60 Until 2010,
23 new platinum-based drugs have entered clinical trials, and five of them
(excluding cisplatin) are approved worldwide or regionally (Figure 1.5).17, 19
Figure 1.5 Approved platinum anticancer drugs worldwide (cisplatin, carboplatin
and oxaliplatin) or regionally (nedaplatin, lobaplatin and heptaplatin).
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1.2.2.1 Cisplatin derivatives
The initial structure-activity relationships for further platinum-drug development
obey the following rules:61, 62
 The active complexes must be cis geometry and must be uncharged.
 Leaving groups should be adequately strongly but not tightly bound.
 Amine ligands with more alkyl substituents reduce the activity.
This resulted in the development of carboplatin (cis-diammine-[1,1-
cyclobutanedicarboxylato]platinum(II), see Figure 1.5) in the mid-1980s,54 which is,
broadly speaking, equally effective to cisplatin, but with a more acceptable side-
effect profile. Carboplatin was based on the hypothesis that a more stable leaving
group than chloride might lower toxicity without affecting antitumour efficacy. This
hypothesis turned out to be correct.15
After ca. 30 years searching for improved anticancer agents in the many analogues
of cisplatin, little improvement in spectrum of activity had been observed. Recent
devotion to the analogues of cisplatin was concentrated on improving the
cytotoxicity and lowering the system toxicity and side effects of the platinum
complexes. For example, a water-soluble heptaplatin analogue can improve
antitumor activity and reduce toxicity,63 coupling cisplatin with a androgenic steroid
delivery vector can improve the delivery to estrogen-dependent tissues,64-66 and
incorporating other active anticancer agents such as CDK inhibitor bohemine67 or
dichloroacetate68 in cis-platinum complexes can acquire multiple cytotoxic effect.
Recent evidence suggests that the cisplatin analogues usually form a similar range of
DNA adducts as cisplatin.69 Consequently, attention turned to the synthesis of non-
triditional platinum anticancer drugs for improved accumulation, oral bioavailability,
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and tumour targeting.70 The classic structure-activity relationships were soon broken
and a large number of novel platinum complexes was developed forming a different
range of DNA adducts and displaying a different spectrum of anticancer activity
compared to cisplatin, as discussed below.
1.2.2.2 Trans-platinum complexes
In the early days, it was shown that transplatin exhibits little antitumor activity
because of the limited ability to form intrastrand adducts with DNA.71, 72 On the one
hand, steric constraints preclude transplatin from formation of 1,2-intrastrand cross-
links in DNA. On the other hand, in the hydrolysis kinetics for transplatin shown in
Figure 1.6, both k1 and k-1 are faster as compared to cisplatin, but both k2 and k-2 are
smaller for the trans over the cis isomer.62 This is due to the trans effect (Cl > N >
O).
Figure 1.6 Hydrolysis kinetics of transplatin. Data from ref. 62
However, in recent years, it is recognized that substitution of NH3 in transplatin to
aromatic heterocycle N-donors, sulphoxide, sterically hindered aliphatic amine or
imino iminoethers ligands leads to cytotoxic effects on a par with cisplatin.62, 73, 74
For example, Navarro-Ranninger and co-workers reported that trans-
[PtCl2(DMA)(MA)] (MA = methylamine, DMA = dimethylamine, Figure 1.7) is
more toxic towards MCF-7 cell lines than cisplatin.75 The aquation chemistry of this
compound was examined and compared with its analogues. It was suggested that
properly designed bulky carrier ligands may reduce the rate of hydrolysis of chlorido
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ligands so as to lower the acute detoxification of trans platinum complexes before
arriving at the target cells and thus increase their antitumor activity.76, 77
More importantly, trans platinum complexes often act with mechanisms different
from that for cisplatin, so as to circumvent cisplatin resistance. It was also suggested
that the Pt-DNA adducts formed by the trans isomer are not recognized by HMGB1
protein (modulating the repair of DNA damage in mammalian cells78) and the level
of DNA repair is lowered. For example, Gibson and coworkers reported novel
cationic trans PtII complexes with piperazine ligands that are active against cisplatin-
resistant ovarian cancer cell lines.79 Trans-[PtCl2(isopropylamine)(1-
methylimidazole)] (Figure 1.7) tends to form higher level of DNA interstrand
crosslinks between complementary guanine and cytosine residues over its cis
isomer.80 Jakupec and coworkers recently reported that the trans-configured PtII
oxime complexes lead to higher cytotoxicity, extraordinary cellular accumulation,
higher levels of platination with DNA and higher degree of DNA damage in cancer
cells over the corresponding cis isomers.81 In general trans platinum complexes
exhibit a different spectrum of cytostatic activity from cisplatin.82
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Figure 1.7 Recent developed platinum antitumor complexes with novel mechanism
of activity.
1.2.2.3 Monofunctional platinum complexes
It is generally accepted that cisplatin exerts the antitumor activity by forming
bifunctional intrastrand crosslinks (CLs) with DNA (vide supra). But in recent years,
rule-breaking monofunctional PtII anticancer complexes have been rationally
designed and display promising antitumor activities.83-85 Notably, pyriplatin (cis-
[PtCl(NH3)2(pyridine)]+, Figure 1.7)86 has a distinct cytotoxicity proﬁle from that of 
cisplatin in cell cultures and inhibits RNA polymerase II in vitro.87 Despite the
different nature of its DNA adducts, this monofunctional platinum complex exhibits
their antitumor activity in a way very similar to that of cisplatin.88 In various
mammalian cells, pyriplatin reacts with DNA as efﬁciently as cisplatin, inhibits 
transcription as strongly as cisplatin, and even its DNA repair mechanism is also
nucleotide-excision repair, similar to cisplatin.
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1.2.2.4 Multinuclear platinum complexes
Multi-nuclear platinum complexes contain two or more platinum centres connected
by designed linkers. One or more Pt centers can covalently bind to DNA, and hence
are capable of forming a completely different array of DNA adducts compared to
cisplatin.89, 90 These multi-nuclear complexes represent a completely new paradigm
for platinum based anti-cancer complexes, and appear to offer great potential as new
anticancer agents.91-96
Of all the multinuclear platinum anticancer complexes, a very successful one that
first entered the clinical trial in vitro and in vivo is BBR3464 ([{trans-
PtCl(NH3)2}2{μ-trans-Pt(NH3)2(NH2(CH2)6NH2)2}]4+, Figure 1.7).97, 98 BBR3464 is
much more active than cisplatin in all cancer cell lines tested, showing comparable
activity at up to 500-fold lower doses in vitro.99, 100 BBR3464 induces a cellular
response different from cisplatin 101, 102 and shows activity even in several cancer cell
lines that are naturally resistant to cisplatin.99 Unfortunately, phase I and phase II
studies of BBR 3464 treatment in patients with ovarian, non-small/small cell lung
cancer and gastric and gastro-oesophageal adenocarcinoma showed limited activity
but severe systemic toxicity.17, 103, 104 Therefore, this drug was not moved into Phase
III trials.
1.2.2.5 Prodrugs
An active drug (including anticancer drug) may suffer from one or more of the
following restrictions: poor aqueous solubility, low lipophilicity or permeability,
parenteral administration, chemical instability, lack of site-specificity, incomplete
absorption through membranes and too rapid excretion.105 In order to overcome these
disadvantages, prodrugs are used as pharmacologically inactive derivatives of drugs
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that are metabolized or activated in the body to release or generate the active drug
(ideally at the site of action).106 In cancer chemotherapy, prodrugs are widely used in
two major aspects. The first is cancer targeting, such as via conjugation of drugs with
antibodies,107 or polymeric cancer cell targeting peptide carriers108-111 for
corresponding cellular receptors, resulting in enhanced permeability and
accumulation of drugs. The second aspect is controlled release at the tumor site,
including acid-promoted liberation, enzymatic cleavage and hypoxia-mediated
release/immunotoxins.106
Tumours are often hyperpermeable towards macromolecules because of
compromised vasculature and lack of effective lymphatic drainage.112, 113 Therefore,
if the therapeutic agent is coupled to a macromolecular carrier, or packed inside a
nano-sized particle, increased drug concentration within the tumour tissue can be
obtained.114
Lippard and coworkers and other groups have developed a series of nanoparticles,
nanotubes and nanorods as prodrugs for targeted delivery of platinum anticancer
complexes115-120. A higher total fraction of drug delivery to tumours and enhanced
anticancer cytotoxicity and efficacy were received.
The cell surface proteins, αvβ3 and αvβ5 integrins and aminopeptidase N (APN or
CD13) are overexpressed in tumour endothelial cells and on certain cancer cells
during tumour growth and metastasis, but are barely detected in resting endothelial
cells.121, 122 Those proteins show high affinity for the peptide motifs RGD (Arg-Gly-
Asp, for αvβ3 and αvβ5)123 and NGR (Asn-Gly-Arg, for APN)124, respectively.
Similarly, luteinizing hormone-releasing hormone (LHRH) has also been found as a
targeting moiety (ligand) for LHRH receptors that are overexpressed in the plasma
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membrane in breast, ovarian and prostate cancer cells and are not expressed
detectably in normal visceral organs.125 Recently, Fukuda and coworkers reported an
IFLLWQR peptide conjugated potent anticancer drug SN-38 efficiently suppressing
human colon HCT116 tumour growth in nude mice at low dosages without apparent
side effects.111 As a result, RGD, NGR, LHRH and IFLLWQR peptides motifs have
been employed as delivery agents for low molecule-weight drugs to the tumour
cells.108-110
Improving the delivery of platinum drugs with liposomal capsules (LipoplatinTM) 126-
130 or polymer-based vehicles (ProLindacTM) 131-133 is another attractive strategy and
has entered clinical trials. They will become the ﬁrst macromolecule-based platinum 
drugs if approved.17
PtIV drugs are also regarded as a group of prodrugs and will be discussed in the next
section.
1.2.2.6 Platinum(IV) prodrugs
Octahedral PtIV complexes are substantially more inert kinetically than their square-
planar PtII analogues, as the substitution reactions of the ligands take place very
slowly under physiological conditions.134, 135 The kinetic inertness of PtIV complexes
provides a promising feature to keep the complex intact before arriving at the
cellular target. Although PtIV complexes with the ligand 1,2-diaminocyclohexane
were found to react with 9-methylxanthine, 9-methylhypoxanthine, and guanosine-
5′-monophosphate directly,136 it is widely accepted that PtIV species have to be
reduced to more reactive PtII form to exert their anticancer activity.69 In other words,
PtIV complexes can be regarded as the prodrugs of the corresponding PtII
complexes.137, 138 PtIV complexes could remain in the higher oxidation state which
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would keep their lower reactivity in the bloodstream. This would diminish unwanted
side reactions and decrease the activity of the drug.
Biological reducing agents, such as ascorbic acid, cysteine (Cys) and glutathione
(GSH) can reduce PtIV to PtII in cancer cells, for which direct evidence in cells has
been obtained.139-142 In addition, the higher lipophilicity of some PtIV complexes
would potentially improve their cellular uptake.137, 143 Recently, Lin and coworkers
reported a targeted release of an oxaliplatin moiety from PtIV based
polysilsesquioxane nanoparticles for cancer chemotherpy.120 However, none of the
PtIV drugs has been approved for clinical use to date. Two failed to pass human
clinical trials (iproplatin and ormaplatin), one is undergoing clinical trials for human
use (satraplatin) and another one is under development (oxoplatin).17, 144 Although a
number of reasons are attributed to the failures, one of them is that they are readily
reduced to PtII in the bloodstream and thus fail to reach their target.
Although a recent report demonstrated that steric hindrance may affect the rate of
reduction of oxaliplatin derivatives,145 it is widely believed that the ease of reduction
is closely related to the nature of the ligands, especially the leaving groups. The
am(m)ine ligands are quite stable on PtIV, by contrast, the chloro, acetato and
hydroxo ligands are vulnerable to substitution and are thus considered as leaving
groups. These leaving ligands play important roles in determining both the reduction
potentials and the rate of reduction by small biomolecules such as ascorbate and
GSH. It is generally accepted that this effect increases in the following order OH− <
OAc− < Cl− < I−.137, 146-148 For example, the reduction potential values of a series of
PtIV complexes are given in Table 1.3. This correlation has guided the design of PtIV
complexes for many years because it was believed to provide a means of predicting
the pharmacology of the prodrugs.
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Table 1.3 Reduction potential values of PtIV complexes with variation of axial
ligands.137
Complex Ligand X Epa (mV)
OH −664 
OC(O)CH3 −326 
OC(O)CH2CH3 −301 
OC(O)CH2CH2CH3 −273 
Cl −4 
a The reduction potential values (Ep) are actually half wave potentials from cyclic
voltammetry measurement and are adjusted to the standard hydrogen electrode.
1.3 Photoactive anticancer agents
1.3.1 Photochemistry
Photochemistry is concerned with the processes that are activated by interaction
between light and matter. Light is a kind of electromagnetic radiation that exhibits
both particle-like and wave-like properties. The energy (E) of a photon at a given
frequency of the radiation (ν) is given by:
E = hν = hc / λ
where h is Planck’s constant, λ wavelength of the radiation and c the velocity of
light.149
There are two fundamental principles for photochemical transformations,150
 The first law (Grotthuss-Draper law): light must be absorbed by a matter so that
a photochemical reaction can take place.
 The second law (Stark-Einstein law): for each photon of light absorbed by a
chemical system, only one molecule can be activated for subsequent reaction(s).
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This law is also referred to as "photo-equivalence law" which was derived by
Albert Einstein when he developed the quantum theory of light.
When a light beam encounters matter the following phenomena can be observed:
reflection, diffusion, transmission, refraction, scattering, absorption, and
luminescence. Only absorption is of importance in photochemistry in generation of
excited states. In photochemical processes, excitation usually takes place by
interaction between one photon and one molecule (multiphoton-excitation will be
discussed in Chapter 6), so called photoexcitation:
R + hν → R* 
where R and R* denote a molecule in its ground and an electronically excited state.
The energy of the molecule in an electronically excited state is generally higher than
that of the ground state by ca. 150 – 1200 kJ/einstein (mole of photons).149
Photoexcitation can only occur if the difference between the energy of any of the
excited states (EE) and the ground state (EG) is equal to the energy of the incident
photon (hν):151
EE − EG = hν
Oscillator strength f is used to describe the possibility of light absorption for a
certain transition and is given by: 151
f  ≡ 
8π2meν|µ|
2
3he2
µ  ≡ ∫ΨGĤΨEdτ
where me is mass of an electron, μ transition dipole moment, e, charge of an electron,
Ĥ, dipole moment operator, ΨG/E, wavefunction of ground/excited state.
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The transition dipole moment μ can be zero for certain transitions, in which cases,
the oscillator strength f is zero and the transition is hence forbidden. The selection
rules states that under the following conditions the transition dipole moment is
zero:149
 between states of different multiplicity (ΔS = 0, spin-forbidden); 
 between states of equal parity (g→g, u→u) (Δl = ± 1, orbitally forbidden, 
also called Laporte Rule);
 the simultaneous excitation of two or more electrons.
Absorption of light in a homogenous medium is often expressed as absorbance (A):
A = log (Pλ0 / Pλ) = −log T
where T is the internal transmittance, Pλ0 the spectral radiant power of incident
radiation at wavelength λ, Pλ the radiant power of transmitted radiation. The
absorbance of a beam of collimated monochromatic radiation in a homogeneous
isotropic solution is proportional to the absorption pathlength l (cm), and to the
concentration c (M):
A = εcl
where ε is called the molar absorption coefficient or extinction coefficient (M-1cm-1).
This law is called the Beer-Lambert Law.
1.3.2 Photochemistry of coordination compounds
1.3.2.1 Electronic transitions
Electronic transitions in general consist in promotion of an electron from one of the
highest occupied molecular orbitals (HOMOs) to one of the lowest unoccupied
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molecular orbitals (LUMOs) of the molecule. For octahedral transition metal
complexes, their molecule orbitals (MOs) can be classiﬁed according to their 
predominant atomic orbital contributions (Figure 1.8):152
1. Strongly bonding, predominantly ligand centered σL orbitals;
2. Bonding, predominantly ligand-centered πL orbitals;
3. Essentially nonbonding, metal-centered πM orbitals of t2g symmetry;
4. Antibonding, predominantly metal-centered σM∗ orbitals of eg symmetry;
5. Antibonding, predominantly ligand-centered πL∗ orbitals;
6. Strongly antibonding, predominantly metal-centered σM∗ orbitals.
Figure 1.8 Molecule orbitals (MOs) and electronic transitions for an octahedral
transition metal complex.149, 152
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Light can induce a variety of electronic transitions of a transition metal coordination
complexes between the MOs shown in Figure 1.8,135, 153 such as ligand-field (LF)
transitions or d-d transitions, ligand-to-metal-charge-transfer (LMCT) transitions,
metal-to-ligand-charge-transfer (MLCT) transitions, charge-transfer-to-solvent
(CTTS) transitions and intra-ligand (IL) transitions. For multinuclear complexes,
there is a transfer from one central atom to the other: inter-valence-charge-transfer
(IVCT) transitions.
The selection rules (vide supra) govern the transition in metal complexes. Any
transitions with equal parity (i.e. the same symmetry) with respect to the inversion
centre, e.g. d→d transitions in a centrosymmetric complex, are Laporte forbidden.
However, forbidden transitions still can be observed experimentally, despite their
low intensity. For example, if the complex is slightly distorted due to the Jahn-Teller
effect, or if the complex undergoes an asymmetrical vibration, the inversion centre is
hence destroyed. Also, when π-acceptor and π-donor ligands are mixed with the d-
orbitals (d-p mixing), the transitions are no longer purely d-d. In these cases, the
Laporte selection rule is relaxed.
The intensities of different transitions are shown in Table 1.4, with clear differences
in the extinction coefficient depending on whether the transition is allowed or
forbidden.
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Table 1.4 Intensities of spectroscopic bands in metal complexes.154
Band/Transition type Allowed/forbidden εmax (L mol-1cm-1)
ΔS = 0 Spin-forbidden < 1
Ligand-field (LF) with
centre of symmetry
Laporte-forbidden ~ 10
Ligand-field (LF) without
centre of symmetry
Laporte-allowed ~ 102
Charge-transfer(CT) Orbital- and spin-allowed 103 – 106
Intra-ligand (IL) Orbital- and spin-allowed 103 – 105
Charge-transfer-to-solvent
(CTTS)
Orbital- and spin-allowed 10 – 103
1.3.2.2 Deactivation pathways
The photoexcitation and the variety of deactivation pathways are shown in Figure
1.9. Absorption of a photon leads to population of the electronic excited state of the
same multiplicity, e.g. from the singlet S0 ground state to the singlet excited state S1,
S2, or Sn state, depending on the absorbed photon energy. When excitation leads to
higher vibrational states of Sn, the molecular entity relaxes fast into vibrational
equilibrium with its environment. The excited state deactivation may also proceed
via internal conversion (IC) or intersystem crossing (ISC). The triplet states (differ
from the ground state multiplicity) are normally populated via intersystem crossing.
The lowest excited states are the relatively long lived, especially those with different
multiplicity from the ground state. Therefore, they are the source of luminescence
and, moreover, are most often responsible for a photochemical reaction.
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Figure 1.9 Jabłoński diagram. All possible physical processes are represented by 
solid (radiative) and dashed (radiationless) lines.149
Radiationless deactivation processes involve vibrational relaxation (VR), internal
conversion (IC), intersystem crossing (ISC), and quenching (Q). Radiative
deactivation processes such as fluorescence (F) (singlet–singlet) and
phosphorescence (Ph) (triplet–singlet) result in an emission of light with a longer
wavelength than that of excitation. Quenching refers to the external environmental
influence or even substituent in the excited molecule may also induce the
deactivation through a non-radiative inter- or intra-molecular process, respectively.
The approximate timescales for these transitions are listed in Table 1.5.
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S1
S0
T3
T2
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S0 = singlet ground state
Sn = singlet excited state
Tn = triplet excited state
Absorption hv
Vibrational relaxation (VR)
Internal conversion (IC)
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Phosphorescence (Ph)
Intersystem crossing (ISC)
Quenching (Q)
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Table 1.5 The approximate timescales for the transitions.150
Process Transition Timescale (s)
Photoexcitation S0 → Sn ca. 10-15 (instantaneous)
Internal Conversion Sn → S1 10-14 to 10-11
Vibrational Relaxation Sn* → Sn 10-12 to 10-10
Intersystem Crossing S1 → T1 10-11 to 10-6
Fluorescence S1 → S0 10-9 to 10-6
Phosphorescence T1 → S0 10-3 to 102
Non-Radiative Decay
S1 → S0 10-7 to 10-5
T1 → S0 10-3 to 102
1.3.2.3 Photochemical reactions
Photochemical reaction is another deactivation pathway competing with the
photophysical decay mechanisms, such as fluorescence and phosphorescence.
Photochemical reactions start from excited states, and are hence distinct from
thermal reactions that originate from ground electronic states. The energy of a
molecular entity in an excited state is usually 150 – 1200 kJ/mol over its ground state,
and hence exceeds very much the typical ground state thermal reaction activation
energy (Ea = 30 kJ/mol). The activation of an excited reactant needs only negligible
activation energy (Ea* ca. 8 – 17 kJ/mol); thereby some new reaction channels can be
opened (Figure 1.10).
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Figure 1.10 Comparison of thermal and photochemical reaction courses; R and R*
are the ground state and excited state of the reactant, TS and TS* the corresponding
transition states, Ea and Ea* the corresponding activation energies, respectively; IP
means the intermediate photochemical product; Pt and Pph signify products of the
thermal and photochemical reactions, respectively. (Adapted from ref.149)
The transition of electron to an excited state is accompanied by angular or spatial
electron shift, leading to the weakening of some bonds within the molecule. The
reaction of an excited state may be generally classified as intramolecular or
intermolecular. The major types of photoreaction are illustrated in Figure 1.11.
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Figure 1.11 Major types of photochemical reactions.149
1.3.2.4 Photochemistry of platinum complexes
The photochemical properties of platinum compounds were first recognized in
photographic processes during the 1850s.155 The solutions of PtIV complexes are long
believed to undergo rapid photochemical reaction in light.10 In 1970s, the
photochemistry of [Pt(CN)nX2] (n = 2 or 4 for PtII or PtIV complexes, respectively)
was reported.135 In aqueous solution, when X = Cl−, photoaquations,
photosubstitutions and photoisomerisations are often observed; whereas when X =
N3− and NO2−, photoreductions, i.e. PtIV to PtII, prevail. Interestingly, when the
solvent is methanol, irradiation towards the PtIV complex [Pt(CN)4Cl2]2− into its
LMCT bands lead to an effective photoreduction, resulting the [Pt(CN)4]2− complex.
When water is the solvent, photoaquation occurs, forming [Pt(CN)4OH2]2−.135
In metal azido complexes, azide is asymmetric with bond lengths which compare
well with those of diimide (1.23 Å), and N2 (1.095 Å).6 The structure of bound azide
is therefore best described as a resonance hybrid (Figure 1.12). By contrast, the free
Photochemical
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molecular
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molecular
Photo-dissociation
Photo-isomerization
Photo-redox
Photo-addition
Photo-polymerization
Photo-redox
Photo-substitution
Photo-sensitized reactions
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azide anion (N3−) in aqueous solution is linear and symmetric, possessing equal N-N
distances of ~1.17 Å.
Figure 1.12 Bond lengths and angles of azide in the form of free anion (N3−), bound
to hydrogen (hydrazoic acid HN3) and bound to a metal (M-N3).6
Photochemistry of metal azido compounds has been reviewed recently.156, 157 It has
been stated in the literature that almost any transition metal azide complex is light
sensitive regardless of its oxidation state.158-160 The photoreaction of metal azido
complexes can involve the following processes.
 Forming nitrene intermediate 161-166
 Forming nitrido complexes167-169
 Forming azidyl radicals (which recombine to give N2)170-173
 Photoeliminations 170, 174, 175
 Photosubstitutions 176, 177
 Photoisomerizations 178, 179
 Photosensitize singlet oxygen 180, 181
This thesis is focused on the photoredox chemistry of platinum azido complexes.
Hence an example of first report in 1978 of photoreductive elimination of azide from
a platinum centre is described here. Irradiation into the LMCT bands (N3→Pt, 302 
nm,  = 18300 M-1 cm-1) of the PtIV complex [Pt(CN)4(N3)2]2− leads to [Pt(CN)4]2−
H
N N N
N N N[ ]
1.17 Å
1.13 Å1.24 Å
1.02 Å
109° 171°
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and two •N3 radicals, via a simultaneous two-electron reduction avoiding a
platinum(III) intermediate (Figure 1.13).182 The •N3 radicals quickly undergo
recombination to give N2.
2
2
4
2
423 3N][Pt(CN)](CN))[Pt(N 
 hv
Figure 1.13 Possible mechanism for the photoreduction of a PtIV diazido complex.182
In summary, the photochemistry of metal azido complexes is extensive and varied,
so is not simple to predict. The nature of the leaving ligands and the solvent plays
important role in determining the photochemical pathway. Therefore, care must be
taken with investigations elucidating the pathway(s).
1.3.3 Photodynamic therapy
Photodynamic therapy (PDT) is a treatment using a photosensitive agent (called
photosensitizer (PS)) and a particular wavelength of light. The PSs show low or no
toxicity towards both tumour and healthy organs and tissues in the absence of
irradiation. When the PS is exposed to a specific wavelength of light, the molecule is
excited from ground state (singlet state) to excited state (triplet state).
The excited triplet state PS can undergo two types of energy transfer to return to the
ground state. In the type I reaction, it can react directly with a substrate, such as the
cell membrane or other molecule, and obtain a hydrogen atom (with one electron) to
form radicals. These radicals interact with oxygen to produce oxygenated products.
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In the type II reaction, energy is transferred from the triplet PS to the ground state
oxygen (triplet state, 3O2), and hence a highly reactive oxygen species (singlet
oxygen, 1O2) is generated.(Figure 1.14) The effects of almost all PSs are oxygen-
dependent; photosensitization generally does not occur in anoxic areas of tissue.183-
185
Figure 1.14 Mechanism of photodynamic therapy.183
Three main mechanisms are known for PDT-mediated tumour destruction. First, the
ROS generated by PDT can directly kill cancer cells. PDT can also damage the
vasculature associated with tumour, leading to tumour infarction. Finally, PDT can
activate an immune response against tumour cells.183
A variety of light resources can be applied in the clinical therapy of PDT. Lamps
give a wide spectrum and depending on the filter, various wavelengths can be
obtained. LEDs are recently developed light resources, the choice of which range
from UVA to infrared with a bandwidth of only 5 – 10 nm. The power output can be
up to 150 mW/cm2.186 Lasers usually produce a very narrow bandwidth of
wavelengths. Recent advances in laser and fibre optic technologies allow physicians
Photosensitizer
(excited state)
Photosensitizer
(ground state)
Light
Tissue oxygen
Free radicals
Singlet oxygen
Cellular
toxicity
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to irradiate internal organs with light of sufficient intensity for PDT. It is now
possible to directly irradiate several areas of the body including the bladder,
oesophagus, colon, cervix, lung, eyes, head (brain) and neck. By directing light to a
localized tumour to selectively activate a photosensitive prodrug, the cytotoxic
effects on the tumour can be specifically intensified, thus reducing the side-effects to
the normal tissue.187
The effective wavelength for phototherapeutic purposes is in the range of ca. 600-
800 nm (so called the phototherapeutic window). In general, the depth of penetration
of light is inversely proportional to the wavelength within the spectrum of visible
and near infrared (Figure 1.15).187 For example, light of wavelength 600 – 800 nm is
estimated to penetrate 1.5 – 3-fold deeper into tissues than light of 400 – 500 nm (~2
cm vs ~0.75 cm).188 Near infrared (800 – 1100 nm) penetrates still further,189 but
such a long wavelength has insufficient energy to activate the necessary
photochemical processes. Wavelengths shorter than 400 nm have been shown to
damage the tissue.190-192
Figure 1.15 Light penetration in human tissues. Adapted from ref.193
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One of the most important advantages of PDT is that the reactions only occur in the
immediate locality of the light-absorbing area. Another major advantage is that it is
relatively non-invasive, i.e., repeated dosing is possible and there is no total dose
limitation.135 However, the drawbacks of the photosensitizers seriously impact their
usefulness for PDT.194 The efficiency of PDT is dependent on a reasonably high
level of oxygen in target tissue, but cancer cells are typically hypoxic owing to rapid
growth.195, 196 Sometimes the affinity of photosensitizer for selective accumulation in
tumour cells is not as good as expected. Appreciable dark toxicity of the
photosensitizer may cause nonspecific damage outside of the target tissue. Reactive
oxygen species (ROS) can also damage blood components in normal tissue. Many of
the synthetic porphyrins have long retention times in the skin. The slow excretion of
photosensitizers prolongs the skin photosensitivity, which does extra harm to
patients.
1.3.4 Photoactivatable platinum(IV) anticancer complexes
Based on knowledge of the photochemistry of Pt complexes and the idea of PDT, it
is possible to design a class of PtIV anticancer prodrugs that are stable in the dark, but
become active upon photoinduced reduction to active form with PtII. Compared to
PtII species, PtIV complexes are much more inert to reaction in the ground electronic
state but can be made to readily undergo photoinduced reduction and ligand
substitution. Accordingly, a site-specific cancer therapy can be performed by
exposure of the target tissue to light; the unirradiated drug will be kept intact and
quickly excreted from the body without attacking healthy cells.
The first generation of photoactivatable PtIV anticancer prodrugs was designed and
synthesized by Bednarski’s group, a series of diiodo-PtIV complexes (Figure
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1.16).147 For examples, trans, cis-[Pt(OAc)2I2(en)] and trans, cis-[Pt(OH)2I2(en)]
displayed broad ligand-to-metal charge-transfer (LMCT) bands centred at λ = 389 
and 384 nm respectively, with a tail up to ca. 550 nm.197 The LMCT (Pt-I) bands are
of suitably low energy to give rise to photolytic reduction in the presence of visible
light.
Figure 1.16 Photoactivatable diiodo-PtIV complexes.
However, the photo-induced anticancer activity and DNA platination level of these
complexes are limited, and they were found to be easily reduced by thiols (e.g.
glutathione, an intracellular reductant).197, 198 Therefore, they have been deemed as
unsuitable drug candidates.
The Sadler group developed the second generation of photoactivatable anticancer
prodrugs: PtIV diazidodihydroxido complexes.199-202 (Figure 1.17) These complexes
possess strong LMCT bands (N3→PtIV), with λmax between 250 and 290 nm, and
absorption tails extending to ca. 450 – 500 nm.
The dark stability, photoreactions, nucleotide/DNA binding and cell cytotoxicity for
trans, trans, trans-[Pt(N3)2(OH)2(NH3)(Py)],200 and trans, trans, trans-
[Pt(N3)2(OH)2(Py)2],201 (Figure 1.17) have been investigated and the results are
promising. Both complexes were shown to have high stability in dark conditions, no
reaction with nucleobases such as 5'-GMP and, more importantly, only a very slow
reaction with glutathione (GSH) over a period of several weeks. By contrast, upon
irradiation of these complexes with UVA (365 nm) or blue light (420/458 nm), these
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complexes undergo rapid reductive N3 ligand substitution, and form various
hydrolysis products.199, 200 In the presence of 5'-GMP in aqueous solution, these
complexes can be rapidly reduced to PtII species upon irradiation with UVA/blue
light, producing trans azido/guanine and trans diguanine PtII adducts.
Figure 1.17 Photoactivatable PtIV diazidodihydroxido anticancer complexes
containing either cis or trans diam(m)mies (L, L' = heterocyclic imines/aliphatic
amines). Two examples trans, trans, trans-[Pt(N3)2(OH)2(NH3)(Py)] and trans, trans,
trans-[Pt(N3)2(OH)2(Py)2] are presented.
Upon irradiation with UVA/blue light, these complexes display potent
photocytotoxicity in vitro to a range of cancer cells by binding to DNA and thus
causing cell death (Figure 1.18), despite other possible mechanisms may also be
involved.200, 201 A cytomorphology study showed that upon irradiation, dramatic
changes occurred including rapid rounding up of the cells, then cellular shrinkage,
loss of contact with neighbouring cells, and a large amount of nuclear packing.203
These initial results suggest that the mechanism of action of photoactivatable PtIV
dihydroxidodiazido complexes is different from that of cisplatin.
Figure 1.18 Proposed mechanism for photoinduced binding of trans, trans, trans-
[Pt(N3)2(OH)2(NH3)(Py)] to GMP or DNA.204
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More importantly, it is thought that the DNA binding and anticancer activity are
oxygen-independent. This is potentially advantageous compared to photodynamic
therapy (PDT), because the PDT requires free oxygen at the target site, but the
tumour cells can be hypoxic due to the rapid growth. This treatment is thus named
photochemotherapy, which encompasses photodynamic therapy and also the
chemotherapy with Pt-based complexes. Various light resources can be applied in
the photoactivation, such as lamps, LEDs and lasers.
In recent years, PtIV tetrachlorido complexes 205 and dichloridodihydroxido
complexes206 have been found to be sensitive to light and undergo facile
photoreaction with a range of biomolecules. However, it was later noticed that the
thermolysis (323 K) of PtIV 2,2’-bipyridine complexes lead to identical PtII–DNA
adducts as those from the photoreaction.207 By contrast, the PtIV diazidodihydroxido
complexes are very stable for at least several hours at 323 K. Also, it was found that
PtIV complexes of the type trans,trans,trans-[PtCl2(OH)2LL’] (L and L’ = different
aliphatic amines) are toxic in the absence of irradiation with UVA.148 These results
stopped the further development of PtIV chlorido complexes in photochemotherapy.
Recently, the combination of photochemistry and platinum anticancer drugs has
attracted increasing attention. Donzello and coworkers has reported a series of
dichloridodipyrido PtII complexes externally appended to non-Pt metal-centred
macrocycle photosensitizers as potential active photo/chemotherapeutic anticancer
agents.208 These complexes combine the features of PDT and chemotherapy by
generating singlet oxygen as well as interacting with a G-quadruplex structure of the
telomeric DNA.209 Brewer and coworkers recently reported a RuII-PtII dinuclear
complex that can be activated by red light in the therapeutic window. This
“supramolecule” harvests energy of red light via MLCT excitation of the RuII
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chromophore and the energy is imparted onto the cis-{PtCl2} bioactive site where
photoinduced binding to DNA occurs.210
1.3.5 Other metal-based photoactivatable anticancer complexes
A broad range of other metals has also been involved in the development of
photoactivatable anticancer drugs.211
Ruthenium(II) arene organometallic complexes can exhibit potent anticancer
activity.212, 213 In recent years, Sadler and co-workers have reported the first RuII
arene complex that can selectively photodissociate a pyridine ligand upon excitation
with visible light and form a reactive aqua species, which hence can bind to
nucleobases.214 The structure-activity relationship was examined215 and the photo-
induced pyridine substitution for [RuII(Bpy)2(Py)2]2+ has been studied by time-
resolved X-ray solution scattering.216 Marchan and coworkers have coupled this type
of photoactivatable RuII arene complexes to a series of cancer cell targeting peptides,
such as dicarba analogue of octreotide and RGD tripeptide.217 Upon irradiation with
visible light, reactive aqua species can be released from the conjugates, which
reacted with DNA, forming an 1, 2-GpG intrastrand crosslinks.
In recent years, the Chakravarty group have developed a series of FeIII, VIV and CuII
complexes with (derived) phenanthroline ligands, namely, 1,10-phenanthroline,
dipyridoquinoxaline and dipyridophenazine, as photoactive anticancer agents. The
common features of these complexes are as follows. They can be activated by visible
light and even near-IR irradiation. They act as efficient photosensitizers, forming
singlet oxygen (1O2) or hydroxyl radical (•OH) species. They show DNA photo-
cleavage or photo-binding activity.218-221 Very recently, the Chakravarty group
reported a super multifunctional FeIII complex222 with a derived anthracene ligand, a
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catechol ligand and nitrate as a leaving group. This complex exerts micro-molar
cytotoxicity towards HeLa and MCF-7 cell lines upon irradiation with near-IR-light
and negligible dark toxicity. It is also a powerful photosensitizer that photocleaves
DNA by a hydroxyl radical pathway. It can also act as fluorophore for cellular
imaging. The development of photoactive non-Pt metals anticancer complexes show
promising future, and the application of cheap metals (such as Cu and Fe) into
anticancer medicine may open a gate to reduce the cost of anti-tumour therapy.
Ideal photoactivable anticancer prodrugs should have the following features:
1. Good solubility in physiological media and efficient accumulation in tumour
cells.
2. High stability and low systemic toxicity in the absence of irradiation.
3. Efficient photoactivation with light of as long wavelength as possible in the
therapeutic window (600 – 800 nm).
4. Rapid cell death after photoactivation and lower cross-resistance by novel
mechanisms of action.
Therefore, complexes with broader clinical utility (longer activation wavelength),
greater potency (higher phototocytoxicity) and wider applicability (circumventing
cisplatin cross-resistance) are still needed.
1.4 Aims of the thesis
The specific aims of the work carried out in this thesis were as follows:
1. To design and synthesize novel mixed amine ligands in complexes of the type
trans,trans,trans-[Pt(N3)2(OH)2(amine1)(amine2)] for more potent
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photocytotoxicy, longer activation wavelength, with no compromise of dark
stability, and study their photochemistry and photobiochemistry.
2. To investigate photodecomposition and photoreaction pathways of PtIV
diazidodihydroxido complexes, in particular to detect the production of azide
activation (e.g. N3−, N3•, N2), reactive oxygen species (e.g. 1O2, H2O2) and
adduct with various biomolecules, such as 5'-GMP and a DNA oligonucleotide.
3. To attempt to increase the wavelength of light activation of PtIV (di)azido
complexes by suitable derivation of the amine ligands or by two-photon
activation.
This work involves a wide range of techniques including 1H, 14N, 195Pt NMR, UV-
Vis, HPLC, MS, EPR and fluorescence, etc.
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In this Chapter, an overview of major experimental methods and techniques used in
this work is given. Some further specific details will also be outlined in each chapter.
2.1 Nuclear Magnetic Resonance (NMR) Spectroscopy
The application of NMR can be found in almost all the research field of chemistry
and biology in unveiling information about the chemical environment of
magnetically active nuclei. In this work, multinuclear NMR techniques were applied
in characterizing new compounds, obtaining structure information and monitoring
the reactions, etc.
The NMR relevant properties of some commonly studied nuclei are listed in Table
2.1. In this thesis, the main nuclei studied are 1H, 13C, 14N and 195Pt, although some
experiments were performed on 15N, 19F and 31P. Due to the relevance to this work,
the NMR spectroscopy of 1H, 13C, 14N, 15N and 195Pt nuclei and two-dimensional
NMR techniques will be discussed further.
Table 2.1 NMR properties of common nuclides.1
Nucleus
Natural
Abundance
(%)
Sensitivity
(relative to
13C)
Gyromagnetic
Ratio γ 
rads
Spin
quantum
number I
Frequency
at 14.092 T
(MHz)
1H 99.989 5870 26.75 ½ 600.00
13C 1.070 1 6.73 ½ 150.87
14N 99.634 1.0 × 10-3 2.044 1 43.358
15N 0.368 2.25 × 10-2 -2.71 ½ 60.821
19F 100.0 4900 25.18 ½ 564.56
31P 100.0 391 10.84 ½ 242.89
195Pt 33.83 20.7 5.839 ½ 128.98
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2.1.1 1H-NMR
In organic solvents, e.g. acetone-d6, the resonance of NHx in 1H NMR is usually
broadened due to the quadrupole effect of 14N. In this thesis, most of the NMR
experiments of Pt am(m)ine complexes and their reactions were carried out in
aqueous solutions, such as D2O (99.9%), H2O/D2O (typically 90%/10%, v/v). In
aqueous solvent, the exchange of NHx with D may cause the disappearance of the
signal. For PtII complexes, the exchange at physiological pH is sufficiently slow to
follow the signal.2, 3 However, for PtIV am(m)ine complexes, H2O/D2O (90%/10%,
v/v) is used and also pH needs to be lowered to ca. 5 to slow down the rate of
exchange as the amine ligands on PtIV have lower pKa values. In addition, the pH
may also need to be lowered to enable the detection of protonated amine released
from platinum.
In addition, a water suppression strategy is necessary for experiments in aqueous
solution especially in 90% H2O/10% D2O. Two main techniques were used in this
thesis to suppress the H2O/HOD signal: excitation sculpting (Shaka method)4, 5 and
pre-saturation.6 The Shaka sequence applies pulsed-field gradients to excite from the
opposite sides of the proton pulse but not the solvent peak. This strategy may lead to
badly phased H2O/HOD signal while the other signals are almost unaffected. Pre-
saturation irradiates the solvent peak at exactly its resonance frequency during the
delays of the pulse sequence. This approach gives perfect water suppression but it
may cause considerable suppressions of signals close to the H2O/HOD peak (±1
ppm). Therefore, the integration of signals close the H2O/HOD peak is not reliable.
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2.1.2 13C-NMR
13C is the second most important nucleus after 1H in elucidating chemical structures.
The natural abundance of 13C is 1.1%, the spin quantum number I = ½ and the
magnetic moment ca. ¼ of that of 1H (μ13C/μ1H = 0.252). This leads to ca. ¼ Larmor
frequency of the 13C nucleus as that for 1H in the same external magnetic field. The
sensitivity of 13C nucleus for natural isotopes is only ~1.8 × 10-4 as that for 1H, so
acceptable signal can be obtained by isotope enrichment or accumulation of more
acquisitions.
Also, a series of one dimensional multi-pulse sequences were applied to obtain
intensified signal in this work. JMOD7 (J Modulation) pulse sequences produce
spectra in which the positive signals are from CH2 or quaternary carbons and the
negative signals are from CH and CH3 groups.8 Although the signals can be phased
up or down, they can be phased relating to the solvent signal. Non-proton bearing
13C nuclei give weak signals due to their longer spin-lattice relaxation time T1 and
smaller NOEs (Nuclear Overhauser Effect). DEPT (Distorsionless Enhancement by
Polarization Transfer) was also used to gain an enhancement in signal intensity via
polarization transfer from sensitive nuclei (1H) to 13C nuclei by a factor of γ1H/γ13C.
However this method does not detect non-protonated 13C nuclei, as there is no
polarization transfer from 1H to quaternary carbons. Therefore, a PENDENT9
(Polarization Enhancement During Attached Nucleus Testing) pulse sequence was
also used in which the sensitivity for CH, CH2 and CH3 groups are the same as that
for DEPT and the non-protonated 13C nucleus give stronger signals compared to that
for JMOD.
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In this thesis, the 13C spectra reported have been broadband proton decoupled using a
composite pulse sequence to generate simplified spectra. The integration of 13C
signals was not applied because of two reasons:
 The NOE effect from proton decoupling is not equal for all the carbons. In
particular, quaternary carbons receive very little NOE, and hence their signals
are usually weak.
 Some carbon nuclei have very long spin-lattice relaxation times T1. For
example, the T1 value for quaternary carbons in styrene is 78 s as there are no
close protons to relax it.7
2.1.3 14N NMR
Although 14N (I = 1) has high natural abundant (99.63%), the detection of the 14N
resonances is never simple. The major problem is that in liquid samples, the
bandwidths 14N signals are often broad due to rapid quadrupolar relaxation
(millisecond level),10 especially when the chemical environment of 14N has low
symmetry. Nevertheless, large numbers of acquisitions can be acquired due to the
short relaxation times. Therefore, it has been possible to follow the decomposition
pathways of N3 group in the photochemical reactions of Pt-azido complexes.10-12
Experimental parameters for 14N NMR spectra (43.36 MHz): pulse sequences
zgpg30 (proton broadband decoupled) was used and the digitization mode was in
“baseopt” for improvement of baselines. The spectra were acquired with a relaxation
delay (D1) of 0.25 s. Typical parameters were 32k data points and 64k scans. Data
were processed using a line broadening of 20 Hz for EM window function unless
otherwise stated. With the IUPAC recommended reference CH3NO2 (neat or 90% in
CDCl3) as δ = 0 for 14N nucleus,1 the typical chemical shift range is −400 to 400 ppm. 
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In this work, an external 14NH4Cl (1.5 M) in 1 M HCl was used as reference and a
chemical shift range between −100 and 500 ppm was scanned. The chemical shift 
observed in this way can be converted to CH3NO2 standard by subtracting 380.5
ppm.
2.1.4 15N NMR
15N NMR (I = ½) was also used in a few cases to characterize 15N-labelled
complexes in this thesis. The receptivity of 15N is extremely low, 2.25 × 10−2 relative
to 13C, so 15N-labelled derivatives need to be prepared.
The sensitivity of 15N can be enhanced via inverse detection technique that has now
been routinely used in detecting 15N signals. This method is a two-dimensional
correlation spectroscopy that detects the insensitive nuclei by detecting the sensitive
nuclei attached to it (usually 1H). Inverse detection techniques can, in principle, give
a gain in sensitivity of nuclei X by (γH/γX)5/2 over direct detection. For low γ value
nuclei such as 15N (Table 2.1), this method is even more dramatic. More information
on two-dimensional correlation spectroscopy as well as the range of 15N chemical
shift can be found in Section 2.1.6.
Nevertheless, the direct detection of 15N is still of advantage in some cases, if the 15N
nucleus has no H attached or there is rapid exchange of the NH proton.
2.1.5 195Pt NMR
195Pt (natural abundance 33.8%) is the only NMR-active isotope of platinum and it
has favourable properties for use in NMR, for example, nuclear spin quantum
number I = ½, sensitivity 20 relative to 13C, and gyromagnetic ratio γ = 5.8 × 107 rad
s−1 T−1(Table 2.1). 195Pt resonance is reasonably sensitive to observe and has been
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routinely used in a wide variety of applications including structural elucidation,
relaxation studies, kinetics and mechanistic studies and drug binding studies.13
The chemical shift range of 195Pt is large (15k ppm) and is particularly sensitive to
changes in the oxidation state, ligand substitution, stereochemistry, and even
different isotopes around the 195Pt nucleus.14 For example, the 195Pt chemical shift of
cis-[PtCl2(Me2NH)2] in DMF-d7 is −2188 ppm, while that of trans-[PtCl2(Me2NH)2]
is −2181 ppm.15 By contrast, the Pt chemical shifts of PtIV complexes {PtCl2N2O2}
are ca. 900 ppm.16 The 195Pt chemical shift of [PtCl6]2− is set up to 0 as reference,
and δ of [PtBrCl5]2− is −282 ppm.17 Abbott et al reported 0.5 – 1.0 ppm shift between
two isotopomers K2[Pt(16OH)2(Ox)2] and K2[Pt(16OH)(18OH)(Ox)2] (Ox = oxalate).
The 195Pt chemical shift difference for Pt-35Cl and Pt-37Cl is 0.17 ppm and for Pt-79Br
and Pt-81Br is 0.03 ppm.14
However, such a small difference in 195Pt NMR chemical shift is practically very
difficult to observe due to the line width of the signals. First, the 195Pt NMR
resonance is strongly dependent on the temperature, ca. 1 ppm K−1, so poor
temperature control broadens the resonance.14 Second, am(m)ine ligands containing
14N (natural abundance 99.6%, I = 1) can also broaden the 195Pt resonance by electric
quadrupolar effects,14 although this effect shortens the 195Pt relaxation times and
rapid pulsing can be used without saturation effects. Third, 195Pt signal can also be
broadened due to the chemical shift anisotropy (CSA) relaxation.18
The peak-widths of 195Pt resonances (and also 195Pt satellites, see Chapter 3) are
dependent on the T1 relaxation time of 195Pt. The contribution to T1 of 195Pt from
CSA is dependent on a number of factors:14
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[T1(Pt)]
-1 (CSA)= 6
7
[T2(Pt)]-1 (CSA)= 215 ×γPt2 ×B02×Δσ2×τc
195Pt resonances are broader in PtII complexes which are in square-planar geometry
and hence are less symmetrical (larger anisotropy Δσ), in larger external magnetic
field (B0) and in larger molecules where the correlation time τc is longer.
Experimental parameters for 195Pt NMR spectra (129.4 MHz): Pulse sequences zg
(non-proton-decoupled) was used and the digitization mode was in “baseopt” for
improvement of baselines. The spectra were acquired with a relaxation delay (D1) of
0 s. Typical parameters were 2k data points and 10k acquisitions. Data were
processed by using an exponential line broadening of 100 Hz unless otherwise stated.
2.1.6 Two-dimensional NMR Techniques
In 2D-NMR experiments, another frequency domain is involved to reveal structural
correlations through various magnetic interactions between nuclei. For example, in a
[1H, 1H] COSY (COrrelation SpectroscopY) experiment, two identical 1D spectra
axes are plotted orthogonally, and all the spin-coupled protons are indicated by cross
peaks placed along the diagonal. Usually, COSY spectra can only show the
correlation between two- and three-bond coupled protons. NOESY (Nuclear
Overhauser Effect SpectroscopY) can connect resonances of protons that are
spatially close to each other. In TOCSY (TOtal Correlation SpectroscopY)
experiments, the connectivity of all protons in a spin system is detected as cross
peaks.7
Heteronuclear single (or multiple) quantum coherence (HSQC and HMQC) and
HMBC (Heteronuclear multiple-bond correlation) spectroscopy are powerful inverse
detection techniques that can detect insensitive nuclei (such as 13C and 15N) by
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detecting the attached sensitive nuclei (such as 1H, 31P and 19F).19, 20 In HSQC, the
sensitivity of 15N can be improved by 306 ((|γ1H/γ15N|)5/2) compared to directly
detected 15N. HSQC can detect heteronuclear correlations over one bond, where the
spin-spin coupling to 1H is measurable, e.g. in primary and secondary amines. For
tertiary amines, HMBC is often applied to detect heteronuclear correlations over
longer ranges of about 2 – 4 bonds.
Valuable information can be obtained from 2D [1H, 15N] HSQC spectra (Figure
2.1A), e.g., 15N chemical shift and the 1J(195Pt-15N) coupling constant, which are
highly dependent on the nature of the ligand trans to 15N ligand. As shown in Figure
2.1B, the observed 1H and 15N chemical shift ranges for a number of PtII and PtIV
complexes have been defined.19
Figure 2.1 (A) Typical shape of Pt-15N-H cross peak in a Pt ammine complex in 2D
[1H, 15N] HSQC NMR spectrum. (B) Schematic representation illustrating the areas
of positions of 1H and 15N cross peaks of 2D [1H, 15N] HSQC NMR spectra for
various ligand trans to 15N in PtII and PtIV complexes.19, 20
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2.1.7 Experimental methods
NMR data were acquired by the author under the guidance from Dr. Nicola J. Farrer
and Dr. Ivan Prokes (University of Warwick). NMR spectra were recorded on a
Bruker DPX-400 (1H: 400.03 MHz), a Bruker AV-400 (1H: 399.10 MHz) or a Bruker
AVIII-600 (1H: 600.13 MHz) spectrometer. NMR chemical shifts were recorded in δ
(ppm) and 1H and 13C chemical shifts were referenced to residual 1H/13C-solvent
peaks from deuterated solvents CDCl3 (1H, δ = 7.26; 13C, δ = 77.16), MeOD (1H, δ =
3.31; 13C, δ = 49.00), acetone-d6 (1H = δ 2.05; 13C = δ 29.84, 206.26), DMSO-d6 (1H,
δ = 2.50; 13C, δ = 39.52), and DMF-d7 (1H, δ = 2.75, 2.92, 8.03; 13C, δ = 29.76, 34.89,
163.15).21 For D2O or 90% H2O/10% D2O, chemical shifts were referenced
internally to dioxane (1H, δ = 3.75 in D2O; δ = 3.764 for 90% H2O/10% D2O; 13C, δ
= 67.19 for both solvents).22 195Pt NMR: chemical shifts were externally referenced
to 15 mM K2PtCl6 in D2O (δ = 0). 14N and 15N chemical shifts were referenced to
external 14NH4Cl or 15NH4Cl (1.5 M) in 1 M HCl and 31P to external H3PO4 85% in
D2O at δ = 0. Data processing was carried out by using Topspin 2.0 (Bruker) and
MestReC version 4.9.9.9 (Mestrelab Research S.L.).
2.2 Mass Spectrometry (MS)
2.2.1 Electrospray Ionisation-Mass Spectrometry (ESI-MS)
ESI-MS is a soft-ionization mass spectrometric technique for the analysis of
compounds in aqueous/organic solution. ESI-MS was used routinely in this work to
characterise complexes and the products formed in photoreaction.
Electrospray Ionisation is induced by applying a strong field to a liquid passing
through a nebuliser (capillary needle) at a rate level of microlitres per minute.23 The
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nebuliser is maintained at several kilovolts with respect to an electrode surrounding
it (Figure 2.2). The resulting spray of charged fine droplets then passes through a
space to evaporate the solvent and attach charge to the analyte molecules. As the size
of the droplets decreases, the charge density increased. When the surface tension can
no longer hold the charge, the droplets are torn apart into smaller droplets. The
parameters can be adjusted so the desolvation process is repeated until all solvent is
removed, leaving (multiply) charged analyte molecules. Ion analysis is then
performed using various mass detectors, such as quadrupole, iontrap and time-of-
flight (TOF) mass spectrometer.
Figure 2.2 Schematic ionization mechanism for electrospray.23
The sample must be present in solution as ions and thus adjusting the pH to
protonate (ESI positive) or deprotonate (ESI negative) the analyte molecule is
sometimes necessary. Water, methanol, acetonitrile and isopropanol can be applied
as solvent.
Positive/negative ion electrospray mass spectrometry (ESI-MS) was performed on a
Bruker Esquire 2000 mass spectrometer coupled with an Agilent 1100 HPLC
(without column) as an automatic sample delivery system. All samples were
prepared in 80% acetonitrile/20% water.
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2.2.2 High resolution (HR) ESI-MS
Positive/negative ion high resolution electrospray mass (HR-ESI-MS) spectra were
recorded on a Bruker MaXis UHR-Qq-TOF mass spectrometer. The Bruker MaXis
high resolution mass spectrometer offers ultra-high resolution of 40,000 – 60,000
over a broad mass range, theoretically MS and MS/MS mass accuracy 600 – 800 ppb
for internal calibration, 1 – 3ppm for external calibration.
Platinum complexes samples were filtered with a 0.2 μm ionic membrane and then 
diluted to 10 μM scale in 80% acetonitrile/20% water before use. DNA samples were 
prepared 1.0 μM, in a solution of H2O/isopropanol (50%/50%, v/v) with 50 mM
ammonium acetate. The oligo concentrations of DNA were determined
spectrophotometrically using the absorption coefficient ε260 = 132.52 mM−1cm−1,
calculated by ‘OligoCalc’.24 A solution of HCOONa was also injected as an external
calibration. Data processing and mass/isotope distribution simulation was carried out
on Bruker Daltonics DataAnalysis.
2.2.3 HPLC coupled mass spectrometry (LC-MS)
HPLC-coupled mass spectrometry (LC-MS) was performed on a Bruker HCT-Ultra
mass spectrometer coupled with an Agilent 1200 HPLC system with an Agilent
ZORBAX Eclipse Plus C18 column (4.6 × 250 mm, 5 µm). Analytical separations
for reaction mixtures of Pt complexes with 5′-GMP were carried out with detection 
at 254 nm. Mobile phases were A: 0.1% formic acid in HPLC grade water, and B:
0.1% formic acid in HPLC grade methanol. A 20-min linear gradient from 5% to
55.0% B was applied for all reaction mixtures of Pt complexes and 5′-GMP. The
flow rate was 0.8 mL min−1.
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2.3 Inductively coupled plasma optical emission spectrometry
(ICP-OES)
The platinum content of aqueous solutions was determined by ICP-OES (inductively
coupled plasma optical emission spectrometry) or ICP-MS (mass spectrometry).
2.3.1 ICP-OES
ICP-OES experiments were carried out on a PerkinElmer Optima 5300 DV optical
emission spectrometer with an AS-93 plus autosampler. The atoms/ions of elements
can take up energy from an inductively coupled plasma (ICP), and are thereby
promoted to an excited state. Then the atoms/ions emit a series of characteristic
radiation while fall back into their ground state, so called optical emission spectrum.
The intensity of radiation, in a certain range, is proportional to the concentration of
the element, and is therefore quantitative.
In ICP-OES analysis, the liquid sample is introduced into the inductively generated
argon plasma through a nebulizer system and get excited. The spectrum emitted is
transferred into a spectrometer where it is decomposed into the individual
wavelengths and evaluated. The emission wavelengths detected for Pt were 265.945,
214.423, 299.797, 204.937 and 193.700 nm. The intensities of the spectral lines are
measured by CID semiconductor detectors. The ranges of detecting limit for
different metals are quite different. For Pt in liquid samples, the theoretical lowest
detecting limit on ICP-OES is 50ppb. Samples were calibrated with 5 – 7 standard Pt
solutions (0.5 – 10 ppm) prepared from stock 1000 ppm Pt solutions (Sigma Aldrich).
Data analysis was carried out on WinLab32 (version 3.4.1).
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2.3.2 ICP-MS
ICP-MS was carried out on an Agilent 7500 Series ICP-MS spectrometer. Similar to
ICP-OES, an inductively coupled plasma (ICP) is also used, but higher energy
(higher temperature) is given to the sample to atomize and ionize the elements. The
resulting ions are then passed through a series of apertures (cones) into the high
vacuum mass analyser. The isotopes of the elements are identified by their mass-to-
charge ratio (m/z) calibrated internally by standard samples of erbium. The
concentration of an isotope (element) in the sample can be quantified by the intensity
of the m/z peak in the mass spectrum. The theoretical lowest detecting limit for Pt
samples in H2O or 3% HNO3 on ICP-MS is 0.5 ppt. Samples were calibrated with 5
– 7 standard Pt solutions (0.1 ppb – 500 ppb) prepared from stock 1000 ppm Pt
solutions (Sigma Aldrich). Data acquisition was carried out on ICP-MS Top (version
B.03.05) and analysis on Offline Data Analysis (version B.03.05).
2.4 Ultraviolet-Visible Absorption Spectroscopy
Ultraviolet-visible absorption spectroscopy (UV-Vis Spectroscopy, also known as
electronic absorption spectroscopy) is a highly useful technique for studying
electronic excitations of molecules.
UV-Vis spectrum records the transitions between the electronic energy levels of a
molecule. The electrons in a molecule are excited from their ground electronic states
to excited states, induced by the absorption of electromagnetic radiation (photons).
The absorption bands generated from transition metal complexes are commonly
based on three different transitions:
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 ligand field transitions (LF), also known as d→d transition or metal centred 
transitions (MC): electron transfer from a lower to a higher energy metal-centred
orbitals;
 Metal-to-Ligand Charge Transfer (MLCT) or Ligand-to-Metal Charge Transfer
(LMCT): electron transfer from metal-centred orbitals to ligand-centred orbitals
or vice versa;
 Intra-ligand transition (IL): electron transfer from lower to higher-energy ligand-
centred orbitals.
These transitions and estimated extinction coefficients (ε) are further discussed in
Chapter 1. The orbital energies involved in electronic transitions have fixed values,
but practically, many available vibrational and rotational states in the molecule are
associated to each electronic excited state. Therefore, each observed broad
absorption band present in the UV-Vis spectrum often contains closely packed but
discrete lines.
2.4.1 UV-Vis spectra
UV-Vis absorption spectra were recorded on a Varian Cary 300 UV-Vis
spectrophotometer in 1cm path-length cuvettes. The spectral width was 200 – 800
nm and the bandwidth was 1.0 nm, the scan rate 600 nm/min. An Ocean Optics
USB4000-UV-Vis spectrophotometer was also used to continuously follow UV-Vis
spectra in situ with light irradiation. All spectra were referenced to neat solvent and
data were processed with OriginLab Origin 7.0. Extinction coefficients (ε) were
determined over a concentration range (Amax ~ 0.4 – 1.6 units) with at least 4 data
points, using Pt concentrations determined by ICP-OES/MS.
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2.5 pH measurement
pH values for NMR samples were measured at ambient temperature directly in the
NMR tube with a Corning 145 pH-meter equipped with an Mettler Toledo U402-
M3-S7/200 extra-long micro electrode, calibrated with standard buffer solutions at
pH 4, 7 and 10 from Sigma Aldrich.
2.6 Irradiation methods and devices
Photoactivation of Pt complexes was carried out at 293 K by using a LZC-ICH2
photoreactor (Luzchem Research Inc.) (Figure 2.3) equipped with a temperature
controller and 16 UVA lamps (Hitachi, λmax = 361 nm) or 16 Luzchem LZC-420
lamps (λmax= 420 nm) with no other sources of light filtration. ACULED® VHL™
LEDs were also used (λmax = 450 nm) for irradiation of the samples (Figure 2.4). A
modified Shimadzu RF-551 Fluorescence HPLC Monitor (Figure 2.5) was used as
the light source to give low power monochromatic irradiation with PWHH (Peak
Width at Half Height) of ca. 15 nm. A B&W® 72mm UV filter was used to eliminate
the second/higher order diffraction of shorter wavelengths in the specified longer
wavelength monochromatic light from the grating.25
Figure 2.3 LZC-ICH2 photoreactor (Luzchem Research Inc.) equipped with a
temperature controller and 16 UVA lamps (Hitachi, λmax = 365 nm) or 16 Luzchem
LZC-420 lamps (λmax= 420 nm)
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Figure 2.4 (A) ACULED® VHL™ LEDs (λmax = 450 nm) and power supply; (B) a
solution in an NMR tube being irradiated.
Figure 2.5 Irradiation set up using a modified Shimadzu RF-551 Fluorescence
HPLC monitor (A). Light from an optical fibre was directed to the sample in a
cuvette (B).
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2.7 Light measurements
Power levels were measured with an International Light Technologies Powermeter
(ILT1400-A) equipped with a SEL033 detector and either a UVA/TD filter (315-390
nm) for UVA irradiations or a flat response visible filter F/W (400-1064 nm) for
visible wavelengths. The spectrum of each of the light sources was recorded on the
Ocean Optics USB4000-UV-Vis spectrophotometer (see Appendix 2 for all the
output spectra). The number of incident photons (einstein/s) was measured and
calculated using a potassium ferrioxalate actinometer for the wavelength-dependent
photodecomposition study.26-29
2.8 Electron Paramagnetic Resonance (EPR) spectroscopy
The EPR experiments and data analysis were carried out with the assistance of
Jennifer S. Butler in University of Warwick. All EPR measurements were run on a
Bruker EMX (X-band) spectrometer. The room temperature experiments (ca. 293 K)
were recorded using the 1.0 mm quartz tubes. Typical instrument settings were:
modulation amplitude 2.0 G and microwave power 0.63 mW. An aqueous solution
of sample (5 mM) was added to an excess of spin trap, DMPO (5, 5-dimethyl-
pyrroline-N-oxide), 10 mM. Known concentrations of the EPR standard TEMPO
(2,2,6,6-Tetramethylpiperidine 1-oxyl) were run to obtain a standard calibration
curve. From this curve, the concentration of spin adduct was determined. The 450
nm LED was used as the source of irradiation at a distance of ca. 30 cm from the
EPR cavity. Samples were irradiated for 2 hours and signals were recorded every 5
min. Controls of both DMPO and sample, irradiated and non-irradiated were run as
reference spectra. EPR spectra were analysed using the Bruker WINEPR software
and simulations were run using the SIMFONIA.
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2.9 X-ray crystallography
The data collection, structure determination and refinement were carried out by Dr
Guy Clarkson of the University of Warwick. Structure analysis was performed by
the author. Diffraction data for the complexes were collected with Mo-Kα radiation 
(λ = 0.71073 Å) on an Oxford Diffraction Gemini four-circle system with Ruby 
CCD area detector. The crystal was glued to a glass fibre and the data recorded at
296 K. The structure was solved by direct methods using SHELXS (Sheldrick, 1990)
(TREF) with additional light atoms found by Fourier methods. Hydrogen atoms were
added at calculated positions and refined using a riding model. Anisotropic
displacement parameters were used for all non-H atoms; H-atoms were given
isotropic displacement parameters equal to 1.2 (or 1.5 for OH hydrogen atoms) times
the equivalent isotropic displacement parameter of the atom to which the H-atom is
attached. ORTEP diagrams and for short contacts were generated using Mercury 2.3.
2.10 Cytotoxicity test for non-light-sensitive complexes
The cytotoxicity of non-light-sensitive platinum(II) dichlorido complexes was
determined by Dr Ana Pizarro of the University of Warwick. The A2780 human
ovarian cell line was obtained from the ECACC (European Collection of Animal
Cell Culture, Salisbury, United Kingdom). The cells were maintained in RPMI 1640
media, which was supplemented with 10% foetal calf serum, 1% L-glutamine, and 1%
penicillin/streptomycin. All cells were grown at 310 K in a humidified atmosphere
containing 5% CO2. Stock solutions of the Pt complexes were freshly prepared in
DMSO to assist dissolution and then diluted into saline and medium (maximum final
concentration of DMSO 1% and saline 6%). After plating 5000 A2780 cells per well
on day 1, Pt complexes were added to the cancer cells on day 3 at concentrations
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ranging from 0.01 to 100 µM, depending on the preliminary activity data obtained in
screening assays. Cells were exposed to the complexes for 24 h, washed with PBS,
supplied with fresh medium, and allowed to grow for three doubling times (72 h),
and then the protein content (proportional to cell survival) was measured using the
sulforhodamine B (SRB) assay.30 The standard errors are based on two independent
experiments of three replicates each. 31
2.11 Photo/dark-cytotoxicity test for light-sensitive complexes
The photoactivated dose-dependent inhibition to cell viability for light-sensitive
platinum(IV) diazidodihydroxido complexes was determined by Dr Julie A. Woods
of the University of Dundee. Cell culture work was performed at ambient light levels
below 1 lux (Solatell, UK). HaCaT cells were maintained in Dulbecco’s modified
Eagle’s medium containing 5% foetal bovine serum (FBS). All other lines were
maintained in RPMI medium containing 10% FBS. Cells were maintained in
antibiotic-free culture in a humidified atmosphere of 95% air: 5% CO2 and regularly
screened for mycoplasma. Complexes were prepared in Earle’s balanced salt
solution just before use and filtered. Irradiations were performed using a bank of 2 ×
6 ft Cosmolux RA Plus (Cosmedico; λmax: 365 nm) 15500/100W light sources
filtered to attenuate wavelengths below 320 nm; or 2 × 3 ft TL03 (Philips; λmax: 420
nm) light sources filtered to attenuate wavelengths below 400 nm. Irradiance was
measured with an International Light meter, fitted with the appropriate detector and
diffuser and calibrated to each source using a double grating spectroradiometer
(Bentham, UK) in the UKAS accredited optical physics laboratory (Photobiology
Unit, Dundee). The delivered dose was 5 J/cm2 for both sources, equivalent to about
1 hour or less sunlight exposure at midday on a summer day at 56º north (Dundee).
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All experiments were controlled for solvent, test compound and irradiation.
Cytotoxicity was measured using the neutral red uptake phototoxicity assay and
DNA reactivity was measured using the single cell gel electrophoresis (‘comet’)
assay as described in the literature.32 For analysis of comet assay slides, the samples
were coded so that their identity was unknown to the scorer. The concentration of
complex required to inhibit dye uptake by 50% (IC50 value) was determined by curve
fitting (Graphpad). Goodness of fit was assessed by R2 values and the 95%
confidence interval. All cell experiments were performed in duplicate/triplicate and
repeated independently a minimum of two times. Where appropriate statistical
analysis was performed using Anova followed by Dunnett’s test.
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3.1 Introduction
Platinum-based anticancer drugs (e.g. cisplatin, cis-[PtCl2(NH3)2]) are amongst the
most important anti-tumour agents currently available in the clinic, which have
proved to be highly effective towards a variety of solid tumours1-4 (also see Chapter
1). However, severe toxic and dose-limiting side-effects, including nausea, vomiting
and nephrotoxicity accompany the treatment, which limits their application.5 In
addition, intrinsic or acquired resistance of tumours and cross-resistance with other
platinum-based drugs with similar structures reduces their efficacy.6, 7 To overcome
these drawbacks a vast number of new strategies have been investigated, such as
structural modifications,8-10 varying trans/cis geometries,11, 12 different binding
modes13-15 and the strategy of prodrugs.16, 17
Prodrugs are pharmacologically inactive precursors, which undergo chemical and/or
biological transformation to generate (or release) the active drug at the site of
action.18 Apart from reducing the platinum(IV) anticancer prodrugs with biological
molecules, photochemical reduction is also an efficient way to activate them.19
Photoactivatable PtIV diazidodihydroxido anticancer complexes (Figure 3.1) are a
group of prodrugs that are inert and non-toxic in a biological environment in the dark.
Upon irradiation with light these complexes can be selectively activated to become
potently cytotoxic against a number of cancer cell lines.20-24
Metal azides have long been known to be sensitive to light.25 The introduction of
azido ligands into platinum anticancer complexes plays a major role in tuning the
photoactivity of this family of compounds. Apart from the azido ligands, the
selection of the other leaving groups is also of great importance. Previous studies
have shown that PtIV complexes with dihydroxido ligands have lower reduction
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potentials compared to corresponding PtIV complexes with dichlorido ligands26, 27 or
diacetato ligands.28 This decrease in the reduction potential of dihydroxido
complexes makes them stable in the presence of reductive biomolecules.17, 29 In other
words, the PtIV complexes with dihydroxido ligands are stable in the absence of
irradiation, which lowered the potential of side effects. Furthermore, the addition of
dihydroxido group substantially increased the solubility of PtIV complexes in
aqueous solutions. Therefore, in this work, diazidodihydroxido ligands are used with
the aim of developing novel PtIV anticancer prodrugs that are more potent upon
irradiation with light and have low toxicity in the dark.
Figure 3.1 Trans- and cis- photoactivatable platinum(IV) diazidodihydroxido
anticancer complexes. L, L′ = heterocyclic imines/aliphatic amines.  
Although this class of complex exhibits very good photoactivated anti-tumour
activity, there are still several hurdles to overcome. Ideally the complexes would be
activated with light of the longest possible wavelength in the so-called therapeutic
window (up to 600 − 800 nm30, 31) to allow treatment of larger tumours given that
tissue-penetration of light is wavelength-dependent (Chapter 1). In addition, cross-
resistance to cisplatin-resistant cells was also observed.21, 24 By changing the ligands
on the PtIV complexes, compounds with broader clinically utility (longer activation
wavelength), greater potency (higher phototoxicity) and wider applicability
(circumventing cisplatin cross-resistance) can be developed.
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It was previously demonstrated that trans isomers of complexes containing aliphatic
or heterocyclic imines are more photocytotoxic than their cis isomers.20, 23 Also,
replacing NH3 ligands with pyridine (Py) in trans,trans,trans-
[Pt(N3)2(OH)2(NH3)(Py)]21 to form trans,trans,trans-[Pt(N3)2(OH)2(Py)2]24 lead to
higher photocytoxicity for visible light activation. This study reviews that replacing
the NH3 with aliphatic amine or replacing the pyridine by thiazole (Tz) which are
other approaches to obtain potent photocytoxicity and in turn more efficient
anticancer complexes.
Replacing NH3 ligands with aliphatic amines such as methylamine (MA),
dimethylamine (DMA) and isopropylamine (IPA) (Scheme 3.1) or aromatic imines
such as pyridine and thiazole will affect the hydrophilicity/lipophilicity of this type
of complex. This will vary the cellular uptake of the complex and the steric
hinderance of the platinum fragment on platinated DNA. Therefore, it is possible to
obtain higher cytotoxicity by improved cellular accumulation or reduced DNA repair
rate.
Thiazole (Tz) (Scheme 3.1), is a five-membered aromatic ring. The sulfur atom in
Tz is sp2 hybridized, leaving one lone pair in the π system and the other in the plane 
of the ring. Tz is aromatic and very stable to a broad range of reaction conditions.32
Tz ring is widely present in a variety of biomolecules, such as vitamin B1, and it also
exists as a functional group in epothilone, a new cancer drug.33 By replacing the Py
by Tz, it is possible to vary the bulkiness of the molecule and its optical absorption
properties. This in turn will hopefully lead to more efficient platinum complexes and
different activation wavelengths.
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N N
S
NH NH2NH2
methylamine (MA) dimethylamine (DMA) isopropylamine (IPA)
pyridine (PY) thiazole (TZ)
Scheme 3.1 Aliphatic amine/heterocyclic imine ligands used in this Chapter.
This chapter reports the synthesis, characterisation and (photo) cytoxicity of a series
of novel PtIV diazidodihydroxido complexes and their trans platinum(II) dichlorido
precursors. Their toxicities toward several carcinoma cell lines in the presence and
absence of light are reported.
3.2 Experimental
Caution! While no problems were encountered during this work, heavy metal azides
are known to be shock sensitive detonators,34-36 therefore it is essential that any Pt
azido compound is handled with care.
3.2.1 Materials
All materials were used as obtained from commercial sources unless otherwise stated.
K2PtCl4 was obtained from Precious Metal Online and Alfa Aesar, KI, KOH, and
NaCl from Fisher Scientific, AgNO3 from Fluka, NaN3, H2O2 (30%) and all other
chemicals from Sigma-Aldrich. All solvents for common use were analytical reagent
grade from Fisher Scientific and were used as supplied. Distilled water was purified
using a Millipore water purification system. Water used in ICP-OES was purified
using Purelab UHQ water purification system.
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3.2.2 Synthesis and Characterisation
3.2.2.1 Cis-[PtI2(MA)2] (1)
Cis-[PtI2(MA)2] (1) was synthesized according to a reported method.37 K2[PtCl4]
(2.08 g, 5.0 mmol) was dissolved in H2O (30 mL) and KI (8.30 g, 50 mmol) added.
After stirring for 30 min, 40% MA aqueous solution (0.78 mL, 10 mmol) was added.
The mixture was stirred for a further 30 min after which the yellow precipitate was
collected by filtration, washed with cold water, ethanol and diethyl ether and dried
under vacuum.
Yield: 2.18 g (85 %)
1H NMR (400 MHz, MeCN-d3): δ (ppm) 3.90 (broad, NH2, 4H), 2.49 (t, CH3,
3J(195Pt, 1H) = 48 Hz, 6H).
Elemental Analysis: C2H10I2N2Pt, Calc. C 4.70%, H 1.97%, N 5.48%, I 49.67%,
Found: C 4.61%, H 1.87%, N 5.23%, I 49.78%.
3.2.2.2 Cis-[PtCl2(MA)2] (2)
Cis-[PtI2(MA)2] (1.02 g, 2.0 mmol) was suspended in H2O (30 mL) to this AgNO3
(0.76 g, 4.0 mmol) was added. The mixture was stirred at 328 K overnight. AgI
precipitate was filtered off with celite followed by an inorganic membrane filter
(Sartorius, Minisart, 0.2 µm). NaCl (0.47 g, 8.0 mmol) was added and the mixture
was stirred for a further 30 min after which the yellow precipitate was collected by
filtration, washed with minimal cold water, ethanol and diethyl ether then dried
under vacuum.
Yield: 0.61 g (93 %)
1H NMR (400 MHz, MeCN-d3): δ (ppm) 3.90 (broad, NH2, 4H), 2.44 (t, CH3, 3J
(195Pt, 1H) = 48 Hz, 6H).
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Elemental Analysis: C2H10Cl2N2Pt, Calc. C 7.32%, H 3.07%, N 8.54%, Cl 21.61%,
Found: C 7.16%, H 2.94%, N 8.46%, Cl 21.73%.
From this point on all syntheses were carried out under controlled (dim) lighting
conditions.
3.2.2.3 Trans-[Pt(Cl)2(MA)(Py)] (3)
Cis-[PtCl2(MA)2] (0.33 g, 1 mmol) was suspended in 9 mL H2O, then pyridine (240
mg, 3 mmol) was added. The reaction was heated to 353 K with stirring and kept at
this temperature for 90 min. The solution was allowed to cool to room temperature
and HCl (12M, 1 mL) was added and stirred at 368 K for 65h.The flask was cooled
on ice and the product was filtered, washed successively with minimal cold H2O,
ethanol, and diethyl ether and then dried under vacuum. The yellow product was
further purified by recrystallized from 0.1 M HCl.
Yield: 0.306 g (81.3%)
1H NMR (400 MHz, Acetone-d6): δ (ppm) 8.83 (dd, H2, 6, 3J (195Pt, 1H) = 32 Hz, 2H),
7.98 (tt, H4, 1H), 7.45 (ddd, H3, 5, 2H), 4.31 (broad, NH2, 2H), 2.49 (t, CH3, 3J (195Pt,
1H) = 35 Hz, 3H).13C NMR (150.9 MHz, Acetone-d6): δ (ppm) 154.1 (C2, 6), 139.3
(C4), 126.2 (C3), 33.7 (CH3). 195Pt NMR (129.4 MHz, Acetone-d6): δ = −2085.3 ppm. 
ESI-MS: [M − 2Cl − H]+ (m/z) Calc., 304.0, Found, 304.1.
Elemental Analysis: C6H10Cl2N2Pt, Calc., C, 19.16%; H, 2.68%; N, 7.45%; Found, C,
19.26%; H, 2.60%; N, 7.37%.
3.2.2.4 Trans-[Pt(N3)2(MA)(Py)] (4)
Trans-[Pt(Cl)2(MA)(Py)] (0.188 g, 0.5 mmol) was suspended in H2O 50 mL, and
AgNO3 (0.17g, 1.0 mmol) added and the solution stirred at 323 K for 16 h. AgCl
precipitate was filtered off with celite followed by an inorganic membrane filter
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(Sartorius, Minisart, 0.2 µm). NaN3 (0.65g, 10 mmol) was added and the solution
stirred (323 K, 6h) and the volume of the solution was reduced under vacuum to ca.
3 mL and cooled to 277 K overnight. The yellow precipitate was filtered using a
Buchner funnel, washed with minimal ice cold H2O, EtOH, and ether then dried
under vacuum.
Yield: 0.153 g (78.7%)
1H NMR (400 MHz, Acetone-d6): δ (ppm) 8.79 (dd, H2, 6, 3J (195Pt, 1H) = 34 Hz, 2H),
8.08 (tt, H4, 1H), 7.61 (t, H3, 5, 2H), 4.43 (broad, NH2, 2H), 2.50 (t, CH3, 3J (195Pt, 1H)
= 41 Hz, 3H). 13C NMR (150.9 MHz, Acetone-d6): δ (ppm) 153.5 (C2, 6), 139.9 (C4),
127.3 (C3), 33.2 (CH3). 195Pt NMR (129.4 MHz, Acetone-d6): δ = −2202.4 ppm. 
ESI-MS: [M + Na]+ (m/z) Calc., 421.06; Found, 421.0.
3.2.2.5 Trans,trans,trans-[Pt(N3)2(OH)2(MA)(Py)] (5)
Trans-[Pt(N3)2(MA)(Py)] (39 mg, 0.1 mmol) was suspended in H2O2 (20 mL, 30%)
and stirred at 323 K for 1 h. The volume of the solution was reduced using rotary
evaporation to ca. 4 mL, to form a bright yellow solution (usually takes 1~2 hours).
It was important to maintain the temperature below 323 K. Water (50 mL) was
added and the solution was lyophilised. Crystals suitable for X-ray analysis were
obtained via crystallisation in water-ethanol with ether diffusion. The solution was
filtered (Buchner) to collect the product which was washed with minimal ether and
dried under vacuum.
Yield: 21 mg (50 %)
1H NMR (400 MHz, 90% H2O / 10% D2O, pH~5): δ (ppm) 8.72 (d, H2, 6, 3J (195Pt,
1H) = 22 Hz, 2H), 8.30 (t, H4, 1H), 7.84 (t, H3, 5, 2H), 6.65 (broad, NH2, 2H), 2.42 (s,
CH3, 3J(195Pt, 1H) = 28 Hz, 3H). 13C NMR (100.6 MHz, D2O): δ (ppm) 149.60 (C2, 6),
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142.77 (C4), 127.62 (C3, 5, 3J(195Pt, 13C) = 25 Hz), 30.50 (CH3). 195Pt NMR (129.4
MHz, D2O): δ = 888.66 ppm.
ESI-MS: [M + Na]+ (m/z) Calc., 446.1; Found, 446.0.
Elemental Analysis: C6H12N8O2Pt, Calc., C, 17.02%; H, 2.86%; N, 26.47%; Found,
C, 16.87%; H, 2.65%; N, 26.87%.
εmax(289) = 16200 L mol-1 cm-1 (H2O)
3.2.2.6 Trans-[Pt(Cl)2(MA)(Tz)] (6)
Cis-[PtCl2(MA)2] (0.33 g, 1 mmol) was suspended in 9 mL H2O, then thiazole (255
mg, 3 mmol) was added. The reaction was heated to 353 K and stirred for 2 h. The
solution was allowed to cool to room temperature and HCl (12M, 1 mL) was added.
The solution was heated at 368 K and stirred overnight (~16 h). The solution was
cooled on ice and the yellow product was filtered, washed successively with minimal
cold H2O, ethanol, and diethyl ether and then dried under vacuum. The product was
recrystallized from a minimal amount of 0.1 M HCl.
Yield: 0.280 g (73.5%)
1H NMR (400 MHz, Acetone-d6): δ (ppm) 9.50 (d, H2, 3J(195Pt, 1H) = 26 Hz, 1H),
8.26 (d, H4, 3J(195Pt, 1H) = 15 Hz, 1H), 7.81 (dd, H5, 1H), 4.37 (broad, NH2, 2H),
2.50 (t, CH3, 3J(195Pt, 1H) = 36 Hz, 3H). 13C NMR (150.9 MHz, Acetone-d6): δ (ppm)
157.8 (C2), 144.7 (C4), 120.9 (C5), 33.6 (CH3). 195Pt NMR (129.4 MHz, Acetone-d6):
δ = −2111.6 ppm.  
ESI-MS: [M − 2Cl − H]+ (m/z) Calc., 310.0; Found, 310.0.
Elemental Analysis: C4H8Cl2N2PtS, Calc., C, 12.57%; H, 2.11%; N, 7.33%; Found,
C, 12.68%; H, 2.04%; N, 7.46%.
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3.2.2.7 Trans-[Pt(N3)2(MA)(Tz)] (7)
Trans-[Pt(Cl)2(MA)(Tz)] (0.190 g, 0.5 mmol) was suspended in H2O 50 mL, to this
AgNO3 (0.17g, 1.0 mmol) was added and the solution stirred at 323 K for 24 h.
AgCl precipitate was filtered off with celite followed by an inorganic membrane
filter (Sartorius, Minisart, 0.2 µm). NaN3 (0.65g, 10 mmol) was added, the solution
stirred (323 K, 6h) and the solvent reduced under vacuum to ca. 3 mL. The solution
was then cooled before to 277 K overnight. The yellow precipitate was filtered with
a Buchner funnel, washed with minimal ice cold H2O, EtOH, and ether then dried
under vacuum.
Yield: 0.182 g (92%)
1H NMR (400 MHz, Acetone-d6): δ (ppm) 9.44 (d, H2, 3J(195Pt, 1H) = 28 Hz, 1H),
8.14 (d, H4, 3J(195Pt, 1H) = 20 Hz 1H), 7.98 (dd, H5, 1H), 4.54 (broad, NH2, 2H), 2.52
(t, CH3, 3J(195Pt, 1H) = 44 Hz, 3H). 13C NMR (150.9 MHz, Acetone-d6): δ (ppm)
158.0 (C2), 144.3 (C4), 122.7 (C5), 33.4 (CH3). 195Pt NMR (129.4 MHz, Acetone-d6):
δ (ppm) −2203.0 ppm. 
ESI-MS: [M+Na]+ (m/z) Calc., 418.0; Found, 417.9.
3.2.2.8 Trans,trans,trans-[Pt(N3)2(OH)2(MA)(Tz)] (8)
Trans-[Pt(N3)2(MA)(Tz)] (20 mg, 0.05 mmol) was suspended in H2O2 (10 mL, 30%)
and stirred at 323 K for 1 h. The volume of the solution was reduced to ca. 2 mL,
forming a bright yellow solution (usually takes 1~2 hours). It was important to
maintain the temperature below 323 K. Water (50 mL) was added and the solution
was lyophilised. Crystals suitable for X-ray diffraction were obtained via slow
diffusion of ether into water-ethanol. The solution was filtered under vacuum
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yielding a yellow precipitate which was washed with minimal ether and dried under
vacuum.
Yield: 12 mg (56 %)
1H NMR (400 MHz, 90% H2O/10% D2O): δ (ppm) 9.59 (d, H2, 3J(195Pt, 1H) = 16 Hz,
1H), 8.27 (d, H4, 3J (195Pt, 1H) = 14 Hz, 1H), 8.12 (d, H5, 1H), 6.66 (broad, NH2, 2H),
2.37 (s, CH3, 3J(195Pt, 1H) = 29 Hz, 3H). 13C NMR (150.9 MHz, D2O): δ (ppm) 149.6
(C2), 140.4 (C4), 123.6 (C5), 30.39 (CH3).195Pt NMR (129.4 MHz, D2O): δ (ppm)
906.71.
ESI-MS: [M+Na]+ (m/z) Calc., 452.0; Found, 451.9.
Elemental Analysis: C4H10N8O2PtS, Calc., C, 11.19%; H, 2.35%; N, 26.10%; Found,
C, 10.95%; H, 2.26%; N, 25.71%.
εmax(289) = 18600 L mol-1 cm-1 (H2O)
3.2.2.9 Cis-[PtI2(DMA)2] (9)
K2[PtCl4] (2.075 g, 5.0 mmol) was dissolved in H2O (30 mL) and KI (8.300 g, 50
mmol) added. After stirring for 30 min at room temp., DMA (25% in H2O, 1.9 mL,
10.0 mmol) was added. The mixture was stirred for a further 3 h after which the
brown precipitate was collected by filtration, washed with minimal cold water,
ethanol and diethyl ether and dried under vacuum.
Yield: 2.59 g (96.1 %)
1H NMR (400 MHz, Acetone-d6): δ (ppm) 4.95 (broad, NH, 2H), 2.78 (d, CH3, 3J
(195Pt, 1H) = 46 Hz, 12H).
Elemental Analysis: C4H14I2N2Pt, Calc., C, 8.91%; H, 2.62%; I, 47.08%, N, 5.20%;
Found, C, 8.75%; H, 2.35%; I, 46.95%, N, 5.12%.
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3.2.2.10 Cis-[PtCl2(DMA)2] (10)
Cis-[PtI2(DMA)2] (0.539 g, 1 mmol) was suspended in H2O (50 mL) and AgNO3
(340 mg, 2 mmol) was added. The mixture was stirred at 328 K overnight. AgI
precipitate was filtered off with celite followed by an inorganic membrane filter
(Sartorius, Minisart, 0.2 µm). NaCl (234 mg, 4 mmol) was added and the solution
stirred overnight, after which the volume was reduced to 10 mL and the yellow
precipitate was collected by filtration, washed with minimal cold water, ethanol and
diethyl ether and dried under vacuum. The product was recrystallized from a
minimal amount of 0.1 M HCl.
Yield: 278 mg (77 %)
1H NMR (400 MHz, MeCN-d3): δ (ppm) 4.60 (broad, NH, 2H), 2.62 (d, CH3, 3J
(195Pt, 1H) = 41 Hz, 12H).
ESI-MS: [M + Na]+ (m/z): Calc., 378.0; Found, 378.0.
Elemental Analysis: C4H14Cl2N2Pt, Calc., C, 13.49%; H, 3.96%; N, 7.87%; Found, C,
13.16%; H, 3.84%; N, 7.72%.
3.2.2.11 Trans-[PtCl2(DMA)(Tz)] (11)
Cis-[PtCl2(DMA)2] (106 mg, 0.3 mmol) was suspended in 5 mL H2O, then Tz (92
mg, 1.08 mmol) was added. The reaction was heated to 353 K with stirring and kept
at this temperature for 90 min. N.B. This intermediate is light sensitive! The solution
was allowed to cool to room temperature and HCl (12M, 0.5 mL) was added and the
solution was heated at 368 K over the weekend (~65h). The flask was cooled on ice
and the product was filtered, washed successively with minimal cold H2O, ethanol,
and diethyl ether and then dried under vacuum.
Yield: 97.5 mg (82.3%)
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1H NMR (400 MHz, acetone-d6): δ (ppm) 9.48 (d, H2, 3J (195Pt, 1H) = 27 Hz, 1H),
8.23 (d, H4, 1H), 7.81 (dd, H5, 1H), 4.99 (broad, NH, 1H), 2.64 (d, CH3, 3J (195Pt, 1H)
= 31 Hz, 6H). 13C NMR (150.9 MHz, acetone-d6): δ (ppm) 158.3 (C2), 145.0 (C4),
121.1 (C5), 43.8 (CH3). 195Pt NMR (129.4 MHz, acetone-d6): δ (ppm) −2086.1. 
ESI-MS: [M − 2Cl − H]+ (m/z) Calc., 324.0, Found, 324.1.
Elemental Analysis: C5H10Cl2N2PtS, Calc., C, 15.16%; H, 2.54%; N, 7.07%; Found,
C, 15.12%; H, 2.39%; N, 7.01%.
3.2.2.12 Trans-[Pt(N3)2(DMA)(Tz)] (12)
Trans-[PtCl2(MA)(Tz)] (40 mg) was suspended in H2O 25 mL, and AgNO3 (34 mg)
was added and the solution stirred at 333K for 16 h. AgCl precipitate was filtered off
with celite followed by an inorganic membrane filter. NaN3 (65 mg, 10 molar
equivalents) was added and the solution stirred at room temperature for 6h before
cooling to 277 K overnight. The yellow precipitate was filtered, washed successively
with minimal cold H2O, ethanol, and diethyl ether and then dried under vacuum.
Yield: 35 mg (84%)
1H NMR (400 MHz, acetone-d6): δ (ppm) 9.48 (d, H2, 3J (195Pt, 1H) = 22 Hz, 1H),
8.17 (d, H4, 1H), 8.01 (dd, H5, 1H), 4.98 (broad, NH, 1H), 2.63 (d, CH3, 3J (195Pt, 1H)
= 36 Hz, 6H). 13C NMR (150.9 MHz, acetone-d6): δ (ppm) 158.3 (C2), 144.5 (C4),
122.9 (C5), 43.6 (CH3). 195Pt NMR (129.4 MHz, acetone-d6): δ (ppm) −2193.2. 
ESI-MS: [M − 2N3 − H]
+ (m/z) Calc., 324.0, Found, 324.1.
Elemental Analysis: C5H10N8PtS, Calc., C, 14.67%; H, 2.46%; N, 27.37%; Found, C,
14.57%; H, 2.28%; N, 27.13%.
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3.2.2.13 Trans, trans, trans-[Pt(N3)2(OH)2(DMA)(Tz)] (13)
Trans-[PtCl2(MA)(Tz)] (20 mg) was dissolved in H2O2 (10 mL, 30%) and stirred at
323 K for 1 h. The volume of the solution was reduced to ca. 3 mL, forming a dark
yellow solution. It was important to keep the temperature below 323 K. Water (50
mL) was added and the solution was lyophilised. Crystals suitable for X-ray
diffraction were obtained by diffusion of diethyl ether into a solution of product in
water-ethanol.
Yield: 11 mg (51%).
1H NMR (400 MHz, D2O): δ (ppm) 9.54 (d, H2, 3J (195Pt, 1H) = 16 Hz, 1H), 8.26 (d,
H4, 1H), 8.04 (d, H5, 1H), 2.49 (s, CH3, 3J (195Pt, 1H) = 27 Hz, 6H). 13C NMR (150.9
MHz, D2O): δ (ppm) 157.9 (C2), 140.5 (C4), 123.7 (C5), 42.11 (CH3, 2J (195Pt, 13C) =
14.5 Hz).195Pt NMR (129.4 MHz, D2O): δ (ppm) 941.1.
ESI-MS: [M + Na]+ (m/z) Calc., 466.0; Found, 465.9.
Elemental Analysis: C5H12N8O2PtS, Calc., C, 13.55%; H, 2.73%; N, 25.27%; Found,
C, 13.32%; H, 2.62%; N, 25.62%.
3.2.2.14 Trans-[PtCl2(DMA)(Py)] (14)
Trans-[PtCl2(DMA)(Py)](14) was synthesized by a similar procedure as for trans-
[PtCl2(DMA)(Tz)] (11) using Py instead of Tz.
Yield: 81%
1H NMR (400 MHz, acetone-d6): δ (ppm) 8.79 (d, H2, 6, 3J (195Pt, 1H) = 32 Hz, 2H),
7.98 (t, H4, 1H), 7.45 (t, H3, 5, 2H), 4.90 (broad, NH, 1H), 2.63 (d, CH3, 3J (195Pt, 1H)
= 30 Hz, 6H).13C NMR (150.9 MHz, acetone-d6): δ (ppm) 154.3 (C2, 6), 139.4 (C4),
126.2 (C3, 5), 43.7 (CH3). 195Pt NMR (129.4 MHz, acetone-d6): δ (ppm) −2062.2. 
ESI-MS: [M + Na]+ (m/z) Calc., 412.0; Found, 412.1.
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Elemental Analysis: C7H12Cl2N2Pt, Calc., C, 21.55%; H, 3.10%; N, 7.18%; Found, C,
21.72%; H, 3.04%; N, 7.18%.
3.2.2.15 Trans-[Pt(N3)2(DMA)(Py)] (15)
Trans-[Pt(N3)2(DMA)(Py)] (15) was synthesized by a similar procedure as for trans-
[Pt(N3)2(DMA)(Tz)] using complex 14.
Yield: 78.2%
1H NMR (400 MHz, acetone-d6): δ (ppm) 8.81 (d, H2, 6, 3J (195Pt, 1H) = 34 Hz, 2H),
8.08 (tt, H4, 1H), 7.64 (t, H3, 5, 2H), 4.84 (broad, NH2, 2H), 2.61 (d, CH3, 3J (195Pt, 1H)
= 35 Hz, 6H).13C NMR (150.9 MHz, acetone-d6): δ (ppm) 153.9 (C2, 6), 140.1 (C4),
127.5 (C3, 5), 43.5 (CH3). 195Pt NMR (129.4 MHz, acetone-d6): δ (ppm) −2201.0. 
ESI-MS: [M + H]+ (m/z) Calc., 404.1; Found, 404.0.
3.2.2.16 Trans, trans, trans-[Pt(N3)2(OH)2(DMA)(Py)] (16)
Trans, trans, trans-[Pt(N3)2(OH)2(DMA)(Py)] (16) was synthesized by a similar
procedure as for trans, trans, trans-[Pt(N3)2(OH)2(DMA)(Tz)] using complex 15.
Yield: 37%
1H NMR (600 MHz, D2O): δ (ppm) 8.75 (d, H2, 6, 3J (195Pt, 1H) = 24 Hz, 2H), 8.23 (t,
H4, 1H), 7.77 (t, H3, 5, 2H), 2.53 (s, CH3, 3J (195Pt, 1H) = 26 Hz, 6H). 13C NMR (150.9
MHz, D2O): δ (ppm) 149.9 (C2, 6), 142.8 (C4), 127.7 (C3, 5, 3J (195Pt, 13C) = 25 Hz),
42.2 (CH3). 195Pt NMR (129.4 MHz, D2O): δ (ppm) 926.4.
ESI-MS: [M + H]+ (m/z) Calc., 438.1; Found, 438.0.
Elemental Analysis: C7H14N8O2Pt, Calc., C, 19.22%; H, 3.23%; N, 25.62%; Found,
C, 19.28%; H, 3.00%; N, 25.93%.
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3.2.2.17 Cis-[PtCl2(IPA)2] (17)
Cis-[PtCl2(IPA)2] (17) was synthesized by a similar procedure as for cis-
[PtCl2(MA)2] (2), using IPA instead of MA.
Yield: 76%
1H NMR (400 MHz, dmso-d6): δ (ppm) 4.75 (broad, NH2, 2H), 3.11 (septet, CH, 1H),
1.21 (d, CH3, 6H).
Elemental Analysis: C6H18Cl2N2Pt, Calc., C, 18.76%; H, 4.72%; N, 7.29%; Found, C,
18.50%; H, 4.48%; N, 7.06%.
3.2.2.18 Trans-[PtCl2(IPA)(Tz)] (18)
Trans-[PtCl2(IPA)(Tz)] (18) was synthesized by a similar procedure as for trans-
[PtCl2(DMA)(Tz)] (11) using cis-[PtCl2(IPA)2](17).
Yield: 69%
1H NMR (400 MHz, acetone-d6): δ (ppm) 9.52 (d, H2, 3J (195Pt, 1H) = 24 Hz, 1H),
8.28 (d, H4, 1H), 7.81 (dd, H5, 1H), 4.27 (broad, NH, 2H), 3.34 (septet, CH, 1H),
1.38 (d, CH3, 6H).
ESI-MS:  [M − 2Cl − H]+ (m/z) Calc., 338.0, Found, 338.1.
[M + Na]+ (m/z) Calc., 433.0, Found, 432.9.
3.2.2.19 Trans-[PtCl2(IPA)(Py)] (19)
Trans-[PtCl2(IPA)(Py)] (19) was synthesized by a similar procedure as for trans-
[PtCl2(DMA)(Tz)] (11) using Py and trans-[PtCl2(IPA)2] (17).
Yield: 83%
1H NMR (400 MHz, acetone-d6): δ (ppm) 8.84 (dd, H2, 6, 3J (195Pt, 1H) = 30 Hz, 2H),
7.98 (t, H4, 1H), 7.45 (t, H3, 5, 2H), 4.21 (broad, NH2, 2H), 3.34 (septet, CH, 1H),
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1.39 (d, CH3, 6H).13C NMR (150.9 MHz, acetone-d6): δ (ppm) 154.1 (C2, 6), 139.2
(C4), 126.2 (C3, 5), 49.3 (CH), 23.8 (CH3). 195Pt NMR (129.4 MHz, acetone-d6): δ
(ppm) −2088.2. 
ESI-MS: [M − 2Cl − H] (m/z) Calc., 332.1, Found, 332.2.
Elemental Analysis: C8H14Cl2N2Pt, Calc., C, 23.77%; H, 3.49%; N, 6.93%; Found, C,
23.53%; H, 3.36%; N, 6.93%.
3.2.2.20 Trans-[Pt(N3)2(IPA)(Py)] (20)
Trans-[Pt(N3)2(IPA)(Py)] (20) was synthesized by a similar procedure as for trans-
[Pt(N3)2(DMA)(Tz)] (12) using trans-[PtCl2(IPA)(Py)](19).
Yield: 98%
1H NMR (400 MHz, acetone-d6): δ (ppm) 8.80 (dd, H2, 6, 3J (195Pt, 1H) = 30 Hz, 2H),
8.08 (tt, H4, 1H), 7.62 (t, H3, 5, 2H), 4.34 (broad, NH2, 2H), 3.19 (septet, CH,1H),
1.42 (d, CH3, 6H).13C NMR (150.9 MHz, acetone-d6): δ (ppm) 152.5 (C2, 6), 139.0
(C4), 126.3 (C3, 5), 48.3 (CH), 22.8 (CH3). 195Pt NMR (129.4 MHz, acetone-d6): δ
(ppm) −2205.0. 
ESI-MS:  [M − 2Cl − H]+ (m/z) Calc., 332.1, Found, 332.1.
[M + Na]+ (m/z) Calc., 440.1, Found, 440.1.
3.2.2.21 Trans, trans, trans-[Pt(N3)2(OH)2(IPA)(Py)] (21)
Trans, trans, trans-[Pt(N3)2(OH)2(IPA)(Py)] (21) was synthesized by a similar
procedure as for trans, trans, trans-[Pt(N3)2(OH)2(DMA)(Tz)] (13) using trans-
[PtCl2(IPA)(Py)] (19).
Yield: 34%.
1H NMR (400 MHz, D2O): δ (ppm) 8.75 (d, H2, 6, 3J (195Pt, 1H) = 24 Hz, 2H), 8.23 (t,
H4, 1H), 7.78 (t, H3, 5, 2H), 3.29 (septet, CH, 1H), 1.38 (d, CH3, 6H). 13C NMR
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(150.9 MHz, D2O): δ (ppm) 149.5 (C2, 6), 142.8 (C4), 127.6 (C3, 5, 3J (195Pt, 13C) = 25
Hz), 48.4 (CH), 22.44 (CH3, 3J (195Pt, 13C) = 16.6 Hz). 195Pt NMR (129.4 MHz, D2O):
δ (ppm) 935.9.
ESI-MS: [M + Na]+ (m/z) Calc., 474.1. Found, 474.0.
Elemental Analysis: C8H16N8O2Pt, Calc., C, 21.29%; H, 3.57%; N, 24.83%; Found,
C, 21.69%; H, 3.39%; N, 24.51%.
3.2.3 NMR acquisition
NMR data was acquired by the author with the guidance from Dr. Nicola Farrer and
Dr. Ivan Prokes (University of Warwick). Specific parameters, along with other
general parameters for acquisition are found in Chapter 2.
3.2.4 Elemental analysis
Elemental analysis for general samples was performed on an EAI CE440 Elemental
Analyser by the Warwick Analytical Service. For potentially explosive samples
(PtIV-diazido complexes), they were analysed by MEDAC Ltd. in Surrey, UK.
3.2.5 X-ray crystallography
The data collection and analysis were carried out by Dr Guy Clarkson in University
of Warwick. Structures were also analysed by the author. Instrumentation,
acquisition parameters and data processing can be found in Chapter 2.
3.2.6 Cell culture and cytotoxicity for Pt complexes
The photoactivated dose-dependent inhibition to cell viability for light-sensitive PtIV
diazidodihydroxido complexes was determined by Dr Julie A. Woods (University of
Dundee). Cell culture and cytotoxicity for non-light-sensitive PtII dichlorido
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complexes were determined by Dr Ana Pizarro (University of Warwick). Details can
be found in Chapter 2.
3.3 Results and discussion
3.3.1 Synthesis
The platinum(IV)-diazidodihydroxido complexes were synthesized via oxidation of
the respective trans-PtII diazido complexes using a revised reported method.21, 38 All
the new compounds synthesised are listed in Appendix 1. As pictured in Scheme 3.2,
cis-[PtCl2(MA)2], cis-[PtCl2(DMA)2] and cis-[PtCl2(IPA)2] were synthesized
following the method described previously for cisplatin.37, 39 In this step, direct
replacement of Cl− with aliphatic amine ligands L from K2[PtCl4]. This produces
relatively low yields and are often contaminated with impurities such as
“Magnus”green salt [PtL4][PtCl4].40,41 In 1970, Dhara published the procedure for
synthesis of cisplatin which is adapted here.39, 42 The trans effect (see Chapter 1) of
the I− ligand is higher than Cl−. Therefore, excess I− was used in the synthesis to
form [PtI4]2− before the ligand L (e.g. NH3) is added. cis-[PtI2L2] is formed cleanly
without any significant tendency for [PtL4]2+.43 The next step is the removal of
iodido ligands using AgNO3, forming cis-[PtL2(OH2)2] and insoluble AgI. This
precipitate is fine powder and thus is filtered off through celite followed by an
inorganic membrane filter (Sartorius, Minisart, 0.2 µm). After that, NaCl was added
to form cis-[PtCl2L2].
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Scheme 3.2 Synthesis of platinum(IV) diazidodihydroxido complexes.
The synthesis of trans-[PtCl2LL'] was carried out according to the method developed
by Kauffman and Cowan in 1963.11, 44-46 The basis of this method is that the trans
effect of Cl− is slightly stronger than that of heterocyclic imines and aliphatic amine
ligands. In step 5 in Scheme 3.2, the two Cl− in cis-[PtCl2L2] were replaced with L',
forming cis-[PtL'2L2]2+, which is kinetically favoured. In the step 6, the reaction
mixture was refluxed in 1 M HCl at 373 K; this will substitute one of the N-ligands
randomly. Subsequently, the second Cl− substitutes the N-ligand preferentially on the
trans position due to the larger trans-effect of Cl−. Interestingly, the trans-[PtCl2LL']
molecule is neutral and so tends to precipitate in aqueous solution, while the
intermediates cis-[PtL'2L2]2+ and [PtClL2L']+ and any additional side products (e.g.,
[PtCl3L']−) are quite soluble. The replacement of Cl− with an N-ligand is an
equilibrium, and disassociation of an N-ligand from PtII is kinetically much slower
than that of Cl−; thus excess acid must be used to protonate the N-ligand to push this
equilibrium forward.
However, in some cases, step 6 produces the corresponding tetrachloro PtIV species,
trans-[PtCl4LL'], as a side product. Although the facile oxidation of PtII to PtIV in
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aqueous HCl has been observed previously,47-49 the mechanism of oxidation is still
not fully understood.
There is a simplified synthetic route to make such mixed-ligand trans platinum(II)
complexes (Scheme 3.3).10, 46, 48 Silver nitrate was added to cis-[PtCl2L2] to remove
the Cl− and the L’ was added immediately after that. The disadvantage of this route
is that the nitrate can act as an oxidative reagent, especially after HCl is added in the
next step. The reduction potential of HNO3 is +0.96 V, which is much higher than
the reduction potential of cis-[PtIVCl4L2] (ca. −40 mV).50, 51 Therefore, this reaction
tends to generate more PtIV products.46 In this work, this reaction route produced
almost all PtIV tetrachloridoproducts. For this reason, all the trans PtII
dichloridocomplexes were synthesized according to the route described in Scheme
3.2.
Scheme 3.3. Alternative synthetic routes to mixed-ligand trans PtII complexes.
L=heterocyclic imine ligand, L'=aliphatic amine ligand.
In attempting to synthesize trans-[PtCl2(IPA)(Tz)] (18), great difficulty was
encountered to obtain a pure product. Only after three recrystallizations, could a
satisfactory purity be obtained. A number of attempts were made to optimize the
reaction conditions to increase the purity, including changing the molar equivalent of
Tz, the reaction time and temperature. However, the purity could not be substantially
improved. Therefore, the synthesis of diazido species was not attempted.
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It is important to note at this stage that metal azides and high concentrations of H2O2
are dangerous, so care must be taken when handling them. Metal azides are also heat
sensitive, and thus during the oxidation reactions the temperature should be carefully
optimized. In this chapter, 333K is safe for most of the platinum azido complexes
3.3.2 NMR chemical shifts
The 1H (NHx) and 195Pt NMR chemical shifts for PtII dichlorido/diazido and PtIV
diazidodihydroxido complexes are summarized in Table 3.1. The 1H NMR signal for
amine groups in PtII complexes can be easily observed in acetone-d6, as N-H solvent
exchange is sufficiently slow. However, it is often not possible to observe the NHx
signal of PtIV complexes in D2O, due to H-D exchange at ambient temperature (t1/2
ca. a few minutes).52, 53 It is possible to slow down the H-D exchange rate by
lowering the pH. This approach was used to observe amine protons in aqueous
solution. The 1H NMR experiments for PtIV complexes in this work were carried out
in H2O:D2O = 90%:10%, and the pH was adjusted to < 5. In general, the 1H NMR
chemical shifts for NHx in all the PtII complexes are in the range of 4 – 5 ppm, and
are 6 – 7 ppm for the PtIV complexes. Compared to the MA complexes, the 1H
chemical shifts of all DMA complexes shift downfield by 0.5 – 0.6 ppm and all IPA
complexes shift upfield by 0.1 ppm.
The assignments of 195Pt NMR spectra are consistent with published data.54, 55 The
195Pt NMR chemical shifts for the trans-[PtIICl2L2], trans-[PtII(N3)2L2] and trans,
trans, trans-[PtIV(N3)2(OH)2LL'] complexes are close to −2100 ppm, −2200 ppm and 
900 ppm, respectively. In the literature, the 195Pt chemical shifts of trans-{PtIICl2N2}
range from −1950 to −2250 ppm; trans-{PtIIN4} from −2150 to −2650 ppm; trans,
trans-[PtIVN4O2] from 800 to 1200 ppm.56 In general the resonances for PtIV
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complexes appear at lower field than those for their PtII precursors. The chemical
shifts of 195Pt nuclei are very sensitive to the coordinated ligands. Generally speaking,
the order of increased shielding effects of 195Pt for coordinating atoms is: O < Cl−< N
(imine) < Br− <N (amine) < S ~ I− < As < P.54, 55 For example, in the results
presented in Table 3.1 of this thesis, the shielding effect of N3− to 195Pt nuclei is
slightly higher than that for Cl−.
In the formation of the Pt-N σ-bond, the extent of the electron donation of the 
heterocyclic imine ligands is smaller than that of the amine ligands leading to a less
electron shielding on the Pt nucleus. The electron density on the Pt nucleus is thus
reduced, resulting in deshielding of 195Pt nucleus. For instance, the δ(Pt) of trans-
[PtIICl2MA2] and trans-[PtIICl2Py2] are −2181 and −1948,56 respectively, and the
mixed ligand trans-[PtIICl2LL'] complexes in Table 3.1 fall in between.
In the trans-[PtIICl2LL'] complexes, the 1H chemical shifts of NHx in Tz complexes
are at lower field (ca. 0.09 ppm) than the corresponding Py complexes, while the
195Pt chemical shifts are at higher field (ca. 25 ppm). In the trans-[PtII(N3)2LL'] the
changes in aliphatic amine or heterocyclic imine ligands do not alter the chemical
shifts of 195Pt very much, but the chemical shifts of NHx are different. In the trans,
trans, trans-[PtIV(N3)2(OH)2LL'] complexes, the Tz ligand shift the chemical shifts
of 195Pt nuclei downfield by ca. 20 ppm when compared to the corresponding Py
complexes. Therefore, the shielding effect of Py and Tz vary in different types of Pt
complexes.
In summary, a definite relationship between the structures and the amine (imine) 1H
and the 195Pt NMR chemical shifts has been established. The chemical shifts can
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therefore be considered as an unambiguous probe to distinguish the PtII and PtIV
diazidodihydroxido complexes.
Table 3.1 1H (imine/amine) and 195Pt NMR chemical shifts for platinum(II)
dichlorido/diazido and PtIV diazidodihydroxido complexes.
General structures of
complexes
Compound
Number
L' L
δ (1H)
(NHx)
(ppm)
δ (195Pt)
(ppm)
3 Py MA 4.31 −2085.3 
14 Py DMA 4.90 −2062.5 
19 Py IPA 4.21 −2088.2 
6 Tz MA 4.37 −2111.6 
11 Tz DMA 4.99 −2086.1 
18 Tz IPA 4.27 −2113.9 
4 Py MA 4.43 −2202.4 
15 Py DMA 4.84 −2201.0 
20 Py IPA 4.34 −2205.0 
7 Tz MA 4.54 −2203.0 
12 Tz DMA 4.98 −2193.2 
5 Py MA 6.65 888.7
16 Py DMA NT 926.4
21 Py IPA NT 935.9
8 Tz MA 6.66 906.7
13 Tz DMA NT 941.1
NT: not tested.
Last but not least, line broadening of the 195Pt coupled 1H NMR signals due to
chemical shift anisotropy (CSA) relaxation was observed in the 1H NMR spectra of
platinum complexes. Figure 3.2 shows the differences in the shape of 195Pt satellites
of 1H NMR signals for H2,6 of the Py ligand of PtII and PtIV complexes at different
magnetic fields. The effect of CSA relaxation for a particular nucleus is correlated
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with the range of chemical shift for the nucleus. It turns out that 195Pt, which has a
large chemical shift range, also has a large CSA effect.54 Also, the PtII complexes
have square-planar geometry and so a large chemical shift anisotropy. By contrast,
PtIV complexes with higher symmetry (octahedral geometry) are expected to have
smaller anisotropy. The CSA effect influences the proton nucleus coupled to Pt
nucleus. Due to the lower symmetry of the PtII species, their 195Pt satellites are much
broader compared to those in the PtIV complexes.(Figure 3.2) Also, CSA relaxation
increases with the square of the applied magnetic field, nuclear screening anisotropy,
molecular weight and lowering of the temperature.57 As shown in Figure 3.2, at
higher 1H resonance frequency (600 MHz), the Pt satellites on either side of the
proton signal for H2,6 are broader than at lower frequency (400 MHz).57, 58 This effect
is more significant for the PtII complexes compared to the PtIV complexes, as the PtII
complexes have larger CSA. The CSA relaxation is also discussed in Chapter 2.
Figure 3.2 The 1H NMR signal of the H2,6 in the Py ligand of complexes trans-
[Pt(N3)2(IPA)(Py)] and trans, trans, trans-[Pt(N3)2(OH)2(IPA)(Py)] recorded in
different frequencies (400 MHz and 600 MHz).
-50-2502550 -50-2502550 -50-2502550 -50-2502550
Acetone-d6 D2O
400 MHz 600 MHz 400 MHz 600 MHz
Hz Hz Hz Hz
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3.3.3 X-ray structures
Crystals for X-ray diffraction studies of trans, trans, trans-[Pt(N3)2(OH)2(MA)(Py)]
(5), trans, trans, trans-[Pt(N3)2(OH)2(MA)(Tz)] (8), trans, trans, trans-
[Pt(N3)2(OH)2(DMA)(Tz)] (13) and trans, trans, trans-[Pt(N3)2(OH)2(DMA)(Py)]
(16) were obtained by diffusion of diethyl ether into an ethanolic solution of the
product at 298 K. The crystallographic data are summarized in Table 3.2.
Table 3.2 Crystallographic data for complex 5p, 5q, 8, 13 and 16.
Complex 5p 5q 8 13 16
Chemical
structure
Empirical
formula
C6H12N8O2Pt C6H12N8O2Pt C4H10N8O2PtS C5H12N8O2PtS C7H14N8O2Pt
Formula
weight
423.33 423.33 429.35 443.38 437.35
Crystal
description
Block Block Block Block Block
Crystal
colour
Yellow Yellow Yellow Yellow Yellow
Crystal
system
Triclinic Monoclinic Orthorhombic Triclinic Monoclinic
Space group P-1 C2/c P2(1)2(1)2(1) P-1 P2(1)/c
a (Å) 8.0249(5) 17.4032(5) 6.84656(14) 7.9713(13) 18.2758(7)
b (Å) 8.2392(5) 5.7967(2) 12.5237(2) 8.9621(17) 13.7047(5)
c (Å) 8.6317(5) 22.7173(8) 12.9730(3) 9.1501(17) 10.2777(4)
α (°) 84.236(5) 90 90 75.237(16) 90
β (°) 79.453(5) 93.863(3) 90 78.152(15) 90.026(4)
γ (°) 83.981(5) 90 90 84.912(15) 90
Volume (Å3) 556.05(6) 2286.54(13) 1112.36(4) 618.18(19) 2574.20(17)
Z 2 8 4 2 8
Pt
NH2CH3
N3
N3
N
OH
OH
Pt
NH2CH3
N3
N3
OH
OH
N
S
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Dcalcd (g/cm3) 2.528 2.459 2.564 2.382 2.257
F (000) 396 1584 800 416 1648
μcalcd (mm-1) 12.624 12.280 12.804 11.524 10.912
Measurement
temp. (K)
100(2) 100(2) 100(2) 296(2)K 100(2)
θ Range (°) <32.74 <32.76 <32.65 <31.06 <29.40
Reflections
collected
11442 13569 14240 10824 9565
Independent
reflections
3781 3836 3812 3574 5619
Goodness-of-
fit F2
1.104 0.971 1.030 0.994 1.093
Conventional
R1
0.0224 0.0249 0.0216 0.0453 0.0398
wR2 0.0579 0.0556 0.0467 0.1087 0.0999
3.3.3.1 Trans, trans, trans-[Pt(N3)2(OH)2(MA)(Py)] (5)
Two different crystal structures were isolated and analysed for complex 5 (Figure
3.3 for 5p and 5q), which were the first polymorphs found for PtIV-diazido
complexes. The two structures have identical formulae, with the PtIV adopting
octahedral geometry, but their lattice system, space group and the dimensions of unit
cells are different. The structure 5p adopts the triclinic lattice system, the space
group is P-1 and the unit cell has two molecules, whereas the structure 5q adopts the
monoclinic lattice system, the space group is C2/c and the unit cell has eight
molecules. It is of interest that their azido groups adopt different orientations. The
dihedral angles of NPy–Pt–N9–N10 and NPy–Pt–N12–N13 are −34° and 97°, 
respectively, in the structure of 5p, whereas the corresponding angles in the structure
of 5q are −6° and −23°.  
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Figure 3.3 X-ray crystallographic structure of complexes 5p and 5q with ellipsoids
set at 50% probability. (100 K)
The different orientations of the azido ligands are influenced by the intra- and
intermolecular H-bonds (see Figure 3.4 and 3.5). It is widely acknowledged that the
hydrogen bond is an attractive interaction between a hydrogen atom from a molecule
or a molecular fragment D–H in which D (donor) is more electronegative than H,
and an atom A (acceptor) or a group of atoms in the same or a different molecule
(D−H∙∙∙A).59 Generally, the H∙∙∙A lengths below 1.5 Å, from 1.5 to 2.2 and from 2.2 
5p
5q
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to 3.2 are regarded to be strong, medium and weak H-bonds respectively.60 The
preferred donor (D) and acceptor (A) atoms are F, O and N, etc. C−H can also form 
weak H-bonds in the presence of strong acceptors. As shown in Figure 3.4 and 3.5,
in the crystal structures of 5p and 5q, medium H-bonds are in many cases formed
with the types of O−H∙∙∙N, N−H∙∙∙O and O−H∙∙∙O, while weak H-bonds are formed 
as intramolecular O−H∙∙∙N, C−H∙∙∙N and intermolecular C−H∙∙∙N. The angles of 
D−H∙∙∙A are between 90° and 180°.  
Figure 3.4 Extensive intra- and inter- molecular H-bonds network formed by azido
and hydroxido ligands in the structure of 5p which determines the orientation of the
azido ligands.
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Figure 3.5 Extensive intra- and inter-molecular H-bonds network involving azido
and hydroxido ligands in the structure of 5q which determine the orientation of the
azido ligands.
In the structures of 5p and 5q, Pt–N and Pt–O bond lengths are similar to those of
related published complexes, e.g., trans, trans, trans-[Pt(N3)2(OH)2(NH3)(Py)]
(22),21 trans, trans, trans-[Pt(N3)2(OH)2(NH3)(Tz)](23)38 and trans, trans, trans-
[Pt(N3)2(OH)2(Py)2](24),24 and the azido groups are approximately linear (N–N–N
angles 174° − 175°). Selected bond length and angles are listed in Table 3.3.
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Table 3.3 Selected bond lengths [Å] and angles [°] for structures 5p and 5q.
Bond/angle 5p 5q
Pt(1)-O(16) 2.006(2) 2.005(2)
Pt(1)-O(15) 2.013(2) 2.011(2)
Pt(1)-N(12) 2.044(3) 2.026(3)
Pt(1)-N(7) 2.048(3) 2.056(3)
Pt(1)-N(9) 2.049(3) 2.063(3)
Pt(1)-N(1) 2.055(3) 2.068(3)
O(16)-Pt(1)-O(15) 176.41(8) 176.65(10)
N(12)-Pt(1)-N(9) 174.90(10) 176.43(13)
N(7)-Pt(1)-N(1) 177.38(9) 176.10(11)
N(10)-N(9)-Pt(1) 118.7(2) 115.4(2)
N(11)-N(10)-N(9) 174.6(3) 174.9(4)
N(13)-N(12)-Pt(1) 117.1(2) 116.2(2)
N(14)-N(13)-N(12) 174.6(4) 175.5(4)
In the structures of 5p, an offset π – π stacking interaction between two neighbouring
pyridines was observed (Figure 3.6). The π – π stacking interactions adopt a “face-
to-face” geometry and the two pyridine planes have a centroid-centroid distance of
3.95 Å. These rings are parallel as they are related by an inversion centre. According
to a search in Cambridge Structural Database (CSD) to the reported π – π stacking
between metal coordinated pyridines,61 up to the year of 2000, the relative maximum
of the centroid–centroid contacts between two pyridine fragments in the number of
examples was found around 3.8 Å. Therefore, the π – π interaction in 5p is medium-
weak. Generally, there are two conformation of π – π stacking: face-to-face and T-
shape. Face-to-face stacking does not necessarily have to be a perfect face-to-face
alignment of the aromatic rings but can also be oﬀset or slipped packing. As shown
Chapter 3 — Develop Novel Photoactivatable Anticancer Pt Complexes
111
in Figure 3.6 for structure 5p, the parallel displacement of two centroids is ca. 2.4 Å,
which is a relative large value.
Figure 3.6 The “face-to-face” π–π stacking interactions in structure of 5p between
two parallel Py ligands in adjacent molecules (centroid-centroid distance, 3.949 Å).
In the structure of 5q, a zigzag chain of Py fragments was found along the a axis
(Figure 3.7). The centroid-centroid distances between neighbouring Py rings are
4.89 and 5.43Å, respectively and the angle of the two Py planes is 60.2°. These
centroid-centroid distances and the inter-plane angles are too large to classify this as
π–π stacking. Previous studies61 have shown that the majority of intermolecular
metal coordinated-pyridine plane contacts are close to parallel with a certain amount
of displacement. Also, centroid-centroid distances over 4.6 Å are not considered to
be π–π stacking.
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Figure 3.7 A zigzag chain of pyridines along the a axis in structure of 5q. The
centroid-centroid distances between neighbouring Py rings are 4.889 and 5.433 Å,
respectively. The angles of two Py planes are 60.20°.
3.3.3.2 Trans, trans, trans-[Pt(N3)2(OH)2(MA)(Tz)] (8)
In the structure of trans, trans, trans-[Pt(N3)2(OH)2(MA)(Tz)](8), PtIV adopts an
octahedral geometry (Figure 3.8). In previous published X-ray crystal structures of
PtII and PtIV thiazole complexes trans-[PtCl2(Tz)2],62 trans-[PtCl2(NH3)(Tz)]63 and
trans, trans, trans-[Pt(N3)2(OH)2(NH3)(Tz)],38 platinum is always bound to the
nitrogen atom of thiazole. Calculations on the electron density of thiazole have
shown that the net charge of the thioether-type sulphur is positive,63 whereas the
negative charge is located on the nitrogen and it is therefore a much better donor to
platinum. For this reason, in complex 8, it was assigned that thiazole bind through
the nitrogen. Various levels of intra- and inter-molecular H-bonds were also found
between Nα and Nγ in azido group and adjacent protons of hydroxido ligands. The
extensive H-bonds network is depicted in Figure 3.9, in which the shortest contact is
1.84Å. In the structure of 8, Pt–N and Pt–O bond lengths are similar to those of
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published complexes,21, 24, 38 and the azido groups are approximately linear (N–N–N
angles 173° – 174°) (Table 3.4).
Figure 3.8 X-ray crystal structure of trans, trans, trans-[Pt(N3)2(OH)2(MA)(Tz)] (8)
with ellipsoids set at 50% probability. (100 K)
Figure 3.9 Extensive intra- and inter-molecular H-bonds networks involving azido
and hydroxido ligands in the crystal structure of trans, trans, trans-
[Pt(N3)2(OH)2(MA)(Tz)] (8).
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Table 3.4 Selected bond lengths [Å] and angles [°] for trans, trans, trans-
[Pt(N3)2(OH)2(MA)(Tz)] (8).
Bond/angle Å/°
Pt(1)-O(14) 2.010(3)
Pt(1)-O(15) 2.021(2)
Pt(1)-N(6) 2.032(3)
Pt(1)-N(8) 2.041(3)
Pt(1)-N(1) 2.049(3)
Pt(1)-N(11) 2.061(3)
O(14)-Pt(1)-O(15) 178.40(12)
N(6)-Pt(1)-N(1) 176.99(13)
N(8)-Pt(1)-N(11) 175.70(13)
N(9)-N(8)-Pt(1) 117.5(3)
N(10)-N(9)-N(8) 174.6(5)
N(12)-N(11)-Pt(1) 116.6(3)
N(13)-N(12)-N(11) 173.7(4)
3.3.3.3 Trans, trans, trans-[Pt(N3)2(OH)2(DMA)(Tz)] (13)
In the crystal structure of trans, trans, trans-[Pt(N3)2(OH)2(DMA)(Tz)] (13), PtIV
again adopts an octahedral geometry (Figure 3.10). The thiazole was refined as
disordered over two positions by rotation of 180 degrees about the Tz N-Pt bond in a
ratio of 70:30. Similar to complex 8, it was assigned that Tz bonding was through the
nitrogen atom. Various levels of intra- and inter- molecular H-bonds were found
between Nα of the azido group and adjacent NH or OH protons, (Figure 3.11) in
which the shortest contact is 1.89 Å. In this structure, there are also very weak π–π
stacking interactions adopting “face-to-face” geometry and the centroid-centroid
distance of the rings is 4.455 Å (Figure 3.12). In the structures of 13, Pt–N and Pt–O
bond lengths are similar to those of related published complexes,21, 24, 38 and the
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azido groups are close to linear (N–N–N angles 173° – 175°). Selective bond length
and angles are listed in Table 3.5.
Figure 3.10 X-ray crystal structure of trans, trans, trans-
[Pt(N3)2(OH)2(DMA)(Tz)](13) with atom numbering. The minor disordered
component of the thiazole ring has been removed for clarity. Ellipsoids are set at 50%
probability. (296 K)
Figure 3.11 Intra- and inter- molecular H-bonds in the X-ray crystal structure of
trans, trans, trans-[Pt(N3)2(OH)2(DMA)(Tz)] (13)
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Figure 3.12 The weak “face-to-face” π–π stacking interactions in structure of 13
between two parallel Tz ligands in neighbouring molecules (centroid-centroid
distance, 4.455 Å).
Table 3.5 Selected bond lengths [Å] and angles [°] for trans, trans, trans-
[Pt(N3)2(OH)2(DMA)(Tz)] (13).
Bond/angle Å/°
Pt(1)-O(10) 2.021(6)
Pt(1)-O(9) 2.022(5)
Pt(1)-N(14) 2.050(6)
Pt(1)-N(6) 2.059(7)
Pt(1)-N(11) 2.064(6)
Pt(1)-N(1) 2.071(18)
O(10)-Pt(1)-O(9) 178.6(2)
N(1A)-Pt(1)-N(6) 179.1(12)
N(14)-Pt(1)-N(11) 178.0(3)
N(6)-Pt(1)-N(1) 172.9(4)
N(12)-N(11)-Pt(1) 117.2(5)
N(13)-N(12)-N(11) 174.9(9)
N(15)-N(14)-Pt(1) 116.9(6)
N(16)-N(15)-N(14) 173.1(9)
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3.3.3.4 Trans, trans, trans-[Pt(N3)2(OH)2(DMA)(Py)] (16)
The crystal trans, trans, trans-[Pt(N3)2(OH)2(DMA)(Py)] (16) chosen was refined as
monoclinic with a beta angle very close to 90° (90.026°) emulating orthorhombic.
The asymmetric unit contains two molecules. The PtIV adopts an octahedral
geometry (Figure 3.13) and the Pt–N and Pt–O bond lengths are similar to those of
related published complexes (Table 3.6).20,23,36 Various levels of intra- and inter-
molecular H-bonds were found between Nα of the azido group and adjacent NH or
OH protons are depicted in Figure 3.14, in which the shortest contact is 1.83 Å.
There is no observed π–π stacking interaction between the pyridine rings in this 
structure as the closest contact is >5 Å away.
Figure 3.13 X-ray crystal structure of trans, trans, trans-
[Pt(N3)2(OH)2(DMA)(Py)](16) with atom numbering. The asymmetric unit contains
two molecules. Ellipsoids are set at 50% probability. (100 K)
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Figure 3.14 Intra- and inter-molecular H-bond network in the X-ray crystal structure
of trans, trans, trans-[Pt(N3)2(OH)2(DMA)(Py)] (16)
Table 3.6 Selected bond lengths [Å] and angles [°] for trans, trans, trans-
[Pt(N3)2(OH)2(DMA)(Py)] (16). A comparison is made between the two molecules
in the asymmetric unit Pt(1) and Pt(2).
Bond/angle Å/° Bond/angle Å/°
Pt(1)-O(210) 2.003(5) Pt(2)-O(110) 2.020(5)
Pt(1)-O(211) 2.008(5) Pt(2)-O(111) 2.000(5)
Pt(1)-N(215) 2.052(7) Pt(2)-N(115) 2.069(7)
Pt(1)-N(212) 2.059(7) Pt(2)-N(112) 2.036(6)
Pt(1)-N(201) 2.062(7) Pt(2)-N(101) 2.031(7)
Pt(1)-N(207) 2.074(6) Pt(2)-N(107) 2.057(8)
O(210)-Pt(1)-O(211) 179.3(3) O(111)-Pt(2)-O(110) 178.6(2)
N(215)-Pt(1)-N(212) 179.2(3) N(112)-Pt(2)-N(115) 179.5(3)
N(201)-Pt(1)-N(207) 178.0(3) N(101)-Pt(2)-N(107) 176.6(3)
N(213)-N(212)-Pt(1) 116.1(6) N(113)-N(112)-Pt(2) 116.4(5)
N(214)-N(213)-N(212) 174.2(9) N(114)-N(113)-N(112) 176.6(9)
N(216)-N(215)-Pt(1) 115.7(5) N(116)-N(115)-Pt(2) 112.7(5)
N(217)-N(216)-N(215) 174.2(9) N(117)-N(116)-N(115) 176.3(9)
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3.3.4 Photocytotoxicity of platinum(IV) diazidodihydroxido complexes
The photoactivated dose-dependent inhibitions to cell viability (IC50 values against a
number of human cell lines) for complexes 5 and 8 are summarised in Table 3.7.
The corresponding data for cisplatin, trans, trans, trans-[Pt(N3)2(OH)2(NH3)(Py)]
(22),21 trans, trans, trans-[Pt(N3)2(OH)2(NH3)(Tz)] (23)38 and trans, trans, trans-
[Pt(N3)2(OH)2(Py)2] (24),24 are also listed for comparison. In the absence of light,
complexes 5 and 8 were not substantially cytotoxic to HaCaT (human keratinocytes),
A2780 (cisplatin sensitive ovarian adenocarcinoma cells), A2780cis (the cisplatin-
resistant subline of A2780) or OE19 (oesophageal adenocarcinoma cells) under the
experimental conditions used. However, upon irradiation with UVA (λmax = 365 nm),
the cytotoxicities of complexes 5 and 8 towards the above cells were increased and
were observed to be greater than that of cisplatin (50 – 65-fold) under the
experimental conditions used (light dose 5 J/cm2). It is notable that towards HaCaT
cells, complexes 5 and 8 were more potent with activation by UVA or blue light
(TL03 lamp, λmax = 420 nm) than complexes 22 and 23. Although complexes 5 and 8
were slightly less photocytotoxic against A2780 cells upon irradiation with UVA
than the previously reported complexes 22 and 24, they were ca. 3-fold more toxic
towards the cisplatin-resistant subline A2780cis. The resistance factor (RF, IC50
resistant/parent line)9 for complexes 5 and 8 are about 1.9 and 1.6, respectively,
much lower than that for complexes 22, 23 and 24 (8.9, 2.9 and 10.3). Upon
irradiation with TL03, complexes 5 and 8 were still highly cytotoxic against A2780,
A2780cis and OE19 cell lines, although they were generally less potent than upon
irradiation with UVA. Remarkably, the photocytotoxicity of complex 5 against
OE19 cell lines and complex 8 against A2780 cell lines upon irradiation with blue
light was comparable to the cytotoxicity upon irradiation with UVA. When
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comparing complexes 5 and 8, it was observed that 5 was slightly more active
against HaCaT, A2780 and A2780cis cell lines upon irradiation with UVA and
against OE19 cell lines with TL03, while complex 8 was more active towards OE19
cells upon irradiation with UVA and towards HaCaT, A2780 cell lines upon
irradiation with TL03.
Table 3.7 Phototoxicity (IC50 valuea/μM) of trans, trans, trans-
[Pt(N3)2(OH)2(MA)(Py)] (5) and trans, trans, trans-[Pt(N3)2(OH)2(MA)(Tz)] (8),
with comparison to cisplatin, complexes 22, 23 and 24.
Complex
HaCaT A2780 A2780cis OE19
UVA TL03b shame UVA TL03 sham UVA TL03 sham UVA TL03 sham
5 2.6 15.0 >236.3c 2.3 34.3 >236.3 4.4 14.1 >236.3 10.1 13.9 >236.3
8 3.5 11.2 >232.9 3.2 2.2 >232.9 5.3 14.0 >232.9 6.2 19.3 >232.9
2221 6.8 85.9 >244.4 1.9 NTd >244.4 16.9 NT >244.4 10.0 NT >244.4
2364 4.5 19.8 >241.0 5.5 NT 186.9 16.2 NT >241.0 NT NT NT
2424 2.2 6.8 >212.3 1.4 NT >212.3 14.5 NT >212.3 4.7 8.4 >212.3
Cisplatin
(26)
144.0 NT 173.3 151.3 NT 152.0 261.0 NT 229.0 NT NT NT
a IC50 is the concentration of complex that inhibited cell growth by 50%. The lower
value indicates higher toxicity to cells. Each value is mean of two or three
independent experiments.
b TL03 is a blue light lamp (λmax = 420 nm).
c > indicates IC50 greater than the concentration range used.
d not tested.
e sham: dark control.
By comparing complexes 5, 8 and 22 – 24, several structure-activity relationships
can be established. (a) Substituting pyridine by thiazole can improve the
photocytotoxicity towards HaCaT and A2780 cell lines upon irradiation with blue
light. (b) Changing NH3 to MA can in many cases increase the cytotoxicity upon
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irradiation with UVA towards HaCaT, A2780, A2780cis and OE19 cell lines, and
the phototoxicity towards HaCaT cell lines upon irradiation with TL03 was
substantially increased. (c) The complexes with MA were very potent towards
A2780cis cells upon irradiation with UVA, with a resistance factor < 2. Even upon
irradiation with blue light, the IC50 values were still smaller than the other
compounds upon irradiation with UVA.
The differences in photocytotoxicity values may depend on a number of factors. The
cells are very sensitive towards even very tiny changes in the structures of
complexes. Firstly, different aliphatic amine and heterocyclic imine groups have
effects on the photochemistry of the complexes. The extinction coefficient,
photochemical reaction rate and extent can be very different. A study to explore this
difference is carried out in Chapter 4. Secondly, different aliphatic amine and
heterocyclic imine groups also change the hydrophilicity/lipophilicity of the
complexes and the shape of the molecules which can impact on their cellular uptake
and accumulation within the cell. Furthermore, if the complexes bind to DNA and
this plays a role in the mechanism of action then the ligands will affect DNA
distortions, such as bending, kinking and unwinding. Experiments related to these
possibilities are currently being carried by our collaborators. Thirdly, it was of
interest to discover that complexes 5 and 8 exhibit lower cross-resistance to cisplatin
towards A2780cis cell lines than the other complexes. A2780cis is an acquired
cisplatin-resistant subline derived from A2780 ovarian carcinoma cells.65 One or
more of the following mechanisms may correspond to the resistance: insufficient
platinum may reach and bind to the target DNA (by reduced accumulation or
increased cytoplasmic detoxification by cellular thiols); increased DNA
repair/tolerance of platinum-DNA adducts may lead to failure to achieve cell death.6,
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66 Experiments designed to explore these possibilities are also being carried by our
collaborators.
3.3.5 Cytotoxicity of platinum(II) precursors
In trans, trans, trans-[Pt(N3)2(OH)2LL'], N3− and OH− are leaving groups upon
irradiation with light, and the L and L' groups can be regarded as non-leaving
groups.67, 68 After binding to DNA, L and L' remain with the Pt on the DNA lesion
(also see Chapter 4). Therefore, it is reasonable to assume that the PtII complexes
with the formula trans-[PtCl2LL'] may partly have similar properties as the PtIV
diazidodihydroxido complexes. In other words, the PtIV diazidodihydroxido
complexes can act to a certain extent as the prodrugs of the corresponding trans-
[PtCl2LL'] complexes.
Although transplatin is not active towards cancer cells, a number of novel platinum
complexes with trans-geometry have been found to be very toxic to cancer cells.69-71
More importantly, these complexes often act with mechanisms different from that for
cisplatin, so as to circumvent cisplatin resistance. If the DNA binding behaviour of
complexes 5 and 8 is different from cisplatin, but similar to transplatin or other trans
platinum complexes, this would contribute to their lower resistance factors.
In order to investigate the similarity and difference between the PtIV
diazidodihydroxido complexes and their PtII dichlorido analogues trans-[PtCl2LL'],
the cytotoxicities of complexes trans-[PtCl2(MA)(Py)] (3), trans-[PtCl2(MA)(Tz)]
(6), trans-[PtCl2(DMA)(Tz)] (11), trans-[PtCl2(DMA)(Py)] (14) and trans-
[PtCl2(IPA)(Py)] (17) were determined. The toxicity was not photoinduced, as they
are not photoactive. To the best of the author’s knowledge, no cytotoxicity data for
this class of trans-PtII complexes with mixed aliphatic amine/heterocyclic imine
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ligands has been previously reported. The data and comparison with cisplatin are
listed in below (Table 3.8). Although the cell-line examined in this experiment was
limited to A2780 only, some useful results and conclusions can be obtained. This
class of complexes is very potent tytotoxic towards the A2780 cells compared to the
published trans-PtII compounds.72-75 The IC50 values of complex 3, 11 and 14 are
comparable to cisplatin despite having a trans geometry. The details of mechanism
of action have yet to be fully elucidated. Complex 3 is ca. three times more cytotoxic
compared to complex 6 against A2780 cells. However, the difference in
photocytotoxicity of corresponding PtIV diazidodihydroxido complexes 5 and 8 is
small. The difference can be attributed to their photochemistry, as will be explored in
Chapter 4.
Table 3.8 Cyototoxicity data for a series of trans-[PtCl2LL'] complexes towards the
A2780 cell linea in comparison with cisplatin.
Compound
No.
L/L'
IC50/μMb
(A2780)
3 MA/Py 2.4±0.7
6 MA/Tz 6.9±2.3
11 DMA/Tz 2.1±0.3
14 DMA/Py 2.3±0.3
17 IPA/Py 5.9±0.9
Cisplatin – 1.5±0.3
a This experiment was carried out in ambient light conditions.
b Each value is mean of two independent experiments.
In summary, complexes 3 and 6, as the precursors of complexes trans, trans, trans-
[Pt(N3)2(OH)2(MA)(Py)] (5) and trans, trans, trans-[Pt(N3)2(OH)2(MA)(Tz)] (8), are
also highly cytotoxic to cancer cells (Table 3.8). The IC50 values of complexes 11,
14 and 17 towards A2780 cells are also within the micromolar range. Although
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cytotoxicity testing for all PtIV complexes is on-going, there appears to be a
relationship between the photocytotoxicity of the PtIV complexes and the cytotoxicity
of their PtII precursors.
3.4 Conclusion
A series of platinum(IV) diazidodihydroxido complexes has been synthesized and
characterized and their activities as photoactivatable anticancer prodrugs has been
determined. Their X-ray crystal structures have been determined and interesting H-
bond and π-π stacking effects have been found. The 195Pt NMR chemical shifts and
chemical shift anisotropy (CSA) relaxation in the 1H NMR spectra for the new
platinum complexes have been studied. The replacement of NH3 by methylamine
dramatically improved the photocytotoxicity against A2780 cisplatin-resistant
ovarian cancer cells upon irradiation with UVA. When they were irradiated with
blue light (420 nm), the photocytotoxicity against the A2780, A2780cis, OE19 and
HaCaT cell lines are still potent. These results suggest that these complexes are
promising candidates for use in the cancer photochemotherapy of thin-walled organs.
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4.1 Introduction
The photochemical properties of Pt compounds were first recognized in
photographic processes during the 1850s.1 In the 1970s, the earliest examinations of
the photoreduction and photo-solvation of platinum(IV) complexes, namely
[Pt(CN)4Cl2]2− and [Pt(CN)4(N3)2]2−, were reported.2 In the cases of chlorido PtIV
complexes, photoisomerisations, photosubstitutions and photoaquations are common,
whereas for PtIV azido and nitrito complexes, photoreductions prevail. For example,
irradiation into the LMCT bands of [Pt(CN)4(N3)2]2− leads to [Pt(CN)4]2− and two
•N3 radicals, via a simultaneous two-electron reduction avoiding a PtIII intermediate.3
The charge transfer transition from orbitals of the ligand to the d orbitals of the metal
(LMCT) can cause reductive eliminations whereby the leaving ligand(s) is (are)
oxidized.4 In addition, LMCT can also cause ligand substitutions, the pathway of
which depends significantly on the nature of the leaving ligand and the solvent.
Usually, a mixture of photo-reductions and photo-substitution occurs. Thus, the
photochemistry of Pt complexes is not easily predictable and the photoproducts must
be investigated carefully to establish the pathway(s).
The photochemistry of photoactivatable PtIV diazidodihydroxido anticancer
complexes, namely, trans,trans,trans-[Pt(N3)2(OH)2(NH3)2], cis,trans,cis-
[Pt(N3)2(OH)2(NH3)2] and trans,trans,trans-[Pt(N3)2(OH)2(NH3)(Py)](22), has been
studied during the last six years.5-10 On the one hand, in the absence of light, these
complexes exhibit minor or very low cytotoxicity towards cancer cells. In cell-free
media or aqueous solutions, they do not react with biological reductants, e.g.,
glutathione (GSH), neither do they react with 5'-guanosine monophosphate (5'-GMP)
or DNA. On the other hand, upon irradiation with UVA or blue light, these
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complexes undergo rapid N3 ligand substitution and form various hydrolysis
products.5, 6 The photodecomposition of complexes trans,trans,trans-
[Pt(N3)2(OH)2(NH3)2] or cis,trans,cis-[Pt(N3)2(OH)2(NH3)2] was reported to involve
the generation of N3− anions, N3• radicals, nitrogen gas and oxygen gas.7, 8 Some
platinum(III) and nitrene intermediates can also be captured during the photolysis of
trans,trans,trans-[Pt(N3)2(OH)2(NH3)(Py)](22).9, 11 It was also reported that upon
irradiation with UVA, this type of complex may also generate oxygen gas (O2),7, 8
but no direct evidence has been previously reported for the energy state of the
released oxygen. In the presence of 5'-GMP in aqueous solution, these complexes
can be rapidly reduced to PtII species upon irradiation with UVA/blue light,
producing trans azido/guanine and trans diguanine PtII adducts. In vitro, upon
irradiation with UVA/blue light, these complexes display potent photocytotoxicity to
a range of cancer cells by binding to DNA and thus causing cell death (other possible
mechanisms may also be involved).
In Chapter 3, it was demonstrated that replacing the NH3 ligand by aliphatic amine
in trans,trans,trans-[Pt(N3)2(OH)2(NH3)(Py)](22) can produce potent
photocytotoxicity (especially to cisplatin-resistant cancer cells) and higher activity
by blue light. In this Chapter, the photochemistry of the complexes with a
methylamine and a heterocyclic imine group (pyridine/thiazole) is explored by 1H
NMR, 14N NMR, UV-Vis, electron paramagnetic resonance (EPR) spectroscopy and
gas phase chromatography (GC). The photoreactions of these complexes with 5'-
GMP were also studied by 1H NMR, 195Pt NMR, HPLC-MS and high-resolution
mass spectrometry (HR-MS). Their photoreactions with a single strand DNA short
oligonucleotide were investigated by HR-MS.
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Also in this Chapter, the energy state of the oxygen gas released from the
photodecomposition of PtIV diazidodihydroxido complexes was studied by a singlet
oxygen (1O2) fluorescence probe. Singlet oxygen is a very reactive and toxic species
and it reacts with various biomolecules, including several amino acids, and some
DNA bases (preferentially guanosine).12-14 It has been proved to be an important
source of oxidative DNA damage15 and the major cytotoxic species in photodynamic
therapy (PDT).16 The most common method to generate 1O2 is photosensitization,
which produces 1O2 by energy transfer from a photo-excited sensitizer to ground
state oxygen (triplet state, 3O2).17 The reaction of hydrogen peroxide with
hypochlorite in water can also generate 1O2.18 It has been reported that platinum
complexes can work as 1O2 photosensitizers and generate 1O2 by energy transfer
processes involving PtII complexes in their MLCT excited states.19, 20 These
strategies require the availability of oxygen at the target site. However, tumour cells
can be hypoxic due to the rapid growth. In this Chapter, it was discovered that 1O2
was released intrinsically, independent of dissolved O2, from the photoreaction of
trans,trans,trans-[Pt(N3)2(OH)2(MA)(Py)](5), which may partly contribute to its
high photocytotoxicity. This is the first discovery of a PtIV diazidodihydroxido
complex which release singlet oxygen upon irradiation with UVA or blue light in the
absence of any exogenous source of oxygen gas.
4.2 Experimental
4.2.1 Materials
All chemicals used were obtained from Sigma-Aldrich or Fisher Scientific, if
unspecified. The water used in the experiments was deionised water from a Millipore
water purification system. D2O and 5'-guanosine monophosphate (5'-GMP) were
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obtained from Sigma-Aldrich, 15N-labelled NaN3 (1-15N, >98%) from Cambridge
Isotopes Lab, 5, 5-dimethyl-pyrroline-N-oxide (DMPO) from Enzo Life Sciences (≥ 
98%). Quartz tubes (1.0 mm ID × 1.2 mm O.D) were purchased from Wilmad
Labglass. A 50 µL Hamilton HPLC syringe needle was purchased from Hamilton
Company and used to fill the quartz tubes. T-Blu Tac® was used to seal the quartz
tubes. The dodecamer d(TATGGTACCATA)2 sodium salt (I) was obtained from
DNA Technology A/S (Aarhus, DK) as an HPLC-purified oligonucleotides. Singlet
Oxygen Sensor Green (SOSG) was obtained from Molecular Probes®, Inc.
Quantofix® Peroxide 25 Test Sticks was obtained from Sigma-Aldrich, with a
detection limit of 0.5 ~ 25 mg/L. All chemicals were used as received without any
further purification, unless specified.
4.2.2 Methods and Instruments
Photochemical reactions of Pt complexes with or without 5'-GMP were carried out at
298 K by using a LZC-ICH2 photoreactor (Luzchem Research Inc.) equipped with a
temperature controller and 8 UVA lamps (Hitachi, λmax = 365 nm, 3.5 mW/cm2) or 8
Luzchem LZC-420 lamps (λmax= 420 nm, 4.3 mW/cm2) with no other sources of
light filtration. ACULED® VHL™ LEDs were also used (λmax = 450 nm, 50
mW/cm2) for irradiation of the samples.
NMR spectra were recorded on either a Bruker AV-600 (1H, 600.13 MHz; 13C,
150.9MHz; 195Pt, 129.4 MHz; 15N, 60.8 MHz; 14N, 43.4MHz) or a Bruker DPX-400
spectrometer (1H, 400.03 MHz).
ESI-MS was performed on a Bruker Esquire 2000 mass spectrometer, HPLC-ESI-
MS on a Bruker HCT-Ultra mass spectrometer coupled with an Agilent 1200 HPLC
system with an Agilent ZORBAX Eclipse Plus C18, 5 μm, 4.6 × 150 mm column for 
Chapter 4 — Photochemistry of PtIV Diazidodihydroxido Complexes
135
experiments in Section 4.3.3.3 or a 4.6 × 250 mm column for experiments in Section
4.3.4.1. Flow rate, 1.0 ml/min; detecting wavelength, 254 nm; mobile phase A, H2O
with 0.1% formic acid (FA); mobile phase B, MeOH with 0.1% FA. A linear
gradient from 5% to 55% B over 15 min was applied to separate the photoreaction
mixture of Pt complexes with GMP. ESI-HR-MS and CID (collision-induced
disassociation) tandem MS/MS was performed on a Bruker MaXis UHR-Qq-TOF
high resolution ESI-MS spectrometer in positive-ion mode. Samples containing 50.0
μM Pt were prepared in 20% H2O/80% methanol.
UV-Vis electronic absorption spectra were recorded on a Varian Cary 300 UV-Vis
spectrophotometer in a 1 cm path-length quartz cuvette. All spectra were referenced
to neat solvent and data were processed with OriginLab Origin 7.0. Extinction
coefficients (ε) were determined over a concentration range (Amax ~ 0.4 – 1.6) with at
least 4 data points, using Pt concentrations determined by ICP-MS.
The EPR spectra were recorded on a Bruker EMX (X-band) spectrometer by Jennifer
S. Butler in University of Warwick. Specific details, along with other general
methods and parameters for acquisition are found in Chapter 2.
The intensity of fluorescence was measured on a Jasco FP-6500 fluorometer. The
output light was used for both excitation and irradiation by adjusting to the
wavelength required. The excitation and the emission slit widths were set to 3 nm.
Filters were used to eliminate second order diffraction of shorter wavelengths from
the specified longer wavelength monochromatic light. Power of individual
wavelengths: 365 nm, 21 µW/cm2; 420 nm, 0.85 mW/cm2; 450 nm, 0.80 mW/cm2.
Fluorescence response time was 0.1 second and sensitivity was medium. Power
levels were measured with an International Light Technologies Powermeter
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(ILT1400-A) equipped with a SEL033 detector and either a UVA/TD filter (315-390
nm) for UVA irradiations or a flat response visible filter F/W (400-1064 nm) for
visible wavelengths.
4.2.3 Photo-induced DNA platination
For platination of the single strand DNA dodecamer (ss-DNA, I), PtIV complex (100
or 200 μM) and ss-DNA I (100 μM) were mixed in 500 μL H2O to make up a
solution of 1:1 or 2:1 molar ratios of complex to ss-DNA I. The mixtures were
incubated with irradiation at 450 nm for 1 h at 298 K. The mixture was desalted and
diluted 100-fold in a solution of H2O/isopropanol (50%/50%) with 50 mM
ammonium acetate for direct injection to ESI-HR-MS. The m/z of Pt-DNA adducts
were calibrated internally with the m/z of the ss-DNA I species. The oligo
concentrations of aqueous stock solutions of I were determined
spectrophotometrically using the absorption coefficient ε260 = 132.52 mM−1cm−1,
calculated by ‘OligoCalc’.21
4.2.4 Synthesis and characterisation
4.2.4.1 Platinum(IV) diazidodihydroxido complexes
The complexes trans,trans,trans-[Pt(N3)2(OH)2(MA)(Py)] (5) (MA = methylamine，
Py = pyridine) and trans,trans,trans-[Pt(N3)2(OH)2(MA)(Tz)] (8) (Tz = thiazole)
were synthesized as described in Chapter 3.
4.2.4.2 Trans,trans,trans-[Pt(15N3)2(OH)2(MA)(Py)] (5*)
15N-N3 labelled trans,trans,trans-[Pt(15N3)2(OH)2(MA)(Py)] (5*), was synthesized
by the same method as for complex trans,trans,trans-[Pt(N3)2(OH)2(MA)(Py)] (5)
(see Chapter 3) except with the use of 15N-labelled NaN3 (99% Na[15N=14N=14N]).
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195Pt NMR (D2O, 129.4 MHz): δ = 898.8 ppm. 15N NMR (D2O, 60.8 MHz): δ (Nγ) =
165.6 ppm (3JPt-N = 24 Hz); δ (Nα) = 51.4 ppm (1JPt-N = 222 Hz).
4.2.4.3 Trans-[Pt(MA)(Py)(5'-GMP)2 − 2H] (5a) 
Trans-[Pt(MA)(Py)(5'-GMP)2 − 2H] (5a) was synthesized with a slight revised
reported method.6 Trans-[PtCl2(MA)(Py)] (3.76 mg, 10 μmol) was suspended in 
D2O (3 mL) and AgNO3 (3.4 mg, 20 μmol) added. After stirring for 24 h at 333 K, 
the insoluble AgCl was filtered off. An NMR sample was prepared using 0.54 mL of
the above solution and 60 μl of D2O, 5'-GMP (2.6 mg, 40 μmol) was added. The 
1H
and 195Pt NMR spectra were acquired after 24 h and then the sample was analyzed
by ESI-MS. 1H NMR (600 MHz, D2O): δ (ppm) 8.64 (d, H2, 6, 2H), 8.81 (s, H8 5'-
GMP, 1H), 7.86 (t, H4, 1H), 7.38 (t, H3, 5, 2H), 2.17 (s, CH3, 3J (195Pt, 1H) = 13 Hz,
3H). 195Pt NMR (129.4 MHz, D2O): δ = −2398 ppm. ESI-MS: [M + H]+ (m/z) Calc.,
1030.2; Found, 1030.3.
4.2.4.4 (SP-4-2)-[Pt(N3)(MA)(Py)(5'-GMP) − H] (5b) 
(SP-4-2)-[Pt(N3)(MA)(Py)(5'-GMP) − H] (5b) was synthesized with a slight revised
reported method.6 Trans-[PtCl2(MA)(Py)] (3.76 mg, 10 μmol) was added to a D2O
solution of NaN3 (3 mL, 3.3 mM), and left stirring at 303 K for 24 h. 5'-GMP (10
μmol, 3.63 mg) was added and the solution stirred for another 24 h at 298 K. Signals 
due to trans-[Pt(N3)(MA)(Py)(5'-GMP) − H] were present in both the NMR and 
mass spectra. 1H NMR (600 MHz, D2O): δ (ppm) 8.70 (s, H8, 5'-GMP, 1H), 8.69 (d,
H2, 6, 2H), 7.91 (t, H4, 1H), 7.46 (t, H3, 5, 2H), 2.26 (s, CH3, 3H). 195Pt NMR (129.4
MHz, D2O): δ = −2328 ppm. ESI-MS: [M + H]+ (m/z) Calc., 710.1; Found, 710.1.
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4.2.4.5 Trans-[Pt(MA)(Py)(H2O)2](BF4)2 (5g)
Trans-[Pt(Cl)2(MA)(Py)] (0.85 mg) was suspended in 1 mL H2O, and AgBF4 (8.7
mg, 2.1 mol equiv) was added and stirred at 333 K for 24 h. AgCl precipitate was
filtered off by an inorganic membrane filter (Sartorius, Minisart, 0.2 µm).The filtrate
was transferred to an NMR tube with 10% D2O for NMR experiments. This aqua
product was not isolated but only used for NMR spectroscopic experiments. 1H
NMR (600 MHz): δ (ppm) 8.66 (d, H2, 6, 2H), 8.03 (t, H4, 1H), 7.61 (t, H3, 5, 2H),
2.35 (s, CH3, 3J (195Pt, 1H) = 13 Hz, 3H). 195Pt NMR (129.4 MHz): δ = −1498 ppm.  
4.2.4.6 Trans-[Pt(MA)(Tz)(5'-GMP)2 − 2H] (8a)  
Trans-[PtCl2(MA)(Tz)] (3.82 mg, 10 μmol) was suspended in D2O (3 mL) and
AgNO3 (3.4 mg, 20 μmol) added. After stirring for 24 h at 333 K, the AgCl 
precipitate was filtered off. An NMR sample was prepared using 0.54 mL of the
above solution and 60 μl of D2O, 5'-GMP (4 mol equiv, 2.6 mg) was added. 1H and
195Pt NMR spectra were acquired after 24 h and then the sample was analyzed by
ESI-MS. δ (ppm) 9.20 (d, H2, 1H), 8.84 (s, H8, 5'-GMP, 1H), 7.92 (d, H4, 1H), 7.65
(d, H5, 1H), 2.15 (s, CH3, 3H). 195Pt NMR (129.4 MHz, D2O): δ = –2356 ppm. ESI-
MS: [M + H]+ (m/z) Calc., 1036.1; Found, 1036.1.
4.2.4.7 (SP-4-3)-[Pt(N3)(MA)(Tz)(5'-GMP) − H] (8b)  
Trans-[PtCl2(MA)(Tz)] (3.82 mg, 10 μmol) was added to a D2O solution of NaN3 (3
mL, 3.3 mM), and left stirring at 303 K for 24 h. 5'-GMP (10 μmol, 3.63 mg) was 
added and the solution stirred for another 24 h at 298 K. Signals due to (SP-4-3)-
[Pt(N3)(MA)(Tz)(5'-GMP) − H] were present in both the NMR and mass spectra. δ
(ppm) 9.28 (d, H2, 1H), 8.65 (s, H8, 5'-GMP, 1H), 8.00 (d, H4, 1H), 7.75 (d, H5, 1H),
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2.26 (s, CH3, 3H). 195Pt NMR (129.4 MHz, D2O): δ = −2294 ppm. ESI-MS: [M + 
H]+ (m/z) Calc., 716.1; Found, 716.2.
4.3 Results
4.3.1 Photochemistry
4.3.1.1 Dark stability
Complexes trans,trans,trans-[Pt(N3)2(OH)2(MA)(Py)] (5) and trans,trans,trans-
[Pt(N3)2(OH)2(MA)(Tz)] (8) have very good aqueous solubility (>40 mM) and are
very stable in water and in EBSS (Eagle’s balanced salt, a biological cell culture
medium) for >7 months in the dark, as monitored by 1H NMR. They do not react
with two equivalents of 5'-GMP or L-ascorbic acid (VC) in the dark, observed by 1H
NMR for three days. Those complexes react with glutathione (GSH, reduced form)
very slowly, only 2% of complex 5 and 10% of 8, respectively, were consumed after
incubation for three days.
4.3.1.2 Photolysis study by UV-Vis spectroscopy
Complexes 5 and 8 exhibit similar absorption maxima (azido ligand-to-metal-
charge-transfer band) at 289 nm and the absorption extends up to ca. 500 nm (for
their extinction coefficients at various wavelengths, see Table 4.1 ).
Table 4.1 Extinction coefficients (ε, M−1 cm−1) for complexes trans,trans,trans-
[Pt(N3)2(OH)2(MA)(Py)] (5) and trans,trans,trans-[Pt(N3)2(OH)2(MA)(Tz)] (8) at
various wavelengths.
Complex 5 8
ε289 (max) 16200 18600
ε365 496 607
ε420 129 138
ε450 66 65
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Irradiation of an aqueous solution of 5 or 8 at 365 nm (2.35 mW/cm2) or 420 nm
(5.10 mW/cm2) or 450 nm (50 mW/cm2) resulted in a decrease in intensity of
absorption at 289 nm (Figure 4.1), indicating loss of the PtIV-N3 bond(s), i.e., the
LMCT band. A lower dose of 365 nm irradiation induced the decomposition of
complexes faster than a ca. twice higher dose of 420 nm light, which is consistent
with their different extinction coefficients at these wavelengths.
Figure 4.1 UV-Vis spectra recorded for complexes 5 (trans,trans,trans-
[Pt(N3)2(OH)2(MA)(Py)], 50 μM) and 8 (trans,trans,trans-[Pt(N3)2(OH)2(MA)(Tz)],
60 μM) in H2O upon irradiation at 365 nm (light dose 0, 0.7, 2.1, 4.2, 8.4 J/cm2), 420
nm (light dose 0, 1.5, 4.6, 9.2, 18.4 J/cm2) and 450 nm (light dose 0, 15, 45, 90, 18
J/cm2).
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4.3.1.3 1H NMR spectroscopy
When a solution of complexes 5 (trans,trans,trans-[Pt(N3)2(OH)2(MA)(Py)]) or 8
(trans,trans,trans-[Pt(N3)2(OH)2(MA)(Tz)]) (10 mM in 90% H2O/10% D2O) was
irradiated at 450 nm light (50 mW/cm2), gas bubbles and a yellow precipitate were
observed within ca. 30 min. The gas generated was assumed to be a mixture of O2
and N2 gas, as they were observed in the previous work in Sadler’s group on related
complexes.7, 8 The precipitate from the irradiated complex 5 was filtered off, dried
and the weight was found to be 1.3 mg, the yield of which was indeed high with
respect to the 2.6 mg starting material dissolved in the NMR sample. The precipitate
was poorly soluble in H2O, MeOH, EtOH, acetone or acetonitrile, but could be
dissolved in DMF, giving a dark brown solution. No 195Pt NMR resonance was
found for the precipitate in DMF-d7 between −6200 and 6200 ppm.  
1H NMR spectroscopy was used to follow the photoreaction. Although every signal
would not be assigned due to the overlap of signals, some useful information could
still be obtained. Taking complex 5 trans,trans,trans-[Pt(N3)2(OH)2(MA)(Py)] as an
example, the methylamine (MA) group exhibits a triplet for the CH3 group in 1H
NMR (Figure 4.2) due to the coupling with the NH2 group, for which the protons
were hardly exchanged by deuterium under the experiment conditions (90% H2O/10%
D2O, pH 4 ± 0.5). A number of new species were formed after irradiation at 450 nm
for only 15 min. After irradiation for 1 hour, < 17% of the starting material was still
left, and after 4 hours, the starting material had all reacted. Three new species
containing Pt-MA moiety were generated, probably by isomerization, ligand
substitution or reduction. In the reaction mixture, a very tiny amount of free
methylamine (MA) was found after irradiation at 450 nm in 1H NMR (δ (CH3) =
2.60 ppm). < 0.5% and < 3% MA release was observed after irradiation for 1 hour
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(180 J/cm2) and 4 hours (540 J/cm2), respectively. (Figure 4.2) The chemical shift of
free MA was confirmed by adding 1 mol equiv free MA to the final irradiated NMR
sample, and adjust the pH value to 4 ± 0.5. Free MA exhibit a singlet as the H-D
exchange rate for the NH2 group is much faster than for MA coordinated to Pt, as the
pKa value of MAH+ is 10.62.22 Also, an independent series of experiments showed
that the pH decreased from 6.22 to 5.88 after irradiation at 450 nm for 1 hour. Since
a significant release of free MA should increase the pH, it is confirmed that MA
group remains strongly bound to Pt in the photo-reactions.
195Pt satellites for PtII species in high frequency 1H NMR spectra are broadened due
to the effects of chemical shift anisotropy (CSA) relaxation.23 But in highly
symmetrical platinum(IV) complexes, the satellites are still sharp in the 600 MHz 1H
NMR spectrum. For example, in the aromatic area of the 1H NMR spectrum of
complex 5 (trans,trans,trans-[Pt(N3)2(OH)2(MA)(Py)]), the resonance for H2, 6 in
pyridine has sharp satellites. After irradiation at 450 nm for 15 min, a series of new
species appeared with satellites, which suggests that the new species are largely PtIV
complexes from photo-induced ligand substitution and isomerization. After
irradiation at 450 nm for 1 hour, more new signals appeared with no satellites, which
indicate that PtII species were generated by photo-induced reduction. After 4 hours,
all the resonances with satellites disappeared, so all the PtIV species were consumed.
At least four new species were formed. The noise level of the 1H NMR spectra
increased during the photoreaction, which is probably due to the lowered
concentration of the sample by generation of precipitate.
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Figure 4.2 Time-dependent 600 MHz 1H-NMR spectra (aliphatic and aromatic area)
of complex 5 complexes 5 (trans,trans,trans-[Pt(N3)2(OH)2(MA)(Py)], 10 μM) in 90% 
H2O/10% D2O upon irradiation at 450 nm (50 mW/cm2, 298 K). The pH value of the
sample was adjusted to 4 ± 0.5 before every NMR experiment. A, no irradiation; B,
15 min; C, 1 h; D, 4 h.
The detailed photochemistry of complex 5 in aqueous solution was then studied.
4.3.1.4 14N NMR spectroscopy
14N NMR spectroscopy was used to probe the photolysis of complex 5
(trans,trans,trans-[Pt(N3)2(OH)2(MA)(Py)]) in aqueous solution. First, the 1D 14N
NMR spectrum of complex 5 in 90% H2O and 10% D2O was recorded (Figure
4.3A). The assignments of the signals listed in Table 4.2 are made according to the
14N NMR studies of the authentic samples or published data for related complexes.7,
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8, 24 It is theoretically possible to quantify these peaks by integration, as the T1
relaxation times of 14N nucleus are quite short (millisecond level).24 However,
practically the signals are often badly overlapped and the bandwidths are very broad.
Therefore, quantification was performed for some of the distinguishable sharp peaks
only.
Figure 4.3 14N NMR (43.4 MHz) spectrum of complex 5 (trans,trans,trans-
[Pt(N3)2(OH)2(MA)(Py)], 10 mM in 90% H2O:10% D2O, pH adjusted to 7.4 ± 0.5).
(A) sample prepared in air and kept in the dark; (B) sample saturated with argon, (C)
sample B irradiated at 450 nm for 60 min; (D) sample B irradiated with UVA for 2 h;
(E) trans-[Pt(MA)(Py)(OH2)2](BF4)2 (5g) (10 mM in 90% H2O:10% D2O).
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The signal at 288 ppm (peak g) was assigned as dissolved nitrogen gas. The signal
disappeared after saturating the solution with argon (Figure 4.3B). Peaks b (228
ppm) c (165 ppm) and the broad signal a (~ 80 ppm) correspond to the central,
unbound terminal and Pt-bound terminal N atoms, respectively, of coordinated N3−
ligands. The resonance of PtIV bound N atoms (a) in azido ligands is exceptionally
broad due to an highly asymmetric electric field gradient at the 14N nucleus.24 Peaks
d (174 ppm) and e (−39 ppm) correspond to the N atoms of the Py and MA, 
respectively. The integrations of the peaks b : (c+d) : e = 2 : 3.05 : 0.93, which is ca.
2 : 3 :1, consistent with the numbers of 14N atoms in the molecule.
After irradiation at 450 nm (50 mW/cm2) at 298 K for 1 hour, new 14N signals
appeared (Figure 4.3C). Peaks b’ (226 ppm) and a’ (78 ppm) are assignable to the
terminal and central nitrogen atoms of free azide (N3−). This assignment was
confirmed regarding the 14N NMR spectrum of NaN3 in D2O and also by literature
data.7, 25 Other new peaks d’ (δ = 179 ppm) and e’ (δ = −60 ppm) are assigned as the 
PtII-coordinated Py and MA ligands, respectively. Their assignment was confirmed
by the 14N NMR spectrum of the di-aqua species of trans-[Pt(MA)(Py)(OH2)2](BF4)2
(5g) synthesized independently (Figure 4.3E). Peaks b (228 ppm) and c (165 ppm)
for the coordinated N3− ligand of complex 5 were still present, but with reduced
intensities. The integration of (b + b’) : a’ = 8.7 : 1, and theoretically a’ : b’ =2 : 1.
Therefore, b : b’ = 16.4 : 1, which means a large amount of N3− ligand remained
bound to Pt. Some was on intact starting materials (~17% from 1H NMR), and the
remainder is possibly N3− mono-coordinated Pt complexes. The signals d and d’
were both very broad due to the quadrupolar effect of 14N, but they could still be
distinguished in Figure 4.3C.
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Remarkably, the sharp peak g corresponding to nitrogen gas (N2) was also observed.
By integration, the ratio of peak g : a’= 2.0 : 1, so the ratio of released N2 molecules
to N3− anions in aqueous phase was 2.0 as well. Considering that part of the N2 gas
was liberated as bubbles from the solvent (solubility of N2 in H2O at 298 K is ca. 17
μg/g) and the NMR tube was kept sealed, the actual amount of generated N2 gas was
much more than the free N3− anions. Peak f is assigned as free nitrate NO3− in
solution, arising as a side-product of the photodecomposition of the azido ligand. 7, 8
The other new peaks h and i were not identified. If ignore the evolved N2 gas, the
molar ratio of the following molecules/ions in the solution is ca.:
Pt-N3 : N3− : N2 = 16.4 : 1 : 2
After irradiation of an argon-saturated solution of complex 5 with UVA (3.46
mW/cm2) for 2 hours, gas bubbles and a lot of precipitate were again observed.
Almost no peaks assignable as coordinated azides were detected, and intriguingly,
the signals for coordinated Py and MA were not observed either (Figure 4.3D). It is
likely that most of the Py and MA ligands were present in the precipitate. Three new
signals b’ (226 ppm), c’ (78 ppm) and g (δ = 288 ppm) were again assignable as the 
terminal and central nitrogen atoms of free azide (N3−) and nitrogen gas, respectively.
A very small amount of free MA (NH2CH3) e” (δ = −3 ppm) and free ammonia NH3
j (δ = −18 ppm) was detected. These signals were confirmed by 14N NMR
experiments for authentic samples and also by literature data.8 The existence of MA
is consistent with the 1H NMR result for this photoreaction. However, it was
surprising to find the signal of free NH3. With the assistance of the following results
and literature report, the source of free NH3 was identified. Upon irradiation with
light, N2 gas may be released directly from the Pt-N3, forming a nitrene intermediate
{Pt-N}.9 This intermediate can thus convert to Pt-NH3, (vide infra) followed by
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photo-disassociation to give free NH3.7, 8, 27, 28 Free N3− anion can also undergo this
series of photoreactions and give free NH3.29 If we ignore the evolved N2 gas, the
molar ratio of the following molecules/ions in the solution is ca.:
Pt-N3 : N3− : N2 : NO3−= 0.59 : 1 : 2.55 : 0.58
This result indicates that upon photoactivation, the azido ligands in the PtIV complex
in aqueous solution are converted to both free azide (N3−) and N2 gas. The nitrogen
gas was probably formed from the combination of the N3• radicals released in this
photoreaction (vide infra).30 The N2 gas may also be released directly from the Pt
bound N3− ligand on forming a nitrene intermediate (vide infra).9 Upon irradiation at
450 nm for 1 hour, the major pathways of azido ligand are either formation of N2 gas
or new Pt-N3 compounds, while upon irradiation with UVA for 2 hours, the major
products for the azido ligands is N2 gas.
Table 4.2 Assignments of 14N NMR signals in Figure 4.3.
Peak δ/ppm Assignment
a 70 – 80 PtIV–NNN
b 228 PtIV–NNN
c 165 PtIV–NNN
a’ 78 NNN−
b’ 226 NNN−
d 174 PtIV–NPy
d’ 179 PtII–NPy
e −39 PtIV–NMA
e’ 60 PtII–NMA
e” −3 NH2CH3
f 354 NO3−
g 288 N2 gas
h ~15 n.a.
i 130 n.a.
j −18 NH3
n.a. = not assigned.
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4.3.1.5 Azidyl radicals (N3•) detected by EPR
An unambiguous method to identify the N3• radicals is electron paramagnetic
resonance (EPR) using spin traps, developed by Rehorek.31 The hyperfine splitting
patterns of the EPR signal and the g-factor are the “finger print” of trapped radicals.
In this work, the generation of azidyl radicals (N3•) was confirmed by EPR
experiment using 5,5-dimethyl-pyrroline-N-Oxide (DMPO) as the spin trap.32, 33
DMPO can effectively capture O-, N-, S- and C-centered radicals and form stable
products which can be studied by EPR.
To detect the N3• radicals, complex 5 (trans,trans,trans-[Pt(N3)2(OH)2(MA)(Py)], 5
mM) with 2 mol equiv of DMPO in aqueous solution was irradiated at 450 nm (50
mW/cm2) at 293 K. The resulting EPR spectrum which is compatible with the adduct
DMPO•-14N3 is shown in Figure 4.4A. The simulation of hyperfine splittings and
the ratios of integrations are illustrated in Figure 4.4B, which consists of a quartet of
triplets (1:1:1:2:2:2:2:2:2:1:1:1). This results from overlap of the hyperfine splitting
constants (HFSC) of the proton (1H2) and the nitroxyl nitrogen (14N1), with further
splitting by the azide nitrogen (14Nα). The EPR signal was observed in the first
spectrum recorded within 5 minutes, (Figure 4.4C) and is in good agreement with
the simulation and previously reported data for N3•.33, 34 The hyperfine splitting
constants (HFSC) were: a(14N1) = 14.4 G, a(1H2) = 14.6 G, a(14Nα) = 3.2 G and the g-
factor = 2.011, (reported results: a(14N1) = 14.8 G, a(1H2) = 14.2 G and a(14Nα) = 3.1
G).34 The decay time of DMPO•-14N3 spin adduct was ca. 25 min.
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Figure 4.4 (A), Structure of spin adduct DMPO•-14N3; (B), Illustrated hyperfine
splittings and the ratios of peaks; (C), EPR spectrum of irradiated (450 nm, 10
mW/cm2, 5 min) sample of complex 5 (trans,trans,trans-[Pt(N3)2(OH)2(MA)(Py)], 5
mM) with DMPO (10 mM) in deionised water (293 K). Spectrum was recorded by
Miss J. Butler.
The hydroxyl radical OH• can also be captured by DMPO, and the EPR signal of
DMPO•-OH should have the hyperfine splitting pattern of 1:2:2:1.33, 35 However, in
this work, no signal corresponding to DMPO•-OH was found. Therefore, it can be
concluded that OH• radicals are not generated in the photolysis of complex 5 under
the conditions used.
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In addition, another experiment was conducted on complex 5 and DMPO in the
presence of 2 equivalents of 5'-GMP, other conditions being identical to above. The
EPR spectrum was identical to above too, indicating that excess 5'-GMP did not
affect the generation or trapping of N3• radical or the spin trap DMPO reacts with the
N3• radical faster than 5'-GMP.
4.3.2 Singlet oxygen (1O2) detection
It has been reported that upon irradiation with UVA, two platinum(IV)
diazidodihydroxido complexes, namely cis,trans,cis-[Pt(N3)2(OH)2(NH3)2] and
trans,trans,trans-[Pt(N3)2(OH)2(NH3)2] generated oxygen gas (O2),7, 8 but no direct
evidence has been previously obtained for the energy state of the released oxygen. In
this work, the nature of the released oxygen was investigated using a fluorescence
probe for singlet oxygen: Singlet Oxygen Sensor Green (SOSG®). SOSG is a highly
selective sensor for 1O2 without any appreciable response to hydroxyl radicals or
superoxides, marketed by Invitrogen/Molecular Probes.36 The structure of SOSG has
not been disclosed, but it is believed to contain a fluorescein bond to a
dimethylanthracene derivative as a fluorescence quencher via charge transfer
(Figure 4.5).37 In the absence of 1O2, SOSG exhibits weak blue fluorescence, but in
the presence of 1O2, the charge transfer is blocked and the fluorescein moiety emits
strong green fluorescence with excitation and emission maxima at 504 nm and 525
nm, respectively.38 Although it was reported that SOSG can itself sensitize the
production of singlet oxygen,39 under our experimental conditions, this fluorescence
probe was stable to light between 365 – 504 nm, with no change in the intensity of
fluorescence.
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Figure 4.5 Formation of the endoperoxide of SOSG (denoted SOSG-EP) upon
reaction of SOSG with singlet oxygen. Adapted from ref.37
A sample of complex 5 (trans,trans,trans-[Pt(N3)2(OH)2(MA)(Py)], 50 µM) and
SOSG (1 µM) was prepared in deionized water with 3% methanol. MeOH was
always added to maintain the solubility of SOSG. The pH of the mixture was ca. 7,
as measured by pH paper. This solution was stable in the dark or even upon
irradiation at 504 nm, which is important because 504 nm is the excitation
wavelength for fluorescence. When it was exposed to very weak 365 nm light (21
µW/cm2), the intensity of the fluorescence at 525 nm (λex = 504 nm) increased
rapidly, at was recorded at certain time intervals as shown in Figure 4.6. The ca. 10-
times increase in the fluorescence after irradiation for 15 min suggested that 1O2 was
generated upon irradiation at 365 nm. The pH of the final solution was still ca. 6,
preventing the SOSG from being activated at alkaline pH.36 A control sample
saturated with argon was irradiated at 365 nm and the fluorescence was even higher.
This result again proved that the 1O2 was not from the dissolved O2 via energy
transfer from a photosensitizer. It also ruled out the possibility that SOSG can act as
photosensitizer. It was very interesting to note that with argon saturation, the
intensity of fluorescence increased faster. Argon alone could not trigger the
fluorescence of SOSG, verified by a blank test with SOSG saturated with argon.
Chapter 4 — Photochemistry of PtIV Diazidodihydroxido Complexes
152
Also, when a sample of complex 5 and SOSG was saturated with N2, the intensity of
the fluorescence after irradiation was similar to that of the sample saturated with Ar.
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Figure 4.6 The time dependent intensity of the fluorescence (λex = 504 nm, λem= 525
nm) of complex 5 (trans,trans,trans-[Pt(N3)2(OH)2(MA)(Py)], 50 µM) and SOSG (1
µM) in 97% H2O/3% MeOH upon a weak irradiation at 365 nm (3 nm slit width, 21
µW/cm2). T = 293 K. Solid squares, no additive; hollow squares, 50% D2O added;
triangles, saturated with argon; solid circles, 0.1 mM formic acid (FA) added;
crosses, 0.1 mM L-ascorbic acid (VC) added. All the data points were the average of
2 ~ 4 independent experiments.
As the life time of 1O2 in D2O is much longer than in H2O, the oxidation reaction by
1O2 may be greatly potentiated in D2O.40, 41 This experiment was carried out in 50%
D2O to confirm the existence of 1O2. Upon irradiation at 365 nm, the intensity of
fluorescence was 3 – 4-fold higher than that of the reaction carried out in H2O
(Figure 4.6). In order to distinguish between the generation of 1O2 and •OH,
appropriate scavengers were used. Two independent groups of experiments with 100
µM L-ascorbic acid (VC) as 1O2 scavenger or 100 µM formic acid (FA) as •OH
scavenger were carried out. The data are plotted in Figure 4.6. Complex 5 does not
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react with VC in the absence of light (see Section 4.3.1.1), given VC is a strong
reductant. In the presence of VC, the fluorescence was totally quenched, whereas in
presence of FA, the fluorescence slightly increased upon irradiation at 365 nm,
although the intensity of the fluorescence was lower than that of the sample without
FA.
More experiments were carried out to compare the efficiency of 1O2 generation with
different irradiation wavelengths and dark or blank controls. As depicted in Figure
4.7, fluorescence was still observed upon irradiation at 420 or 450 nm. Owing to the
higher power densities of 420 and 450 nm light compared to that of 365 nm, the
dose-dependent efficiency of generating 1O2 upon irradiation at 365 nm was still
higher than that with the longer wavelengths. The dark control experiment (with
sham irradiation) for the solution of complex 5/SOSG (50 µM/1 µM) showed very
low intensity of fluorescence (data not shown). The blank control experiment (in the
absence of complex 5) showed low intensity of fluorescence, too.
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Figure 4.7 The time dependent intensity of the fluorescence (λex = 504 nm, λem =
525 nm) of complex 5 (trans,trans,trans-[Pt(N3)2(OH)2(MA)(Py)], 50 µM) and
SOSG (1 µM) in H2O (3% MeOH) upon irradiation at various wavelengths. T = 290
– 295 K. Squares, λirr = 365 nm, 21 µW/cm2; triangles, λirr = 420 nm, 850 µW/cm2;
inverted triangles, λirr = 450 nm, 800 µW/cm2; crosses, dark control; circles, no
complex 5 was added, λirr = 365 nm. All the data points were the average of 2 ~ 4
independent experiments.
The detailed mechanism for the generation of 1O2 could involve the recombination of
released hydroxyl radicals. When hydroxyl radicals are generated at high local
concentrations, they readily dimerize to give H2O2, 42 which is known to decompose
by disproportionation to water and gaseous dioxygen upon irradiation with UV
light.43 In order to investigate this pathway under our reaction conditions, a mixture
of 500 µM H2O2 and 1 µM SOSG was irradiated at 365 nm for 15 min, but no
change in the intensity of the fluorescence was observed. However, when a solution
of complex 5 (50 µM) and SOSG (1 µM) was added to 500 µM H2O2, the intensity
of fluorescence upon irradiation at 365 nm was much higher than that of without
H2O2 (Figure 4.8). Therefore, it is reasonable to postulate that one or more than one
Pt-containing species can catalyse the photolysis of H2O2 and give 1O2, upon
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irradiation with light. In order to verify this, K2PtCl6 or trans-[PtCl2(MA)(Py)] (50
µM) was added to a mixture of H2O2 and SOSG before irradiating, but still no
increase of intensity of fluorescence was observed (Figure 4.8). These results
indicate that only certain Pt-containing intermediate(s) in the photo-reaction mixture
can catalyse the photolysis of H2O2 upon irradiation of light and generate 1O2.
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Figure 4.8 The time dependent intensity of the fluorescence (λex = 504 nm, λem =
525 nm) of Pt complexes (50 µM) and SOSG (1 µM) in H2O (3% MeOH) upon
irradiation at 365 nm. Squares, complex 5 (trans,trans,trans-
[Pt(N3)2(OH)2(MA)(Py)], 50 µM); triangles, complex 5 (50 µM) and 500 µM H2O2;
circles, K2PtCl6 (50 µM) and 500 µM H2O2; crosses, [PtCl2(MA)(Py)] (50 µM) and
500 µM H2O2. All the data points were the average of 2 ~ 4 independent experiments.
Finally, an attempt was made to detect the H2O2 with a peroxide test stick
(Quantofix® Peroxide 25) while the solution of complex 5 was irradiated with light.
The paper zone of the test stick is originally white and turns blue upon exposure of
aqueous peroxide. A small amount (2 μL) of a high concentration complex 5 (20
mM in H2O) was dropped on the paper zone of the test stick; no colour change was
observed. Assuming that each complex molecule releases one molecule of peroxide,
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the theoretical maximum amount of H2O2 released is 20 mM, which is 680 mg/L.
This number is far above the minimum detection limit for the peroxide test sticks.
Therefore, the generation of peroxide under these conditions should be detectable.
Then 2 μL of the complex 5 solution was irradiated with light (450 nm, 30 s – 15
min) and was immediately dropped onto the paper zone of the test stick, there was
still no colour change. However, when the paper zone was stained with an intact
solution of complex 5 and then irradiated at 450 nm, the stained area turned blue
(Figure 4.9). The concentration of H2O2 was semi-quantitively measured as 10 ~ 25
mg/L by comparing to the colour scale.
Figure 4.9 Colour change in the aqueous solution of complex 5 (20 mM) stained
area on the paper zone of the Peroxide 25 Test Sticks (Quantofix®) under various
irradiation conditions. (450 nm, 50 mW/cm2).
Apparently, the peroxide test sticks were activated by some very short lived
oxidative species. According to the product information from the supplier, other
strong oxidative agents may cause false-positive results.44 This experiment leads to
two possibilities. First, the photodecomposition of complex 5 does not involve
peroxide (H2O2) as an intermediate, but some other kinds of strong oxidative species
(e.g., 1O2, nitrenium ion, etc.) can activated the test stick. Second, the peroxide
Stained with intact complex 5,
no irradiation
Stained with irradiated complex 5,
450 nm 20 min
Stained with intact complex 5,
followed by irradiation at 450 nm, 30 s
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(H2O2) was still generated but quickly decomposed upon irradiation with UVA or
through the catalytic effect of the Pt-containing species in the solution. However,
according to the measured concentration of peroxide, if it was, 10 ~ 25 mg/L, it
would not be fully decomposed within only a few seconds. Therefore, it is concluded
that H2O2 itself is not an intermediate in the photodecomposition of complex 5.
4.3.3 Photoreaction with 5'-guanosine monophosphate
The photochemical reaction of Pt complexes with 5'-guanosine monophosphate (5'-
GMP) in aqueous solution was investigated, since guanine is a preferred target for
DNA platination of PtII complexes such as cisplatin.45, 46 The reactions with 5'-GMP
may mimic the platination of DNA in cells.
4.3.3.1 1H NMR spectroscopy
Complexes 5 (trans,trans,trans-[Pt(N3)2(OH)2(MA)(Py)]) and 8 (trans,trans,trans-
[Pt(N3)2(OH)2(MA)(Tz)]) (2 mM) did not react with 5'-GMP (2 mol equiv) in water
in the absence of light over a period of three days, as judged by 1H NMR
spectroscopy. The photo-induced reactions of complex 5 or 8 (3.9 mM in D2O) in
the presence of 2 equivalents of 5'-GMP were monitored by 1H, 195Pt NMR
spectroscopy and HPLC-ESI-MS. During the photoreaction of complex 5 and 5'-
GMP upon irradiation at 450 nm, the yellow colour of the solution grew deeper and
darker, and gas bubbles formed. (Figure 4.10) Interestingly, no precipitate was
observed. Before irradiation, in the 1H NMR spectrum, signals at δ = 8.72, 8.30, 7.84
and 2.42 ppm correspond to H2,6, H4 and H3,5 of the Py ligand and CH3 of the MA
ligand, respectively. δ = 8.12 ppm corresponds to H8 of free 5'-GMP. (Figure 4.11)
After irradiation at 450 nm for 1 hour, the signal of complex 5 nearly vanished and a
new major product was formed with δ = 2.25 and 8.86 ppm, which was assigned as
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CH3 of MA and H8 of Pt coordinated 5'-GMP in (SP-4-2)-[Pt(N3)(MA)(Py)(5'-GMP)
− H] (5b). The identical chemical shift was exhibited by an authentic sample of 5b.
Other characterization methods (195Pt NMR spectroscopy and HPLC-ESI-MS) also
confirmed the assignment of this compound (see Section 4.3.3.3 and 4.3.3.4).
According to the 1H NMR spectra, the reaction between complex 5 and 5'-GMP had
almost finished after irradiation for one hour, and longer exposure to light caused no
obvious change to the major product but only the decomposition of the other
photoproducts. After irradiation of a sample of complex 5 and 5'-GMP at 450 nm,
very little amount of MA was released (1% after 1 hour and 4% after 3 hours of
irradiation), as monitored by 1H NMR (δ (CH3) = 2.59 ppm). The chemical shift of
MA was confirmed by spiking the irradiated NMR sample with free MA.
Figure 4.10 Gas bubbles observed in NMR tube while a D2O solution of complex 5
(3.9 mM)/5'-GMP (7.8 mM) was irradiated with a 450 nm LED over 30 min (298 K).
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Figure 4.11 1H-NMR spectra of complex 5 (3.9 mM) with 5'-GMP (7.8 mM) in D2O
upon irradiation at 450 nm (50 mW/cm2, 298 K) for (A) 0 h; (B) 1 h (180 J/cm2); (C)
3 h (540 J/cm2); (D) after irradiation, the NMR sample was spiked with 1 mol
equivalent of free MA.
Similar experiments were performed for complex 8 with two equivalent of 5'-GMP.
Before irradiation, in the 1H NMR spectrum, signals at δ = 9.51, 8.23, 8.02 and 2.34
ppm correspond to H2, H4 and H5 of the Tz ligand and CH3 of the MA ligand,
respectively. δ = 8.17 ppm corresponds to H8 of free 5'-GMP. (Figure 4.12) After
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2.6 2.4 2.2
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irradiation at 450 nm for only 15 min, the reaction was nearly finished and a new
major product formed with peaks at δ = 8.82 and 2.25 ppm, which were assigned as
CH3 of MA and H8 of Pt coordinated 5'-GMP in (SP-4-3)-[Pt(N3)(MA)(Tz)(5'-GMP)
− H] (8b). Identical chemical shifts were exhibited by an authentic sample of 8b.
Other characterization methods (195Pt NMR spectroscopy and HPLC-ESI-MS) also
confirmed the assignment of this compound (vide infra). According to the 1H NMR
signals, the released MA was <1% after 15 min and ca. 2% after 1 hour irradiation at
450 nm.
Figure 4.12 1H-NMR spectra of complex 8 (3.9 mM) with 5'-GMP (7.8 mM) in D2O
upon irradiation at 450 nm (50 mW/cm2, 298 K) for (A) 0 min; (B) 15 min (45
J/cm2); (C) 1h (180 J/cm2).
7.508.008.509.009.50 2.102.202.302.402.502.60
C 450 nm 1 h
.5 . .5 . .5 .6 .4 .2
(1H) / ppm
Released MA
δ
Complex 8 + 2 eq 5’-GMP
A Dark
B 450 nm 15 min
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4.3.3.2 UV-Vis spectroscopy
The photoreaction of complex 5 (trans,trans,trans-[Pt(N3)2(OH)2(MA)(Py)]) with 5'-
GMP was also followed by UV-Vis spectroscopy. In the UV-Vis spectrum of
complex 5, the absorption band maximum at 289 nm corresponds to the N3-PtIV
LMCT (Ligand-to-Metal-Charge-Transfer) transition. This absorption diminished
upon irradiation with light, e.g., 450 nm (Figure 4.13A) The UV-Vis spectrum of 5'-
GMP was also recorded (Figure 4.13B). 5'-GMP was very stable upon irradiation at
450 nm. Then the UV-Vis spectrum of a mixture of complex 5 with 5'-GMP was
recorded (black line in Figure 4.13C); this curve is approximately equal to the
overlap spectra of complex 5 and 5'-GMP. The mixture was stable in the dark for
over 16 hours, as followed by UV-Vis. This mixture was then irradiated at 450 nm
and the UV-Vis spectra in Figure 4.13C were recorded. Finally, the rate of decrease
in A289 was plotted in Figure 4.13D. According to the slops of the two curves, the
loss of PtIV-N3 bond from complex 5 in the presence of 5'-GMP was ca. 1.5 times
faster than in its absence upon irradiation at 450 nm.
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Figure 4.13 UV-Vis spectra for the photoreaction of complex 5 (trans,trans,trans-
[Pt(N3)2(OH)2(MA)(Py)]) with 5'-GMP in aqueous solution. (A) Complex 5 (75 μM) 
irradiated at 450 nm (50 mW/cm2) for 60 min; (B) 5'-GMP (75 μM); (C) complex 5
(75 μM) and 5'-GMP (75 μM) irradiated at 450 nm for 60 min; (D) comparison of
the decrease in rate of A289 in (A) and (C).
4.3.3.3 HPLC-ESI-MS study
In order to examine the products of the photochemical reaction of complexes 5
(trans,trans,trans-[Pt(N3)2(OH)2(MA)(Py)]) and 8 (trans,trans,trans-
[Pt(N3)2(OH)2(MA)(Tz)]) with 5'-GMP in more detail, the reaction was studied by
HPLC-ESI-MS. A solution of complex 5 (0.5 mM) and 5'-GMP (1.0 mM) in H2O
was irradiated at 450 nm for one hour at room temperature (298 K), and the reaction
mixture was diluted 10-fold and then injected into HPLC-ESI-MS. The
chromatogram is shown in Figure 4.14A and all the major peaks were identified by
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coupled ESI-MS. The peak with a retention time tr = 3.46 min was assigned as 5'-
GMP; tr = 11.10 min was assigned as trans-[Pt(MA)(Py)(5'-GMP)2 − 2H] (5a); tr =
11.47 min was assigned as (SP-4-2)-[Pt(N3)(MA)(Py)(5'-GMP) − H] (5b). The
identical retention times and absorption spectra were verified by the synthesis of
authentic samples of these species. The MS isotope distributions agreed very well
with their corresponding simulations. (Figure 4.15) This result indicated that one
azido ligand and two PtIV bound hydroxyl groups were released during irradiation,
while the PtIV was reduced to PtII and binds to 5'-GMP. Very small amounts of the
complex 5 lost the second azido ligand to form a bis-GMP adduct. Then irradiation
at 450 nm of the reaction mixture was continued for another 2 hours, the HPLC
chromatogram is shown in Figure 4.14B. The difference between the two
chromatograms (Figure 4.14A and B) is very small; the intensity of the peak for 5a
increased slightly. This result indicates that the mono-GMP/N3− adduct can slowly
lose N3− and form the bis-GMP adduct. Then this resulting reaction mixture was
irradiated with UVA for 1 hour and again HPLC-ESI-MS was performed (Figure
4.14C). In this chromatogram, the signal corresponding to 5b completely
disappeared, and the signal for 5a increased a little. Some unidentified Pt-containing
species was found, as shown by the coupled ESI-MS. Therefore, 5b is not stable to
irradiation with UVA; it may lose the N3− and form some new species such as 5a,
which is stable to UVA (Scheme 4.1).
A similar sample of complex 5 (0.5 mM) and 5'-GMP (1.0 mM) in H2O was
irradiated with UVA for 60 min. As expected, the chromatogram in Figure 4.14D
was similar to that in Figure 4.14C, 5a being the major product (Scheme 4.1). This
result indicated that irradiation with UVA induced the loss of two hydroxido ligands
and two azido ligands and Pt binds to two 5'-GMP molecules to form 5a, during
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which the PtIV was reduced to PtII. By contrast, irradiation at 450 nm released two
hydroxido ligands but only one azido ligand, and Pt binds to one 5'-GMP to form 5b.
Thereafter, only a small portion of 5b lost the remaining azido ligand upon
irradiation with UVA and formed 5a. The possible photodecomposition pathways of
5b and the other unidentified products will be discussed in Section 4.3.4.
Figure 4.14 HPLC chromatograms of the photoreaction of complex 5,
trans,trans,trans-[Pt(N3)2(OH)2(MA)(Py)] (0.5 mM) with 5'-GMP (1.0 mM) upon
irradiation at (A) 450 nm 1 h; (B) 450 nm 3 h; (C) 450 nm 3 h and UVA 1 h
successively; (D) UVA 1 h only. (298 K) Retention times and assignments: 3.46 min,
5'-GMP; 11.10 min, trans-[Pt(MA)(Py)(5'-GMP)2 − 2H] (5a); 11.47 min, (SP-4-2)-
[Pt(N3)(MA)(Py)(5'-GMP) − H] (5b).
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Figure 4.15 Mass spectrum isotope distributions of 5a (trans-[Pt(MA)(Py)(5'-
GMP)2 − 2H], m/z for [M + H], calc. 1030.2; found, 1030.3) and 5b (SP-4-2)-
[Pt(N3)(MA)(Py)(5'-GMP) − H], m/z for [M + H], calc. 710.1; found, 710.0. Their
corresponding simulated isotope distributions are labelled with reversed red triangles.
Scheme 4.1 Photoreaction scheme of complex 5 with 5'-GMP upon irradiation with
UVA or 450 nm light.
The photoreaction of complex 8 with 5'-GMP followed a course very similar to that
of complex 5. Irradiation at 450 nm of a mixture of 8 and 5'-GMP (0.5 : 1.0 mM in
H2O) for one hour produced 8b (tr = 10.69, (SP-4-3)-[Pt(N3)(MA)(Tz)(5'-GMP) − H]) 
as the major product and 8a (tr = 10.82 trans-[Pt(MA)(Tz)(5'-GMP)2 − 2H]) as 
minor product (for HPLC chromatogram, see Figure 4.16A). The identical retention
time and absorption spectrum were verified by the synthesized authentic samples of
8a and 8b. Their isotope distributions agree with the simulations. (Figure 4.17)
700 710 720
0
50
100
R
el
at
iv
e
A
bu
nd
an
ce
%
m/z
1020 1030 1040
0
50
100
R
el
at
iv
e
Ab
un
da
nc
e
%
m/z
5a 5b
Chapter 4 — Photochemistry of PtIV Diazidodihydroxido Complexes
166
Compounds 8a and 8b possessed very similar retention times on the HPLC
chromatogram, but they could be clearly identified as two products by coupled mass
spectrometry. The photoproducts in Figure 4.16A did not change much over 2 hours
of additional irradiation at 450 nm (Figure 4.16B), and after irradiation with UVA
for one hour, almost all the mono-N3− adduct 8b was destroyed, leaving 8a only
(Figure 4.16C). The reaction with irradiation of UVA gave 8a as a major product
(Figure 4.16D), similar to Figure 4.16C.
Figure 4.16 HPLC chromatography of the photoreaction of complex 8,
trans,trans,trans-[Pt(N3)2(OH)2(MA)(Tz)] (0.5 mM) and 5'-GMP (1.0 mM) upon
irradiation with (A) 450 nm light 1 h; (B) 450 nm light 3 h; (C) 450 nm 3 h and
UVA 1h successively; (D) UVA 1 h only. (298 K) Retention times and assignments:
3.46 min, 5'-GMP; 10.82 min, trans-[Pt(MA)(Tz)(5'-GMP)2 − 2H] (8a); 10.69 min,
(SP-4-3)-[Pt(N3)(MA)(Tz)(5'-GMP) − H] (8b).
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Figure 4.17 Mass spectrum isotope distribution of 8a (trans-[Pt(MA)(Tz)(5'-GMP)2
− 2H], m/z for [M + H], calc. 1036.1; found, 1036.1) and 8b (SP-4-3)-
[Pt(N3)(MA)(Tz)(5'-GMP) − H], m/z for [M + H], calc. 716.1; found, 716.2. Their
corresponding simulated isotope distributions are labelled with reversed red triangles.
4.3.3.4 195Pt NMR spectroscopy
The products from photoreaction of complexes 5 (trans,trans,trans-
[Pt(N3)2(OH)2(MA)(Py)]) and 8 (trans,trans,trans-[Pt(N3)2(OH)2(MA)(Tz)]) with 5'-
GMP were monitored by 195Pt NMR and the chemical shifts were assigned in
accordance with published data.47, 48 A solution of complex 5 (3.9 mM) and 5'-GMP
(7.8 mM) in D2O was irradiated at 450 nm in an NMR tube and the 195Pt NMR
spectrum was recorded at various time intervals (Figure 4.18 A – C). Before
irradiation, there was only one 195Pt NMR peak (at δ = 892 ppm) corresponding to
complex 5. During the first 30 min of irradiation, this peak decreased in intensity and
a new signal (δ = −2328 ppm) in PtII region appeared, which was assigned as 5b,
(SP-4-2)-[Pt(N3)(MA)(Py)(5'-GMP) − H]. The assignment of the new signal was 
confirmed by the 195Pt NMR chemical shift of a synthesized authentic sample. The
signal of complex 5 completely disappeared after irradiation of the sample for 1 hour,
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while the signal of 5b was still present. The NMR spectrum did not change much
over the following two hours’ irradiation (data not shown). This photoproduct was
quite stable and was not re-oxidized to PtIV species after one week of storing in dark
at room temperature.
Figure 4.18 195Pt NMR (129.4 MHz, 298 K) spectra of complex 5 or 8 (3.9 mM)
with 5'-GMP (7.8 mM) in D2O after irradiation at 450 nm (298 K). Complex 5 with
5'-GMP irradiated (A) 0 min, (B) 30 min and (C) 1 h. Complex 8 with 5'-GMP
irradiated for (D) 0 min and (E) 15 min.
Similar 195Pt NMR experiments were performed for complex 8 as well to follow its
photoreaction with 5'-GMP (Figure 4.18 D and E). The peak for complex 8 (δ = 907
ppm) completely disappeared during only 15 min of irradiation at 450 nm. The new
signal (δ = −2296 ppm) was assigned as 8b (SP-4-3)-[Pt(N3)(MA)(Tz)(5'-GMP) − H] 
and was confirmed by the 195Pt NMR spectrum of a synthesized authentic sample.
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4.3.4 Nitrene intermediates and guanine oxidation
4.3.4.1 Discovery of the side products generated by UVA irradiation
As shown in Section 4.3.3.3, in the photoreaction of complex 5 (trans,trans,trans-
[Pt(N3)2(OH)2(MA)(Py)], 0.5 mM) with 5'-GMP (1.0 mM), trans-
[Pt(N3)(MA)(Py)(5'-GMP) − H] (5b) was the major product upon irradiation at 450
nm for 1 hour, but trans-[Pt(MA)(Py)(5'-GMP)2 − 2H] (5a) was the major product
upon irradiation with UVA for 1 hour. The reaction conditions and the HPLC
conditions were both optimized to examine the other side photo-products generated
by UVA irradiation. When the ratio of complex 5 : 5'-GMP was changed to 2 : 3 and
irradiation with UVA (3.5 mW/cm2) was shortened to 15 minutes, some new species
were found by HPLC (Figure 4.19C, where a new C18 reverse-phase column was
used in the HPLC analysis). Apart from unreacted 5'-GMP, bis-adduct trans-
[Pt(MA)(Py)(5'-GMP)2 − 2H] (5a) and mono-adduct (SP-4-2)-[Pt(N3)(MA)(Py)(5'-
GMP) − H] (5b), compound 5c (m/z=718.1), 5d (m/z=684.1), 5e (m/z=700.1) and 5f
(m/z=685.1) were identified as new Pt-containing species by their isotope
distributions in LC-coupled mass spectrometry (detailed characterization will be
carried out later in this chapter). When the mixture of 0.67 mM complex 5 and 1.0
mM 5'-GMP was irradiated at 420 nm for 30 min or 450 nm for 60 minutes, some of
the side products were also observed (Figure 4.19A, B and C) This clearly shows
that with photons of higher energy, more new species are generated. A control
experiment of 1.0 mM 5'-GMP in the absence of complex 5 was irradiated with
UVA for 15 min and the product was analysed with HPLC as shown in Figure
4.19D. There was no reaction and only 5'-GMP was found. This result suggested that
5'-GMP in aqueous solution is very stable upon irradiation with UVA. The
photoreaction of complex 5 with 5'-GMP was repeated under the protection of argon,
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and identical result was found by HPLC. Therefore, the generation of compounds 5c,
5d, 5e and 5f are all caused by the Pt complex 5.
Figure 4.19 High performance liquid chromatograms (HPLC) of photoreactions of
complex 5 (0.67 mM) with 5'-GMP (1.0 mM) in aqueous solution upon irradiation
with (A) 450 nm light, 50 mW/cm2, 60 min; (B) 420 nm, 4.3 mW/cm2, 30 min; (C)
UVA, 3.5 mW/cm2, 15 min; (D) 5'-GMP (1.0 mM) in aqueous solution irradiated
with UVA for 15 min.
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4.3.4.2 Analysis of the side products by HR-MS and MS/MS
In order to examine the structures of species 5c, 5d and 5e, electrospray ionization
high resolution mass spectra (ESI-HR-MS) and tandem mass (MS/MS) spectra for
these species, as well as for 5b, were obtained (Figure 4.20). Those species were
assigned as listed in Table 4.3. Their MS/MS spectra are in Figure 4.21 and
fragmentations and assignments are listed in Table 4.4 – Table 4.7.
Figure 4.20 High resolution mass spectrometry (HRMS) for compounds 5b, 5c, 5d
and 5e. The major calc. isotope distributions of each species (reversed red triangles)
are consistent with the peaks found in HRMS spectra (labelled with numbers).
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Table 4.3 HRMS and assignments of compounds 5b, 5c, 5d and 5e.
Masses
found m/z
Assigned chemical structures Assigned
chemical formula
Model
m/z
Error
ppm
710.1205
Pt
NH2CH3
N
NH
N
N
O
NH2N
O
OHOH
OPO
O
OH
N3
[Pt(N3)(MA)(Py)(5'-GMP) − H] (5b)
C16H24N10O8PPt
for [M + H]+
710.1164 5.8
718.1337
[Pt(NH3)(MA)(Py)(5'-(RedSp)MP) − 
2H] (5c)
C16H28N8O10PPt
for [M + H]+
718.1314 3.2
684.1228
[Pt(NH3)(MA)(Py)(5'-GMP) − 2H]
(5d)
C16H26N8O8PPt
for [M + H]+
684.1260 4.7
700.1235
[Pt(NH3)(MA)(Py)(5'-(8-oxo-G)MP)
− 2H] (5e)
C16H26N8O9PPt
for [M + H]+
700.1209 3.7
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Figure 4.21 MS/MS spectra (CID) of the species with m/z 710.12 (5b), 718.13 (5c),
684.12 (5d) and 700.12 (5e).
The species with m/z 684.1228 is assigned as [Pt(NH3)(MA)(Py)(5'-GMP) − 2H] (5d)
with an error between found and calculated m/z for [M + H]+ of 4.7 ppm. The
fragments in the MS/MS analysis assignable as [M − NH3 + H]+ (667.1015), [M − 
MA + H]+ (653.0862), [M − Py + H]+ (605.0857) and [Pt(GMP) + H]+ (557.0191)
were found, which confirmed the assignment of [Pt(NH3)(MA)(Py)(5'-GMP) − 2H] 
(5d). The other fragments were all reasonably assigned as Pt with certain
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combinations of NH3, MA, Py, GMP, phosphate and sugar moiety. It was surprising
to find an NH3 ligand in this molecule, as it does not belong to any of the reactants.
A reasonable source of the NH3 ligand is N3−, which can lose N2 upon irradiation of
PtIV-N3 with light to form a {Pt-N−} (nitrene) intermediate. The nitrene intermediate
is electron-deficient so it tends to gain two electrons from reductants. For example,
N− can insert into a C-H or O-H bonds,49, 50 capture an H− and react with one or two
H+, forming R-NH2 or NH3.28 The 5'-GMP was not oxidized in this molecule,
probably because it coordinated after NH3 was formed. However, an oxidized form
of guanine in 5'-GMP was observed in this work (vide infra).
Table 4.4 MS/MS analysis for [Pt(NH3)(MA)(Py)(5'-GMP) − 2H] (5d) [M + H]+ m/z
= 684.12 and assignment of fragments.
Found m/z Assigned structure Formula Calc. m/z Error ppm
667.1015 [M − NH3 + H]+ C16H23N7O8PPt 667.0994 3.1
653.0862 [M − MA + H]+ C15H21N7O8PPt 653.0838 3.7
636.0607 [M – MA − NH3 + H]+ C15H18N6O8PPt 636.0572 5.5
605.0857 [M − Py + H]+ C11H21N7O8PPt 605.0837 3.3
588.0587 [M – Py − NH3 + H]+ C11H18N6O8PPt 588.0572 2.6
574.0427 [M – Py − MA + H]+ C10H16N6O8PPt 574.0415 2.1
557.0191 [M – Py – MA − NH3 + H]+
([Pt(GMP) − H]+)
C10H13N5O8PPt 557.0150 7.4
522.0272 [Pt(Py)(G) + H2PO4]+ C10H12N6O5PPt 522.0255 3.3
460.0108 [Pt(NH3)(G) + H2PO4]+ C5H10N6O5PPt 460.0098 2.2
442.9846 [Pt(G) + H2PO4]+ C5H7N5O5PPt 442.9833 2.9
441.0756 [Pt(NH3)(Py)(G) − H]+ C10H12N7OPt 441.0751 1.1
424.0504 [Pt(Py)(G) − H]+ C10H9N6OPt 424.0486 4.2
388.0035 [Pt(NH3)(Py) + H2PO4]+ C5H10N2O4PPt 388.0026 2.3
376.0489 [Pt(MA)(G) − H]+ C6H9N6OPt 376.0485 1.1
304.0411 [Pt(MA)(Py) − H]+ C6H9N2Pt 304.0414 1.0
Chapter 4 — Photochemistry of PtIV Diazidodihydroxido Complexes
175
The species with m/z 700.1235 is assignable as [Pt(NH3)(MA)(Py)(5'-(8-oxo-G)MP)
− 2H] (5e) with an error between found and calculated m/z for [M + H]+ of only 3.7
ppm, where 5'-(8-oxo-G)MP is 8-oxoguanosine 5'-phosphate. It has an 8-oxo-G (8-
oxo-guanine or 8-hydroxyguanine) moiety in the molecule, which is one of the most
common DNA lesions resulting from reactive oxidants.13, 14, 51 The oxidation of
guanine possibly occurred by the nitrene intermediate. Reactions of nitrene
intermediates in inorganic compounds are rarely reported, however, it is still possible
to find clues from such reactions in organic chemistry.49, 52 A possible mechanism is
proposed in Scheme 4.2, Mechanism 1. The {Pt-N3−} loses N2 upon irradiation with
UVA to form the {Pt-N−} intermediate. Two electrons are transferred from the
guanine moiety to the nitrene and guanine is oxidized to form 8-oxo-guanine, with
the addition of an H2O molecule. The nitrene is reduced and finally forms {Pt-NH3}.
Another possible oxidant is singlet oxygen. As demonstrated in Section 4.3.2 in this
Chapter, the photolysis of complex 5 could release 1O2, which can then oxidize
guanine to 8-oxo-G via a direct [4+2] cycloaddition of 1O2 (Scheme 4.2, Mechanism
2).14
The MS/MS analysis for 5e was performed. A number of fragments corresponding to
the loss of H2O were found, e.g., m/z 682.1123, which is assignable to the formation
of Pt coordinated cyclic phosphodiester (8-hydroxyguanosine 5',8 cyclic
phosphodiester) or cGMP (Figure 4.22).53, 54 The fragments with m/z 537.0373 and
472.0125, assignable as 8-hydroxyguanosine phosphodiester, support the formation
of the cyclic phosphodiester. Other assignable fragments such as [M − MA + H]+
(m/z 669.0810), [M − Py + H]+ (m/z 621.0804) and [M − Py − H2O − NH3 + H]+ (m/z
586.0447) confirm the structure assignment of [Pt(NH3)(MA)(Py)(5'-(8-oxo-G)MP)
− 2H] (5e). It is interesting to note that during the MS/MS, the OH group of the 8-
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OH-G can lose together with a proton to form a dehydrogenated guanine (m/z
374.0339).
Scheme 4.2 Two possible mechanisms for the oxidation of 5'-GMP.
Figure 4.22 Possible Pt coordinated cyclic phosphodiester (8-hydroxyguanosine 5',8
cyclic phosphodiester) and cGMP53, 54 intermediates for m/z = 682.1123.53, 54
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Table 4.5 MS/MS analysis for [Pt(NH3)(MA)(Py)(5'-(8-oxo-G)MP) − 2H] (5e) [M +
H]+ m/z = 700.12 and assignment of fragments.
Found m/z Assigned structure Formula Calc. m/z Error ppm
682.1123
Pt
NH2CH3
N
H3N
NH
N
N
O
NH2N
O
OHOH
O
P
O
O O
+
_
[M − H2O + H]+
C16H24N8O8PPt 682.1103 2.9
669.0810 [M − MA + H]+ C15H21N7O9PPt 669.0787 3.4
651.0704
[M − MA − H2O + H]+
C15H19N7O8PPt 651.0681 3.5
621.0804 [M − Py + H]+ C11H21N7O9PPt 621.0786 2.9
603.0697
[M − Py − H2O + H]+
C11H19N7O8PPt 603.0681 2.7
586.0447
[M − Py − H2O − NH3 +
H]+
C11H16N6O8PPt 586.0415 5.5
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572.0278
[M − MA − Py − H2O +
H]+
C10H14N6O8PPt 572.0259 3.3
537.0373 C10H13N7O5PPt 537.0364 1.7
518.0310 Unspecified
472.0125 C6H10N6O5PPt 472.0098 5.7
457.0687 C10H12N7O2Pt 457.0700 2.8
439.0605 C10H10N7OPt 439.0595 2.3
391.0602 Unspecified
374.0339 Unspecified
360.3218 Contamination.
Also appeared in blank.
350.5639 [M + 2H]2+ C16H27N8O9PPt 350.5638 0.3
304.0416 [Pt(MA)(Py) − H]+ C6H9N2Pt 304.0408 2.6
The species with m/z 710.1205 is assignable as [Pt(N3)(MA)(Py)(5'-GMP) − H] (5b)
with the error between found and calculated m/z for [M + H]+ of 5.8 ppm. The
observed peaks with m/z 700.1230, 669.0810 and 621.0811 are assigned as
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[Pt(NH3)(MA)(Py)(5'-(8-oxo-G)MP − H)]+, [Pt(NH3)(Py)(5'-(8-oxo-G)MP − H)]+
and [Pt(NH3)(MA)(5'-(8-oxo-G)MP − H)]+, respectively. The loss of N2 from M-N3
forming Pt-N in MS/MS has been reported previously and the reaction is described
in Equation 1 and 2. 27, 55
[Pt(L)N3]+ → [Pt(L)N]+ + N2 (1)
[Pt(L)N]+ + H2O→ [Pt(L − 2H + OH)NH3]+ (2)
The peaks with m/z 651.0704, 572.0276, 439.0602, 391.0596, 337.9878 and
319.0527 are assignable as [Pt(N)(MA)(GMP)]+, [Pt(N)(GMP)]+, [Pt(N)(Py)(G)]+,
[Pt(N)(MA)(G)]+, [Pt(N)(MA) + H3PO4]+ and [Pt(N)(MA)(Py)]+, respectively,
corresponding to the [Pt(L)N]+ species in Equation 1. Other assignable fragments
such as [Pt(Py)(GMP) − H]+ (636.0619) and [Pt(N3)(Py)(MA)(G)]+ (498.1091) again
confirm the structure assignment of 5b. The oxidation of guanine may have
happened during the MS/MS process, as the peaks with m/z 586.0447 and 472.0118
were found and assigned as Pt coordinated cyclic phosphodiester. Also, the loss of
H2O of the 8-OH-G was also found, resulting in a dehydrogenated guanine (m/z
374.0336).
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Table 4.6 MS/MS analysis for [Pt(N3)(MA)(Py)(5'-GMP) − H] (5b) [M + H]+ m/z =
710.12 and assignment of fragments.
Found m/z Assigned structure Formula Calc. m/z Error ppm
700.1230 C16H26N8O9PPt 700.1203 3.9
669.0810 C15H21N7O9PPt 669.0781 4.3
651.0704
[Pt(N)(Py)(GMP)]+
C15H19N7O8PPt 651.0676 4.3
636.0619 [Pt(Py)(GMP) − H]+ C15H18N6O8PPt 636.0571 7.5
621.0811 C11H21N7O9PPt 621.0781 4.8
603.0698
[Pt(N)(MA)(GMP)]+
C11H19N7O8PPt 603.0675 3.8
586.0445 C11H16N6O8PPt 586.0410 6.0
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572.0276
[Pt(N)(GMP)]+
C10H14N6O8PPt 572.0253 4.0
498.1091 [Pt(N3)(Py)(MA)(G)]+ C11H15N10OPt 498.1072 3.8
472.0118 C6H10N6O5PPt 472.0092 5.5
439.0602
[Pt(N)(Py)(G)]+
C10H10N7OPt 439.0589 3.0
391.0596
[Pt(N)(MA)(G)]+
C6H10N7OPt 391.0589 1.8
374.0336
[Pt(MA)(G) − H]+
C6H7N6OPt 374.0323 3.5
337.9878 [Pt(N)(MA) + H3PO4]+ CH8N2O4PPt 337.9864 4.1
319.0527 [Pt(N)(MA)(Py)]+ C6H10N3Pt 319.0517 3.1
The species with m/z 718.1337 is assignable as [Pt(NH3)(MA)(Py)(5'-(RedSp)MP) − 
2H] (5c) (RedSp = N-formylamidoiminohydantoin) with an error between found and
calculated m/z for [M + H]+ of 3.2 ppm. Compound 5c is assigned as compound 5e
with hydrolysed 8-oxo-G — RedSp (N-formylamidoiminohydantoin). The
hydrolysis reaction of 8-oxo-G has been reported14 and is shown in Scheme 4.3.
Compound 5c is much more hydrophilic than 5d, 5e, and 5b, so the retention time in
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HPLC for 5c is much shorter. In MS/MS analysis, compound 5c could lose one or
two water molecules, which could lead to the formation of either an 8-cyclic
phosphodiester or a 8-oxo-G (Scheme 4.4), but it is not possible to determine which
water is lost first. For instance, peaks with m/z 700.1227, 683.1052, 669.0807,
665.0862, 621.0807, 603.0710 and 586.0438 can be assigned as [M − H2O + H]+, [M
− H2O − NH3 + H]+, [M − H2O − MA + H]+, [M − 2H2O − NH3 + H]+, [M − Py − 
H2O + H]+, [M − Py − 2H2O + H]+ and [M − Py − 2H2O − NH3 + H]+, respectively.
These fragments also confirm the presence of MA, MH3 and Py groups in the
molecule. The loss of H2O from 8-OH-G (m/z 374.0341) was again found here.
Scheme 4.3 Reaction mechanism for RedSp (N-formylamidoiminohydantoin).
Scheme 4.4 Two steps of dehydrolization of complex 5c in MS/MS, forming an 8-
cyclic phosphodiester or and an 8-oxo-G.
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Table 4.7 MS/MS analysis for [Pt(NH3)(MA)(Py)(5'-(RedSp)MP) − 2H] (5c) [M +
H]+ m/z = 718.13 and assignment of fragments.
Found m/z Assigned structure Formula Calc. m/z Error ppm
700.1227 [M − H2O + H]+ C16H26N8O9PPt 700.1203 3.4
669.0807 [M − H2O − MA + H]
+ C15H21N7O9PPt 669.0781 3.9
665.0862 [M − 2H2O − NH3 + H]+ C16H21N7O8PPt 665.0832 4.5
653.0628 Unspecified
621.0807 [M − Py − H2O + H]+ C11H21N7O9PPt 621.0781 4.2
603.0710 [M − Py − 2H2O + H]+ C11H19N7O8PPt 603.0675 5.8
586.0438 [M − Py − 2H2O − NH3 + H]+ C11H16N6O8PPt 586.0410 4.8
472.0117 C6H10N6O5PPt 472.0092 5.3
452.0200 Unspecified
391.0605 Unspecified
374.0341 C6H7N6OPt 374.0323 4.8
4.3.4.3 Direct evidence for the conversion from Pt-N3 to Pt-NH3
More than 40 years ago, the conversion of [Ir(NH3)5(N3)]2+ to the chloramine
complex [Ir(NH3)5(NH2Cl)]+ was reported, and was believed to involve the nitrene
intermediate [Ir(NH3)5(N)]2+.56 Also, the formation of NH3 in the
photodecomposition of free N3− via a nitrene intermediate has been reported.28, 29 In
recent years, electrospray ionization MS studies of [Pt(L)N3]+ type of coordination
compounds in the gas-phase has revealed the existence of the following species
[Pt(L)N]+, [Pt(L − 2H)NH2]+ and [Pt(L − 3H)]+ + NH3 formed under collision-
induced dissociation (CID).27, 55 However, stable species of the type [Pt(L)n(NH3)]
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generated from the corresponding azido species has not been reported yet. In order to
confirm that the NH3 group was formed from the N3− group, 15N end-labelled NaN3
was used to synthesize trans,trans,trans-[Pt(15N3)2(OH)2(MA)(Py)] (5*), where 15N3
= [15N=14N=14N]−. Then the photoreaction of complex 5* with 5'-GMP upon
irradiation with UVA was carried out under identical conditions as those in Section
4.3.4.1. LC-MS analysis was performed afterwards and an identical chromatogram
was recorded. The MS spectra for species 5b*, 5c* 5d* and 5e* corresponding to
identical retention time as 5b, 5c, 5d and 5e were recorded in Figure 4.23. If the
molecule contains the intact end-labelled 15N3 ligand, the m/z of each peak of the
isotope distributions should be 1 Da larger than that of the unlabelled molecule. If
the molecule contains an NH3 group converted from the end-labelled 15N3 ligand, the
N atom should be a 50%/50% mixture of 15N and 14N. Therefore, the resultant
isotope distributions should be a 50%/50% mixture of M and M + 1. As it was
expected, compound 5b* was 1 Da larger than 5b, which confirms that it has an N3
ligand. The isotope distributions of the other three species 5c*, 5d* and 5e* are all
50%/50% mixture of M and M + 1, so they are all considered as {Pt-NH3} moieties
derived from {Pt-N3} moieties. Therefore, the species in Figure 4.23 are assigned as
[Pt(15N3)(MA)(Py)(5'-GMP) − H] (5b*), [Pt(NH3*)(MA)(Py)(5'-(RedSp)MP) − 2H] 
(5c*), [Pt(NH3*)(MA)(Py)(GMP) − 2H] (5d*) and [Pt(NH3*)(MA)(Py)(5'-(8-oxo-
G)MP) − 2H] (5e*) (NH3*= 50% 15NH3/50% 14NH3).
Chapter 4 — Photochemistry of PtIV Diazidodihydroxido Complexes
185
Figure 4.23 MS spectra for compounds 5b*, 5c* 5d* and 5e* obtained from LC-MS.
The major calc. isotope distributions of each species are labelled with reversed red
triangles.
4.3.5 Photo-induced binding with DNA oligonucleotide
A preliminary DNA binding experiment was carried out since the DNA is regarded
as the major target for platinum based anticancer drugs. A self-complementary single
strand DNA d(TATGGTACCATA) (I) was selected for study since it contains a GG
sequence which is usually the preferred binding site for platinum drugs.57
The photoreaction of complex 5 (trans,trans,trans-[Pt(N3)2(OH)2(MA)(Py)], 100 μM) 
with the ss-DNA I in a 1:1 mol ratio was irradiated for 1 hour with 450 nm light at
298 K, and the products were characterized by ESI-HR-MS. The major species in the
reaction mixture was found to be unreacted ss-DNA I (Figure 4.24), and their m/z
were used as internal calibration in linear mode. A series of platinated products were
also found, assignable as a mono-functional platinum-DNA adduct with one N3
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group remaining on Pt, [I + Pt(N3)(MA)(Py) − H]. The MS peaks detected are listed 
and assigned in Table 4.8. Interestingly, a series of weak signals corresponding the
loss of the second N3 group was also found, assignable as [I + Pt(MA)(Py) − 2H]. 
This species is probably a bifunctional DNA intrastrand crosslink.
Figure 4.24 ESI-HR-MS (negative mode) spectrum for the photoreaction of
complex 5 (100 μM) with ss-DNA I (1:1, in H2O, 450 nm, 1 hour, 298 K).
Assignments are labelled on the spectrum and the species may also be found as nNa+
adducts in the spectrum.
Table 4.8 Negative ions m/z detected by ESI-HR-MS for the photoreaction of
complex 5 (100 μM) with ss-DNA I (100 μM) (in H2O, 450 nm, 1 hour, 298 K)
Species assignment Found m/z Calculated m/z Error/ppm
[I − 5H]5− 727.7234 727.7235 - a
[I − 4H]4− 909.9067 909.9065 -
[I − 3H]3− 1213.5446 1213.5447 -
[I + PtII(N3)(MA)(Py) − 5H]4− 996.4165 996.4190 2.5
[I + PtII(N3)(MA)(Py) − 4H]3− 1328.8916 1328.8948 2.4
[I + PtII(MA)(Py) − 6H]4− 985.6627 985.6647 2.0
[I + PtII(MA)(Py) − 5H]3− 1314.5458 1314.5558 7.6
a The m/z of I are used for internal calibration with linear mode.
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When the molar ratio of complex 5 : ss-DNA I was changed to 2:1, the signal for [I
+ Pt(N3)(MA)(Py) − H] increased, and another product was identified: [I +
2Pt(N3)(MA)(Py) − 2H] (Figure 4.25 and Table 4.9). The signals assignable to
bifunctional DNA intrastrand crosslink [I + Pt(MA)(Py) − 2H] and [I + 2Pt (MA)(Py)
+ N3 − 3H] were again found. The sample was stored in dark at room temperature for 
3 months after irradiation and was analysed by ESI-HR-MS spectrometry again
(Figure 4.26). The mono-functional adduct [I + Pt(N3)(MA)(Py) − H] was still 
found. It is notable that the intensity of the signals corresponding to possible
bifunctional DNA intrastrand crosslinks [I + Pt(MA)(Py) − 2H] increased, even 
higher than for the mono-functional DNA adduct. This suggests that the DNA
binding with platinum is very stable, and the mono-functional adducts was possibly
converted to bifunctional adducts slowly in aqueous solution. The isotopic
distributions of the observed DNA adducts [I + Pt(N3)(MA)(Py) − H] and [I +
Pt(MA)(Py) − 2H] are shown in Figure 4.27, and are consistent with their simulation.
Figure 4.25 ESI-HR-MS (negative mode) spectrum for the photoreaction of
complex 5 (200 μM) with ss-DNA I (100 μM) (in H2O, 450 nm, 1 hour, 298 K).
Assignments are labelled on the spectrum and the species may also be found as nNa+
adducts in the spectrum.
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Figure 4.26 ESI-HR-MS (negative mode) spectrum for the photoreaction of
complex 5 (200 μM) with ss-DNA I (100 μM) 100 days after irradiation (in H2O,
450 nm, 1 hour, 298 K). Assignments are labelled on the spectrum and the species
may also be found as nNa+ adducts in the spectrum.
Figure 4.27 Mass spectrum isotope distributions for photoproducts of complex 5
with ss-DNA I (A): [I + Pt(N3)(MA)(Py) − 4H]3−, m/z calc. 1328.8948, found,
1328.8892 and (B) [I + Pt(MA)(Py) − 5H]3−, m/z calc. 1314.5558; found, 1314.5474.
Their corresponding simulations are labelled with red reversed triangles.
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Table 4.9 Negative ions m/z detected by ESI-HR-MS for the photoreaction of
complex 5 (200 μM) with ss-DNA I (100 μM) (in H2O, 450 nm, 1 hour, 298 K)
Species assignment Found m/z Calculated m/z Error/ppm
[I – 5H]5– 727.7234 727.7235 - a
[I – 4H]4– 909.9067 909.9065 -
[I – 3H]3– 1213.5446 1213.5447 -
[I + PtII(N3)(MA)(Py) – 5H]4− 996.4176 996.4190 1.4
[I + PtII(N3)(MA)(Py) – 4H]3− 1328.8892 1328.8948 4.2
[I + PtII(MA)(Py) – 6H]4− 985.6617 985.6647 3.0
[I + PtII(MA)(Py) – 5H]3− 1314.5474 1314.5558 6.4
[I + 2PtII(N3)(MA)(Py) – 5H]3− 1444.5578 1444.5787 14.5
[I + 2PtII(MA)(Py) + N3 – 6H]3− 1430.2275 1430.2397 8.5
a The m/z of I are used for internal calibration with linear mode.
A similar reaction of complex 8 (trans,trans,trans-[Pt(N3)2(OH)2(MA)(Tz)]) and ss-
DNA I (2:1) was also carried out, monitored by ESI-HR-MS (Figure 4.28). As
expected, apart from the signal of the ss-DNA (I), a signal corresponding to mono-
functional Pt-DNA adduct [I + Pt(N3)(MA)(Tz) − (n + 1)H]n− was detected. Also,
another signal possibly corresponding to bifunctional DNA intrastrand crosslink [I +
Pt(MA)(Tz) − (n + 2)H]n− was found (see Table 4.10). The isotopic distributions
correlated well with the simulations and are summarized in Figure 4.29.
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Figure 4.28 ESI-HR-MS (negative mode) spectrum of complex 8 (200 μM) with ss-
DNA I (2:1 in H2O, irradiated at 450 nm light for 1 hour at 298 K). Assignments are
labelled on the spectrum and the species may also be found as Na+ adducts in the
spectrum.
Figure 4.29 Mass spectrum isotope distribution of photo-adducts of complex 8 with
ss-DNA I: [I + Pt(N3)(MA)(Tz) − 4H]3−, m/z calc. 1330.8813, found, 1330.8879 and
[I + Pt(MA)(Tz) − 5H]3−, m/z calc. 1316.5412; found, 1316.5373. Their
corresponding simulations are labelled with red reversed triangles.
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Table 4.10 Negative ions m/z detected by ESI-HR-MS for the photoreaction
between complex 8 (200 μM) and ss-DNA I (100 μM) (in H2O, irradiated at 450 nm
for 1 hour at 298 K)
Species assignment Found m/z Calculated m/z Error/ppm
[I – 4H]4− 909.9065 909.9065 - a
[I – 3H]3− 1213.5447 1213.5447 -
[I + PtII(N3)(MA)(Tz) – 4H]3− 1330.8879 1330.8813 5.0
[I + PtII(MA)(Tz) – 5H]3− 1316.5373 1316.5412 3.0
a The m/z of I are used for internal calibration with linear mode.
These results suggested that complexes 5 (trans,trans,trans-[Pt(N3)2(OH)2(MA)(Py)])
and 8 (trans,trans,trans-[Pt(N3)2(OH)2(MA)(Tz)]) can quickly form DNA adducts
upon irradiation with blue light, and that the major adducts are mono-functional and
bi-functional adducts were possibly formed. (Figure 4.30) Complex 8 seems to be
able to generate more bi-functional adduct within a short period of time than
complex 5. The binding site cannot be identified at this stage, but is to be determined
in the future work. As the photoreaction took place very rapidly, the Pt complexes
may bind not only to guanine, but also possibly to cytosine and adenine.6, 58 Further
experiments must be carried out to determine the binding sites.
Figure 4.30 Photoinduced DNA binding for complex 5 with ss-DNA I. The reaction
of complex 8 occurs in a similar way.
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4.4 Discussion
4.4.1 Dark stability and reduction potential
Complexes 5 (trans,trans,trans-[Pt(N3)2(OH)2(MA)(Py)]) and 8 (trans,trans,trans-
[Pt(N3)2(OH)2(MA)(Tz)]) are very stable in aqueous solution and do not react with
5’-GMP and the biological reductants such as L-ascorbic acid, and their reactions
with glutathione were very slow. It is generally accepted that for PtIV complexes, the
ease of reduction is determined mainly by their reduction potentials, which are
closely related to the nature of the ligands. The empirical sequence for the ease of
reduction affected by the axial ligands in cis,trans,cis-[PtCl2X2N2] complexes (N =
N-donor ligands) follows this order of X: OH− < OAc− < Cl− < I−.59-61 Therefore, the
PtIV trans-dihydroxido complexes are harder to be reduced than the diiodo,
dichlorido and the diacetato complexes.
4.4.2 Stability of non-leaving groups
Reports from Sadler’s group 6-9 and Bednarski’s group 11 have previously examined
the photoproducts of PtIV diazido complexes. The loss of ammine ligand (NH3) was
observed at a considerable level during the irradiation towards complex
trans,trans,trans-[Pt(N3)2(OH)2(NH3)2] and cis,trans,cis-[Pt(N3)2(OH)2(NH3)2].7, 8
On the other hand, the loss of pyridine from PtIV complexes such as
trans,trans,trans-[Pt(N3)2(OH)2(Py)2] was very low.10 It is widely accepted that the
non-leaving groups, also called “carrier ligands”, e.g., aliphatic imines and aromatic
imines, play a very important role in the anticancer activity.62 The existence of these
ligands may affect the distortion of damaged DNA and enzyme recognition in DNA
repair synthesis. Taking cisplatin as an example, the loss of ammine may partly
account for the deactivation and resistance to the drug in cancer cells.63, 64 Therefore,
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in this work, special attention was paid on the stability of the MA ligand in Pt
complexes. 1H and 14N NMR were both used to examine this issue, and it was found
that the MA ligand was very stable during irradiation at 450 nm. Also, in the
presence of 5’-GMP, little loss of MA was observed. The high stability of MA
ligand after photoactivation indicates that it may largely remain on Pt if the reaction
takes place on DNA. As a result, the high stability of Pt-MA bonds in complexes 5
(trans,trans,trans-[Pt(N3)2(OH)2(MA)(Py)]) and 8 (trans,trans,trans-
[Pt(N3)2(OH)2(MA)(Tz)]) may contribute to their potent photocytotoxicity to cancer
cells.
4.4.3 Photodecomposition pathways of Pt diazidodihydroxido complexes
The photodecomposition pathways for cis or trans platinum(IV) diazidodihydroxido
complexes with one or two NH3 ligand have been investigated previously. 6-9, 11 The
formation of PtII and PtIV products, PtIII and nitrene intermediates, and the release of
N3− anions and free NH3, evolution of N2 gas and O2 gas have been observed. The
release of N3• radicals was postulated but no evidence was given yet. In the current
work, PtIV diazidodihydroxido complexes were designed with methylamine
replacing the NH3 ligand. Also, direct evidence for N3• radicals and nitrene
intermediates were obtained. More importantly, the energy state of the released O2
gas was examined.
4.4.3.1 Azido ligands
For complex 5, trans,trans,trans-[Pt(N3)2(OH)2(MA)(Py)], which was studied
extensively in this work, the photodecomposition pathways for the azido ligands are
very versatile. There are a number of known photoproducts according to this work:
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 In the absence of nucleophiles, such as 5’-GMP,
 Free azide anion N3−
 Azidyl radical N3•
 Nitrogen gas N2
 Mono-azido Pt moiety {Pt-N3}
 In the precipitate
 Nitrene intermediate {Pt-N} followed by forming {Pt-NH3}
 In the presence of nucleophiles (5’-GMP)
 Free azide anions N3−
 Azidyl radical N3•
 Mono-azido Pt complex moiety {Pt-N3}
 Very low nitrogen gas N2 release
 No precipitate
 Nitrene intermediate {Pt-N} followed by forming {Pt-NH3} and
oxidation of GMP
The importance and impact of each pathway are discussed as follows.
The photo-induced generation of azidyl radicals N3• has been reported for a wide
range of metal azido complexes, including cobalt(III), molybdenum(IV),
platinum(II), ion(III) and gold(III) azides.28 The formation of azidyl radicals N3• is
initiated by a LMCT transition followed by a one-electron reduction of the central
atom. The general expression for the homolytic cleavage of the M-N3 bond is as
follows:
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In the present work, upon the release of an azidyl radical N3•, PtIV is reduced to a
PtIII intermediate [PtIII(OH)2(N3)LL’]. The PtIII is not stable so it must obtain or lose
one electron to form a PtII or PtIV species. The PtIII intermediate [PtIII(OH)2(N3)LL’]
tends to lose another azidyl radical N3• or a hydroxyl radical OH• and form PtII
species. In older work, the N3• and OH• radicals were proved by initiating the
polymerization of ethyl acrylate or acrylonitrile via the free-radical chain
mechanism.65-67 Alternatively, the radical N3• and radical OH• can both be identified
by EPR using spin traps, such as 5,5-dimethylpyrroline-1-oxide (DMPO).33, 68 Since
the radical OH• was not detected by EPR in this work, the PtIII intermediate
[PtIII(OH)2(N3)LL’] should lose the azidyl radical N3• and form [PtII(OH)2LL’].
Therefore, a photodecomposition pathway for complex 5 via azidyl radical N3•
formation is postulated, as in Scheme 4.5.
Scheme 4.5 Photodecomposition pathway for complex 5 via the formation of N3•
radical.
Since the N3• radical may be formed in one of the major pathways of the
photodecomposition of PtIV diazidodihydroxido complexes, its reactions in
biological systems are of great interest. On the one hand, it was demonstrated as
early as in 1970 that the N3• radical generated from the photolysis of [Au(N3)4]−,
[Pb(N3)6]2− and NaN3 can recombine to form N2 gas: 30, 65, 69
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where the k1 = 8.8 ± 0.5 × 109 M−1 s−1. On the other hand, the azidyl radical N3• is a
relatively mild and selective oxidant reported to oxidize aromatic oxyanions and
amines directly by electron transfer,30, 70, 71 in general:
For a range of phenols, k2 ~ 4 × 109 M−1 s−1. Oxidation reactions of tryptophan and
tyrosine by N3• radicals have also been reported.72 As a result, it is reasonable to
conclude that N3• holds potential ability to damage proteins in the cells.
Photoinduced release of free azide anions N3− is often accompanied by
photosubstitution with, e.g. a solvent molecule, in general: 28
While this process does not involve any redox reaction of the metal or the ligand, the
photoelimination is usually part of more complicated simultaneously-occurring
decomposition process. For example, in the photodecomposition of complexes
[Pt(N3)4]2−, [Au(N3)2]− and [Hg(N3)3]−, release of N3− is accompanied by the
elimination of N2. For example: 73
This involves formation of the N3• radicals transformed into nitrogen molecules as a
final product and associated with central atom reduction (vide supra). Nevertheless,
azide anion N3− is generally considered to be an acutely toxic species. It is a potent
vasodilator and inhibitor of platelet aggregation.74 In the cells, it is regarded as a
mitochondrial inhibitor 75-78 and myeloperoxidase and catalase inhibitor.34 Therefore,
although the N3− anion is not the main pathway in the photodecomposition of PtIV
diazidodihydroxido complexes, even very low concentration of N3− could greatly
contribute to the photocytotoxic effect of the PtIV diazidodihydroxido complexes.
Chapter 4 — Photochemistry of PtIV Diazidodihydroxido Complexes
197
The release of N2 gas found by 14N NMR has been reported recently for
[Pt(N3)2(OH)2(NH3)2] type of complexes.7, 8 Apart from recombination of two N3•
radicals (vide supra), N2 gas was also released directly from the {Pt-N3} moiety,
forming a {Pt-N} nitrene intermediate. The release of N2 gas in targeted tissues or
cells might potentially cause symptoms similar to decompression sickness, as gas
bubbles may block circulation and cause infarction.
Nitrene is a very reactive intermediate that can be quickly formed by the thermolysis
or photolysis of either metal azides or the free N3− anion.28 It has 6 valence electrons,
which, lacking two electrons, is an electrophile and a powerful oxidant. It tends to
capture two electrons via insertion in to C-H or O-H bond.49, 50 In aqueous solution,
it is responsible for a wide range of DNA lesions.52, 79-82 In 1968, it was reported that
the photodecomposition of Ba(N3)2 produced OH−, NH3 and N2 gas and small
amounts of H2.29 It was also described that the transformation from M-N3− to M-NH3
or free NH3 was found in CID (collision-induced dissociation).27, 55 Also, as was
reported by Ronconi etc.,8 after irradiation of trans,trans,trans-
[Pt(N3)2(OH)2(15NH3)2] with UVA, signal corresponding to free 14NH3 was found by
14N NMR as a photoproduct of azido ligand. To sum up, the discovery of
photogenerated {Pt-NH3} species in this work is again direct and unambiguous
evidence of inorganic nitrene intermediates arising from the photodecomposition of
Pt-N3 complexes. This intermediate exhibits a very strong oxidative property, which
possibly causes oxidative DNA damage.
Last but not least, it was discovered that two azido ligands of PtIV
diazidodihydroxido complexes can be released step by step from Pt. upon irradiation
at 450 nm, the photodecomposition stopped at the first step, releasing only one azido
ligand. After the release of the first azido group, the extinction coefficient of the
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band from the mono-Pt-N3 residual at 450 nm may decrease due to the change in the
structure of the molecule and the oxidation state of Pt. At this point, the second azido
ligand could only undergo photolysis with higher energy irradiation, e.g. UVA (λmax
= 365 nm).
4.4.3.2 Hydroxido ligands
Compared to the azido ligands, the decomposition behaviour of the hydroxido
ligands is still poorly understood. It has been previously reported that upon
irradiation with UVA, [Pt(N3)2(OH)2(NH3)2] type complexes can generate oxygen
gas (O2),7, 8, as detected by an oxygen electrode. However, the source and the energy
state of the evolved O2 are not clear.
It was previously postulated that upon irradiation with UVA, the dihydroxido ligands
are released as hydroxyl radicals OH•. When hydroxyl radicals are generated at high
local concentrations, they readily dimerize to give H2O2,42 which is known to
decompose by disproportionation to water and gaseous dioxygen on irradiation with
UV light.43 However, OH• radical and H2O2 were not detected in this work. The OH•
radical scavenger formic acid (FA) did not fully quench the fluorescence of the
singlet oxygen sensor (SOSG) and the spin trapping experiment by EPR did not
observe the signal of OH• radicals. Also, peroxide test stick did not detect H2O2
unless the solution was irradiated on the stick (in situ). The stability of H2O2 in
aqueous solution is influenced primarily by temperature and pH value. The
decomposition of H2O2 increases sharply with the pH value over 5, and trace amount
of impurities may induce the decomposition. Nevertheless, assuming that H2O2 is the
intermediate, the concentration of which found by the peroxide test stick was > 10
mg/L (see Section 4.3.2), it was not possible for H2O2 at such level fully
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decomposed in a few seconds. Other strong oxidants (e.g., 1O2), although short lived,
may have activated the test stick when the solution was irradiated in situ. Therefore,
it is reasonable to conclude that H2O2 does not exist as an intermediate in the photo-
decomposition of the PtIV diazidodihydroxido complexes studied in this work.
Singlet oxygen (1O2) is a very reactive and toxic species to biological systems. It
causes oxidative stress and is responsible for various types of oxidative DNA
damage. 12-15 This work has shown the first time that singlet oxygen can be generated
from a Pt dihydroxido complex. The control experiments with samples saturated
with argon or N2 showed that the elimination of singlet oxygen is not affected by the
dissolved oxygen gas in the solvent. Therefore, this work provides the first evidence
of the release of singlet oxygen from a PtIV diazidodihydroxido complex upon
irradiation with UVA/blue light in the absence of any exogenous source of oxygen
gas. It is important to investigate the mechanism of oxygen generation and to figure
out the source of oxygen.
Dioxygen transition metal complexes containing one or more O-O coordination
motifs,83 are potential models of key intermediates in catalytic reactions involving
molecular oxygen, hydrogen peroxide, or alkyl hydroperoxide as the oxygen source.
84 Various types of Pt dioxygen complexes have been reported,83, 85-87 two of which
evolve oxygen gas upon irradiation of light: one is a platinum η2-peroxo complex88
and the other is a trapezoid-peroxo complex.89 (Figure 4.31) The photoreleased
oxygen molecules may adopt two different electronic states, namely, the ground
triplet state (3Σg−) and the lowest excited singlet state (1Δg). Since the platinum
complexes in this work are mononuclear, it is reasonable to assume that a η2-peroxo
ligand is a possible intermediate in the photorelease of oxygen gas.
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A B
Figure 4.31 O-O binding motifs: A, η2-peroxo; B, trapezoid-peroxo structures.89
The redox reaction between PtII and PtIV has been extensively studied. On the one
hand, Abbott and coworkers reported the mechanism of oxidation of PtII to PtIV by
hydrogen peroxide.90 The oxidation reaction initiate with the addition of H2O2 to an
axial position of the PtII square, followed by a one-step two-electron transfer. After
that, the other axial site of the PtIV is coordinated by solvent, such as H2O and MeOH.
On the other hand, there are also a number of reports on the reduction of PtIV to PtII.
It is widely accepted that a concerted two-electron transfer from other molecule,
such as ascorbate or guanine, to the PtIV centre is involved.53, 91 Similarly, the
photoreduction of PtIV diazidodihydroxido complex and the release of oxygen gas
may also be a two-electron transfer process. The evidence for the mechanisms is still
being searched for.
4.4.4 Photoreaction with DNA/RNA bases and oligonucleotide
Complexes 5 (trans,trans,trans-[Pt(N3)2(OH)2(MA)(Py)]) and 8 (trans,trans,trans-
[Pt(N3)2(OH)2(MA)(Tz)]) can bind to 5'-GMP rapidly and efficiently upon
irradiation with light. In comparison, the binding of cisplatin to 5′-GMP at 310 K 
takes 7-8 hours to reach 50%.92 The higher photochemistry kinetics of PtIV
diazidodihydroxido complexes leads to various advantages. First, duration of the
therapeutic treatment can be short so that the discomfort and side effects of the light
dose to the patient can be minimized. Second, in the cisplatin-resistant cancer cells,
cytoplasmic detoxification by cellular thiols is a very important mechanism of the
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resistance to cisplatin. 93, 94 Rapid binding to DNA could reduce the side reactions
via reduced chance to react with cellular thiols.
When comparing the binding rate of complexes 5 and 8 upon irradiation with blue
light, it was observed that complex 8 react with 5'-GMP faster than complex 5. The
results from 1H, 195Pt NMR spectroscopy and HPLC-MS all supported this kinetic
difference (see Section 4.3.3). The higher binding rate to guanine of complex 8 than
complex 5 provides a possible explanation to the higher photocytotoxicity of
complex 8 towards HaCaT and A2780 cell lines upon irradiation with blue light (See
Section 3.3.4).
Interestingly, upon irradiation with blue light, complexes 5 and 8 preferentially form
monofunctional [Pt(N3)(MA)(Py/Tz)(GMP)] adducts when reacting with 5'-GMP,
but when reacting with ss-DNA oligonucleotide, higher levels of possible
bifunctional DNA intrastrand crosslinks [Pt(MA)(Py/Tz)(ss-DNA)] were produced
(see Section 4.3.5). Moreover, the yield of bifunctional adducts increased over time.
After the Pt complex bind to one nucleobase, forming [Pt(N3)(MA)(Py/Tz)(ss-
DNA)], it tends to lose the azido group and bind to another nucleobase, forming
[Pt(MA)(Py/Tz)(ss-DNA)]. This is probably because the bidentate adducts formed
from Pt and DNA are more stable than the monodentate adducts.
The novel binding mode of the PtIV diazidodihydroxido complexes to DNA may
provide different features from cisplatin. On the one hand, cisplatin forms
predominantly bifunctional intrastrand crosslinks (CLs) with DNA, namely d(GpG)
1,2 intrastrand (60 – 65% of all adducts) and d(ApG) 1, 2 intrastrand (20 – 25%)
crosslinks,93 which are believed to be the major cause of cell death. On the other
hand, for trans PtII anticancer complexes, monofunctional adducts and a small
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amount of bifunctional interstrand crosslinks are usually formed,95, 96 which may
lower the level of DNA repair synthesis and inhibit the transcription, so the cross-
resistance to cisplatin may thus be overcome. Also, a monofunctional PtII anticancer
complex has been rationally designed, which potently suppresses the growth of
cancer cells by inhibiting RNA polymerase II and nucleotide excision repair.97, 98 For
the platinum complexes in this work, not only are monofunctional DNA adducts
preferably formed, but also bifunctional adducts were possibly formed. As a result,
complexes 5 and 8 can form both bifunctional and monofunctional lesions on DNA,
which is a potential advantage of these novel photoactivatable anticancer complexes.
4.5 Conclusions
In this Chapter, the photochemistry of two Pt diazidodihydroxido complexes 5
(trans,trans,trans-[Pt(N3)2(OH)2(MA)(Py)]) and 8 (trans,trans,trans-
[Pt(N3)2(OH)2(MA)(Tz)]) was investigated using various analytical methods.
Photodecomposition pathways involving the azido ligands and the hydroxido ligands
were elucidated. The release of free azide anion N3−, azidyl radical N3•, nitrogen gas
N2 and nitrene intermediate {Pt-N} were observed. Importantly, it was discovered
that singlet oxygen (1O2) can be generated from the photoreaction. The photoinduced
efficient binding to 5'-GMP and DNA oligonucleotide was also analysed. It was
discovered for the first time that Pt-nitrene intermediates were produced and that the
oxidation of 5'-GMP can occur in the photodecomposition of the Pt
diazidodihydroxido complexes. It was also of importance to discover that singlet
oxygen is generated from this photoreaction which is likely to cause oxidative
damage to guanine. All these features contribute to the high photocytoxicity of this
class of compounds. Also, the feature of releasing singlet oxygen in the absence of
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exogenous source of oxygen overcomes the oxygen dependence of photodynamic
therapy (PDT) and hence the Pt diazidodihydroxido complexes can find
extraordinary application in photochemotherapy.
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5.1 Introduction
Since it was discovered that cisplatin inhibits cell division in the 1960s, platinum-
based drugs have been extensively studied against various tumours.1-3 However,
severe toxic and dose-limiting side-effects, including nausea, vomiting and
nephrotoxicity accompany the treatment, which limit its application.4 The use of
prodrugs to tune the physicochemical, biopharmaceutical or pharmacokinetic
properties of pharmacologically active agents is a promising approach to lower side-
effects.5, 6 Prodrugs are reversible derivatives of drug molecules that undergo an
enzymatic and/or chemical transformation in vivo to release the active parent drug,
which can then exert the desired pharmacological effect at the targeted site.7
Photoactivatable PtIV diazidodihydroxido anticancer complexes are a group of
prodrugs that are inert and non-toxic in a biological environment in the dark. Upon
irradiation with light these complexes can be selectively activated to become
potently cytotoxic against a number of cancer cell lines.8-12 However, these
complexes would ideally be activated with long wavelength light in the so-called
therapeutic window (400 − 800 nm13, 14) to allow treatment of larger tumours, as
tissue-penetration of light is wavelength-dependent (see Chapter 1).
One aim of this work is to develop new PtIV complexes with broader clinical utility
(activation wavelengths within the therapeutic window) by appropriate selection of
the ligands of the complexes. In Chapter 3, it was demonstrated that replacing the
NH3 ligand by an aliphatic amine in trans,trans,trans-[Pt(N3)2(OH)2(NH3)(Py)](22)
can produce enhanced photocytotoxicity to cisplatin-resistant cancer cells and
provide activation by blue light, as found for trans,trans,trans-
[Pt(N3)2(OH)2(MA)(Py)] (5) and trans,trans,trans-[Pt(N3)2(OH)2(MA)(Py)] (8).
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However, these complexes cannot be activated by light with λ > 500 nm. So the aim 
of this Chapter is to develop photoactive anticancer complexes with a longer
activation wavelength.
In mononuclear metal complexes, ligand field (LF), LMCT, MLCT and LLCT are
the most important transitions in the electronic spectra (see Chapter 1). It is
important to lower the energy of these transitions to obtain new complexes with
longer activation wavelengths. In the new PtIV complexes developed in this Chapter,
azido groups and dihydroxido groups are retained to keep the photochemical
properties. Hence, modifications are made on the other groups, such as the aromatic
imine and aliphatic amine ligands.
Computational research by Huichung Tai, in this group, suggested that electron-
withdrawing substituents on the pyridine ligand tend to lower the energies of the
unoccupied orbitals of PtIV diazidodihydroxido complexes, resulting in lowered
energy of absorption.15 Inspired by this result, 4-nitropyridine was used to synthesize
new PtIV complexes, with the aim of performing the achieving at longer wavelength.
Also, for charge-transfer transitions, electron-rich aromatic chromophores can shift
the charge transfer band to longer wavelength. So 2,2'-bipyridine (Bpy) and
terpyridine (Tpy) are used as in electron donors to synthesize new PtIV complexes.
Platinum(II) terpyridine complexes have recently attracted great interest in
bioinorganic chemistry due to their activity in the interaction with nucleic acids and
proteins.16 The structure-function relationship can be easily tuned by altering the
substitution group in the 4' position and the ligand occupying the fourth coordination
site of PtII. There are two intrinsic properties of Pt terpyridine complex cations: (1)
ease of displacement of the fourth coordination site ligand by nucleophiles and (2)
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the propensity for stacking of the Tpy ligand via its π systems.17 So Pt terpyridine
complexes are promising for design of prodrugs with higher photocytotoxicity as
well as longer activation wavelength.
5.2 Experimental
5.2.1 Materials, methods and instrument
4-Nitropyridine 1-oxide, 2,2′-bipyridine, 2,2':6',2''-terpyridine, 1, 5-cyclooctadiene, 
4'-(4-Methylphenyl)-2,2':6',2''-terpyridine, NaN3, H2O2 (30%) and Pt standard for
ICP analysis are from Sigma-Aldrich, All other materials were used as obtained
from commercial sources unless otherwise stated.
NMR spectra were recorded on Bruker DPX-400 (1H, 400.03 MHz) or Bruker
AVIII-600 (1H, 600.13 MHz; 13C, 150.9MHz; 195Pt, 129.4 MHz) spectrometers.
Specific parameters, along with other general parameters for acquisition are found in
Chapter 2.
The X-ray crystallographic data collection and analysis were carried out by Dr Guy
Clarkson in University of Warwick. Instrumentation, acquisition parameters and data
processing can be found in Chapter 2.
Elemental analysis was performed by the Warwick Analytical Service.
Positive/negative ion electrospray mass spectrometry (ESI-MS) was performed on a
Bruker Esquire 2000 mass spectrometer coupled with an Agilent 1100 HPLC
(without column) as an automatic sample delivery system. Samples were prepared in
80% acetonitrile/20% water. HPLC coupled mass spectrometry (LC-MS) was
performed on a Bruker HCT-Ultra mass spectrometer coupled with an Agilent 1200
HPLC system with an Agilent ZORBAX Eclipse Plus reverse phase C18 column
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(4.6 × 250 mm, 5 µm). Flow rate, 1.0 ml/min; detecting wavelength, 254 nm; mobile
phase A, H2O with 0.1% formic acid (FA); mobile phase B, MeOH with 0.1% FA. A
linear gradient from 5% to 55% B over 15 min was applied.
A semi-preparative HPLC method was used to purify the crude products that could
not be purified by other methods. A HPLC analysis method was used to verify the
purity of some of the compounds. Specific columns, mobile phase used and HPLC
conditions are stated in the results section.
Electronic absorption spectra (UV-Vis) were recorded on a Varian Cary 300 UV-Vis
spectrophotometer in a 1-cm path-length quartz cuvette. All spectra were referenced
to neat solvent and data were processed with OriginLab Origin 7.0. Extinction
coefficients (ε) were determined over a concentration range (Amax ~ 0.4 – 1.6) with at
least 4 data points, using Pt concentrations determined by ICP-MS.
ICP-OES and ICP-MS were used to determine Pt concentration for the solubility and
extinction coefficients of PtIV complexes. Five different concentrations diluted from
one sample solution were measured. A series of Pt standards covering the range 1 –
25 ppm (for OES) or 0.25 – 500 ppb (for MS) were made as reference. Standard
1.001 ± 0.002 g/l Pt solution in 3% HNO3 obtained from Sigma-Aldrich was used.
Photodecomposition of Pt complexes was carried out at 298 K by using a LZC-ICH2
photoreactor (Luzchem Research Inc.) equipped with a temperature controller and 8
UVA lamps (Hitachi, λmax = 365 nm, 3.5 mW/cm2) with no other sources of light
filtration. ACULED® VHL™ LEDs (λmax = 450 nm, 50 mW/cm2) and High-Power
38 LED bulb/GU10 Green LEDs (λmax = 517 nm, 25 mW/cm2) were also used for
irradiation of the samples. Their output spectra are listed in Appendix 2.
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Action Spectrum
A modified Shimadzu RF-551 Fluorescence HPLC Monitor was used as the light
source to give monochromatic irradiation with PWHH (peak width at half height) of
ca. 15 nm. Filters were used to eliminate the second and higher order diffraction of
shorter wavelengths in the specified longer wavelength monochromatic light from
the grating.18 Solutions of photoactivatable PtIV complex in a 1-cm path-length UV-
Vis quartz cuvette (0.6 ml) were irradiated with the monochromatic light. The
instrument setup is shown in Figure 5.1.
Figure 5.1 Instrument setup for the action spectrum.
The progress of the photoreaction, time-course data and the spectral output of the
light source were monitored and recorded with a Varian Cary 300 UV-Vis
spectrophotometer and data were processed with OriginLab Origin 7.0. UV-Vis
spectra were recorded every minute during irradiation and the rate of loss of
absorption at λmax (average of 10 data points at 287 ± 1 nm) was monitored. In each
case, the photolysis of the complex was taken to completion (1 – 18 h depending on
λirr), but only data relating to < 10% photodecomposition were considered when
UV-filter
Sample and
stirrer in a
cuvette
Magnetic
stirrer
Light fiber
Connected
to RF551
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analysing the initial rate of photolysis of the complex. The rate data were the average
of two independent runs at each λirr. The number of incident photons (einstein/s) was
measured and calculated using a potassium ferrioxalate actinometer.19, 20 The
absorbance at λmax (A287) was plotted versus time (t); the average photolysis rate
(dc/dt) is given by Equation 5.1, and pseudo quantum yield (Φ) was calculated from
Equation 5.2.
dc
dt
= dA287
dt
1
lε287
(5.1)
Φ = No. of reactionsNo. of incident photons (5.2)
A blank control involving spectral acquisition for 12 h but no irradiation, showed
that light from the UV-Vis spectrophotometer lamp had a negligible effect on the
sample.
Cell Culture and Cytotoxicity for Pt complexes.
The photoactivated dose-dependent inhibition of cell viability for light-sensitive PtIV
complexes was determined by Dr Julie A. Woods (University of Dundee). Details
can be found in Chapter 2.
5.2.2 Synthesis and Characterisation
5.2.2.1 Cis-[PtI2(NH3)2] (25)
Cis-[PtI2(NH3)2] (25) and cis-[PtCl2(NH3)2] (cisplatin, 26) were synthesized
according to the reported method.21 K2[PtCl4] (2.075 g, 5.0 mmol) was dissolved in
H2O (30 mL) and KI (8.300 g, 50 mmol) added. After stirring for 1 h, NH4Cl (0.535
g, 10 mmol) was added and the pH adjusted to 10 using 2 M KOH. The pH was
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monitored and readjusted to 10 until it no longer decreased. The mixture was stirred
for a further 2 – 4 h after which the yellow precipitate was collected by filtration,
washed with minimal cold water, ethanol and diethyl ether and dried under vacuum.
Yield: 2.31 g (95.7 %)
ESI-MS (m/z): [M − I + MeCN]+ found 396.8; calc. 396.9.
Elemental Analysis: PtH6N2Cl2, found (%): H, 0.94, N, 5.62; calc.: H, 1.24, N, 5.80.
5.2.2.2 Cis-[PtCl2(NH3)2] (cisplatin, 26)
Cis-[PtI2(NH3)2] (2.31 g, 4.78 mmol) was suspended in H2O (30 mL) and AgNO3
(1.625 g, 9.56 mmol) added. The mixture was stirred at 328 K overnight. AgI
precipitate was filtered off using celite followed by an inorganic membrane filter
(Sartorius Minisart, 0.2 µm). NaCl (2.80 g, 47.8 mmol) was added and the mixture
was stirred for a further 30 min, after which the yellow precipitate was collected by
filtration, washed with minimal cold water, ethanol and diethyl ether and dried under
vacuum. The product can be recrystallized in a minimal amount of 0.1 M HCl.
Yield: 1.331 g (92.7 %)
1H NMR (d6-DMSO): δ = 3.97 (broad, NH3, 6H).
Elemental analysis: PtH6N2Cl2, found (%): H, 1.94, N, 9.23. Calc.: H, 2.02, N, 9.33.
5.2.2.3 4-Nitropyridine (27)
4-Nitropyridine (4-NO2-Py) was synthesized according to a published method.22 To
1 g. of 4-nitropyridine 1-oxide suspended in 15 ml of ice-cold chloroform, 1.9 ml of
phosphorus trichloride was added slowly and the mixture was heated one hour at 343
– 353 K. Caution, phosphorus trichloride is very toxic and corrosive, and should be
treated with special care. Adding water to excess phosphorus trichloride should be
carried out in well ventilated fume hood. After cooling and the addition of water, the
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reaction mixture was made alkaline by addition of sodium hydroxide and was
extracted with chloroform. The chloroform solution was dried over sodium sulfate,
evaporated to dryness, and the residue was recrystallized from petroleum ether. The
NMR chemical shifts are consistent with those reported.22
Yield: 0.54g (61%).
1H NMR (400 MHz, MeOD): δ = 8.93 (d, H2, 6, 2H), 8.15 (d, H3, 5, 2H), 13C NMR
(150.9 MHz, MeOD): δ = 155.5 (C4), 153.1 (C2, 6), 117.8 (C3, 5).
Elemental Analysis: C2H10Cl2N2Pt, Calc. C 48.39%, H 3.25%, N 22.57%, Found: C
48.31%, H 3.14%, N 22.46%.
5.2.2.4 Trans-[PtCl4(NH3)(4-nitropyridine)] (28)
Cisplatin (200 mg, 0.67 mmol) was suspended in 6 ml H2O, and then 4-nitropyridine
(4-NO2-Py, 248 mg, 2.0 mmol) was added. The reaction was heated to 348 K with
stirring and kept at this temperature for 90 min. N.B. This intermediate is light
sensitive! The solution was allowed to cool to room temperature and HCl (12 M, 0.5
ml) was added and then the solution was heated at 373 K for ca. 48 h. The flask was
cooled on ice and the yellow product was collected by filtration, washed
successively with minimal cold H2O, ethanol, and diethyl ether and then dried under
vacuum. Crystals suitable for X-ray analysis were obtained from a minimal amount
of 0.1 M HCl at 277 K.
Yield: 250 mg (75.6%).
1H NMR (400 MHz, acetone-d6): δ = 9.52 (d, H2, 6, 3J (195Pt, 1H) = 25 Hz, 2H), 8.54
(d, H3, 5, 2H), 6.16 (t, NH3, 1J (14N, 1H) = 54 Hz, 2J (195Pt, 1H) = 54 Hz, 3H). 13C
NMR (150.9 MHz, MeOD): δ = 157.2 (C4), 156.6 (C2, 6), 120.2 (C3, 5, 3J (195Pt, 13C)
= 27 Hz). 195Pt NMR (129.4 MHz, MeOD): δ = −354.3. 
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ESI-MS (m/z): [M + Na]+ Calc., 499.9, Found, 500.0.
Elemental Analysis: C5H8Cl5N3O2Pt (M + HCl), found (%), C, 11.29; H, 1.44; N,
8.55; calc., C, 11.67; H, 1.57; N, 8.17.
5.2.2.5 Trans-[PtCl2(NH3)(4-nitropyridine)] (29)
Trans-[PtCl2(NH3)(4-NO2-Py)] was synthesized according to the reported method
for similar compounds.23, 24 A suspension of trans-[PtCl4(NH3)(4-NO2-Py)]•H2O (50
mg) in water (2 ml) was treated with hydrazine hydrate (N2H4•H2O) (6 μl, 2 mol 
equiv). Caution, hydrazine is toxic, explosive and dangerous for the environment,
and should be treated with care. The reaction mixture was stirred and heated to
reflux for 14 h. The solvent was evaporated under reduced pressure and the yellow
residue obtained was washed with water and dried under vacuum.
Yield: 26 mg (63%)
1H NMR (400 MHz, acetone-d6): δ = 9.30 (d, H2, 6, 3J (195Pt, 1H) = 32 Hz, 2H), 8.23
(d, H3, 5, 2H), 3.95 (broad, NH3, 3H). 13C NMR (150.9 MHz, acetone-d6): δ = 156.6
(C2, 6), 154.7 (C4), 119.5 (C3, 5). 195Pt NMR (129.4 MHz, acetone-d6): δ = −2023.2. 
ESI-MS (m/z): [M – Cl + CH3CN]+ Calc., 413.0, Found, 413.0.
Elemental Analysis: C5H4N2O2, Calc., C, 14.75%; H, 1.73%; N, 10.32%; Found, C,
14.74%; H, 1.54%; N, 10.23%.
5.2.2.6 Trans-[Pt(N3)2(NH3)(4-nitropyridine)] (30)
Caution! No problems were encountered during this work, however heavy metal
azides are known to be shock sensitive detonators, therefore it is essential that any
platinum azide compound is handled with care. From this point on all syntheses
were carried out under controlled (dim) lighting conditions.
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Trans-[Pt(N3)2(NH3)(4-NO2-Py)] was synthesized according to the reported method
for similar compounds.9, 11 Trans-[PtCl2(NH3)(4-NO2-Py)] (20 mg) was suspended in
H2O 10 ml, and AgNO3 (16 mg) was added and stirred at 323 K for 16 h. AgCl
precipitate was filtered off using celite followed by an inorganic membrane filter
(0.2 µm). NaN3 (13 mg, 4 mol equiv) was added and the solution stirred at room
temperature for 6h before leaving the flask in fridge overnight. The yellow
precipitate was collected by filtration, washed with minimal cold H2O and then dried
under vacuum. Crystals qualified for X-ray analysis was obtained from methanol at
277 K.
Yield: 14 mg (68%).
1H NMR (400 MHz, acetone-d6): δ = 9.20 (d, H2, 6, 3J (195Pt, 1H) = 36 Hz, 2H), 8.34
(d, H3, 5, 2H), 4.25 (broad, NH3). 13C NMR (150.9 MHz, Acetone-d6): δ = 155.6 (C2,
6), 155.0 (C4), 120.2 (C3, 5). 195Pt NMR (129.4 MHz, acetone-d6): δ = −2134.9.  
ESI-MS (m/z): [M + Na]+ Calc., 443.0, Found, 443.1.
Elemental Analysis: C5H7N9O2Pt, Calc., C, 14.29%; H, 1.68%; N, 30.00%; Found, C,
14.35%; H, 1.34%; N, 28.56%. The structure of this intermediate was verified by x-
ray crystallography, and the product was only used in the synthesis. Azido
complexes often give rise to larger deviation than normal in the nitrogen analysis.
5.2.2.7 Trans, trans, trans-[Pt(N3)2(OH)2(NH3)(4-nitropyridine)] (31)
Trans-[Pt(N3)2(NH3)(4-NO2-Py)] (30 mg) was placed in H2O (12 ml) and H2O2 (0.66
ml, 30%) added and stirred at 313 K for 2 − 3 h, to give a clear yellow solution after 
filtration. Water (50 ml) was added to the solution which was then lyophilized to
remove all the solvent.
Yield: 18 mg (55%).
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1H NMR (600 MHz, 90% H2O/10% D2O, pH=3.8): δ = 9.12 (d, H2, 6, 3J (195Pt, 1H) =
24 Hz, 2H), 8.56 (d, H3, 5, 2H), 6.18 (t, NH3, 1J (14N, 1H) = 53 Hz, 2J (195Pt, 1H) = 52
Hz, 3H). 13C NMR (150.9 MHz, D2O): δ = 156.5 (C4), 152.6 (C2, 6), 120.9 (C3, 5).
195Pt NMR (129.4 MHz, D2O): δ = 857.7.
LC-ESI-MS (m/z): [2M + H]+ Calc., 909.1, Found, 909.1; [2M − OH]+ Calc., 891.1,
Found, 891.1
Elemental Analysis: C5H9N9O4Pt, Calc. C 13.22%, H 2.00%, N 27.75%, Found: C
13.06%, H 1.94%, N 27.36%.
ε287=18200 L mol-1 cm-1 (H2O)
5.2.2.8 Cis, trans-[Pt(N3)2(OH)2(Bpy)] (32)
Cis, trans-[Pt(N3)2(OH)2(Bpy)] (Bpy = 2,2′-bipyridine) was synthesized according to 
a reported method.25 [Pt(N3)2(Bpy)] 26 (10 mg) was placed in H2O2 (10 mL, 30 %),
stirred at 323 K for 1 h, and the volume of solvent was reduced on a rotary
evaporator to 1~2 ml, forming a bright yellow solution (usually takes 1~2 hours).
Water (50 ml) was added and the solution lyophilized to remove all the solvent.
Yellow needle crystals suitable for X-ray analysis was obtained from diffusion of
ether to a minimal EtOH solution of the product at 277 K. The NMR chemical shifts
are consistent with the reference. 25 The maximum solubility of complex 32 in H2O
at 293 K is > 21.7 mg/ml (46.2 mM), measured by ICP-OES.
Yield: 4.8 mg (84.6%).
1H NMR (D2O): δ = 9.16 (d, H6, 6', 3J (195Pt, 1H) = 24 Hz, 2H), 8.65 (d, H3, 3', 2H),
8.48 (t, H4, 4', 2H), 8.04 (t, H5,5', 2H).
ESI-MS: [M + Na+] (m/z) found, 492.0, calc. 492.1.
Elemental analysis: C10H10N8O2Pt, Calc. C 25.59%, H 2.15%, N 23.88%, Found: C
25.38%, H 2.01%, N 23.61%.
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5.2.2.9 [PtCl(Tpy)]Cl · 2H2O (33)
Caution. Tpy (2,2':6',2''-terpyridine) and its complexes can be absorbed through the
skin. Since these compounds are toxic, gloves should always be worn.
[PtCl(Tpy)]Cl · 2H2O was synthesized according to a reported method.27 K2[PtCl4]
(415 mg, 1 mmol) was dissolved in H2O (20 mL), Tpy (2,2':6',2''-terpyridine) (280
mg, 1.2 mmol) was added and the stirred suspension was heated at reflux for 3.5
days until a clear red solution was received. (N.B. Prolonged heating of the clear
solution may result in product disproportionation, as metallic platinum was
deposited onto the sides of the flask.) The solution was filtered to remove any
unwanted solid residue, and the filtrate was evaporated on a steam bath to a volume
of 4 ~ 5 ml, at which point NaCl (120 mg, 2 mmol) was added to precipitate more
product. The red-orange product precipitated upon cooling and was collected by
filtration and washed with 0.1 N HCl and acetone.
Yield: 326 mg (0.63 mmol, 63%).
1H NMR (400 MHz, D2O) δ = 8.28 ~ 8.18 (5H), 8.04 (d, 4H), 7.55 (t, 2H). For
discussion of NMR chemical shift see Section 5.4.2.
ESI-MS (m/z): [M − 2H2O − Cl]+: Calc., 463.0; Found, 463.0.
Elemental Analysis: C15H15Cl2N3O2Pt, Calc., C, 33.66%; H, 2.82%; N, 7.85%;
Found, C, 33.52%; H, 2.70%; N, 7.74%.
5.2.2.10 [Pt(N3)(Tpy)]PF6 (34)
[Pt(N3)(Tpy)]PF6 was synthesized according to the reported method.28, 29 To an
aqueous solution of [PtCl(Tpy)]Cl · 2H2O (52 mg, 0.1 mmol) was added NaN3 (13
mg, 0.2 mmol). A transparent deep red solution was precipitated. Upon addition of
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NH4PF6 (32 mg, 2 mmol), an orange solid was obtained, which was collected by
filtration, washed with H2O and dried under vacuum.
Yield: 53 mg (92.3 %).
1H NMR (400 MHz, acetone-d6): δ = 8.82 ~ 8.61 (9H), 8.14 (d, 2H).
ESI-MS: [M − PF6]+: (m/z) found, 470.0; calc., 470.1.
5.2.2.11 [Pt(N3)(Tpy)]N3 (35)
[Pt(N3)(Tpy)]N3 was synthesized according to the reported method.29 To an aqueous
solution of [PtCl(Tpy)]Cl · 2H2O (52 mg, 0.1 mmol) was added NaN3 (130 mg, 2
mmol, 20 mol equiv). A red solid was produced. The mixture was stirred for a
further 30 min after which the precipitate was collected by filtration, washed with
minimal cold H2O and dried under vacuum. The 1H NMR was assigned with the
assistance of 2D [1H-1H] CODY NMR spectroscopy.
Yield: 30 mg (60.5 %).
1H NMR (600 MHz, D2O): δ = 8.24 ~ 8.21 (t, H4', 4, 4'', 3H), 8.00 ~ 7.97 (t, H3', 5', 3, 3'',
4H), 7.72 (d, H6, 6'', 2H), 7.59 (t, H5, 5'', 2H). 13C NMR (150.9 MHz, D2O): δ =, 157.7
(C2, 2''); 153.9 (C2', 6'), 149.6 (C6, 6''), 143.7 (C4, 4''), 143.0 (C4'), 130.0 (C5, 5''), 126.2
(C3, 3''), 124.6 (C3', 5'). 195Pt NMR (129.4 MHz, D2O): δ = −2620. 
ESI-MS (m/z): [M − N3]+: Calc., 470.1; Found, 470.0.
5.2.2.12 Trans-[Pt(N3)(OH)2(Tpy)] Cl (36)
[Pt(N3)(Tpy)]PF6 (31 mg, 0.05 mmol) was placed in H2O2 (25 ml, 30% aqueous
solution) and stirred at 323 K for 1 h, and then the volume of solvent was reduced on
a rotary evaporator to ca. 5 ml, forming a bright yellow solution (ca. 1 – 2 hours).
(The temperature was maintained below 323 K to avoid decomposition.) Water (50
ml) was added and the solution was lyophilized to remove all the solvent. The
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residue was purified by semi-preparative HPLC (see Section 5.3.2.2). The fraction
was collected, HCl was added to adjust pH to ca. 0, and the solution was then
lyophilized to remove TFA and all solvents. The 1H NMR was assigned with the
assistance of 2D [1H-1H] COSY NMR spectroscopy.
Yield: 10 mg (24%).
1H NMR (400 MHz, D2O): δ = 9.02 (d, H6, 6'', 3J (195Pt, 1H) = 24 Hz, 2H), 8.80 ~ 8.71
(m, H3', 5', 4', 3, 3'', 5H), 8.61 (t, H4, 4'', 2H), 8.16 (t, H5, 5'', 2H). 13C NMR (150.9 MHz,
D2O): δ = 157.4 (C2, 2''); 152.9 (C2', 6'), 151.3 (C6, 6''), 146.4 (C4'), 145.7 (C4, 4''), 131.2
(C5, 5''), 128.6 (C3, 3''), 127.4 (C3', 5'). 195Pt NMR (129.4 MHz, D2O): δ = 454.1.
ESI-MS (m/z): [M − Cl]+: Calc., 504.0; Found, 504.1.
Elemental analysis: C15H13ClN6O2Pt, Calc. C 33.37%, H 2.43%, N 15.57%, Found:
C 33.46%, H 2.54%, N 15.36%.
5.2.2.13 [PtCl2(COD)] (37)
[PtCl2(COD)] was synthesized according to the reported method.30 To a 10 ml
aqueous solution of K2[PtCl4] (415 mg, 1 mmol), 10 ml acetic acid and 0.41 ml of 1,
5-cyclooctadiene (COD) were added. The mixture was stirred rapidly and heated to
363 K. Over 30 min, the deep red solution slowly became pale yellow and fine
crystals were deposited. The volume was reduced to 5 ml on a rotary evaporator and
the solution filtered to collect the light yellow needles. The product was washed
successively with H2O, ethanol and diethyl ether and then dried at 373 K for 60 min.
N.B., COD is volatile and pungent, so manipulations of COD should always be done
in a fume hood. The spectroscopy data for the product were consistent with those
reported. 30
Yield: 328 mg (81%).
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1H NMR (400 MHz, CDCl3): δ = 5.62 (CH, 4H), 2.71, 2.27 (CH2, 8H).
5.2.2.14 [PtCl(TTpy)]Cl (38)
This compound was synthesized using a slightly modified method from the literature.
30-32 37.4 mg Pt[Cl2(COD)] was suspended in 5 ml MeOH, and 32.3 mg TTpy was
added. The mixture was heated at 333 K overnight, until the white powder in
solution disappeared and only orange precipitate remained. The orange precipitate
was collected by filtration, washed successively with H2O, ethanol and diethyl ether
and then dried under vacuum. The spectroscopic data are consistent with those
reported.30-32
Yield: 45 mg (76.4%).
1H NMR (400 MHz, DMSO-d6): δ = 9.00 (s, H3', 5', 2H), 8.95 (d, H6, 6'', 2H), 8.88 (d,
H3, 3'', 2H), 8.55 (t, H4, 4'', 2H), 8.15 (d, tolyl-H2, 6, 2H) 7.97 (t, H5, 5'', 2H), 7.50 (d,
tolyl-H3, 5, 2H), 2.44 (s, tolyl-CH3, 3H).
ESI-MS (m/z): [M − Cl]+: Calc., 553.1; Found, 553.0.
5.2.2.15 [Pt(N3)(TTpy)]N3 (39)
Trans-[PtCl(TTpy)]Cl (30 mg, 0.05 mmol) was suspended in 5 ml DMF, and NaN3
(65 mg, 1 mmol, 20 mole equivalent) was added. The mixture was stirred at room
temperature, and then the orange precipitate was collected by filtration and was
washed successively with H2O, ethanol and diethyl ether. The product was then dried
under vacuum.
1H NMR (400 MHz, DMSO-d6): δ = 8.70 (s, H3', 5', 2H), 8.67 (d, H3, 3'', 2H), 8.37 (t,
H4, 4'', 2H), 8.21 (d, H6, 6'', 2H), 7.94 (d, tolyl-H2, 6, 2H) 7.84 (t, H5, 5'', 2H), 7.37 (d,
tolyl-H3, 5, 2H), 2.43 (s, tolyl-CH3, 3H). 13C NMR (150.9 MHz, DMSO-d6): δ =
157.7 (C2, 2''); 153.5 (C2', 6'), 152.3 (C4'), 149.1 (C6, 6''), 142.6 (C4, 4''), 142.2 (tolyl-C4),
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131.1 (tolyl-C1), 130.0 (tolyl-C3, 5), 129.2 (C5, 5''), 127.7 (tolyl-C2, 6), 126.1 (C3, 3''),
120.3 (C3', 5'), 21.1(tolyl-CH3). 195Pt NMR (129.4 MHz, DMSO-d6): δ = −2631.2.  
ESI-MS (m/z): [M − N3]+: Calc., 560.1; Found, 560.0.
Elemental Analysis: C22H19N9OPt (M + H2O), Found, C, 42.31%; H, 3.04%; N,
19.93%; Calc., C, 42.58%; H, 3.09%; N, 20.32%.
5.2.2.16 Trans-[Pt(N3)(OH)2(TTpy)]Cl (40)
[Pt(N3)(TTpy)]N3 (5 mg) was placed in H2O2 (5 ml, 30%) and stirred at 313 K for 14
h, before forming a clear yellow solution. Water (50 ml) was added to the solution
which was then lyophilized to remove all the solvent. The residue was purified by
semi-preparative HPLC. The fraction was collected, HCl was added to adjust the pH
to 0, and the solution was then lyophilized to remove TFA and all solvents.
Yield: 2 mg (38%).
ESI-MS (m/z): [M − Cl]+: Calc., 594.1; Found, 594.1.
1H NMR (600 MHz, D2O): δ = 9.03 (d, H6, 6'', 2H), 8.99 (s, H3', 5', 2H), 8.78 (d, H3, 3'',
2H), 8.63 (t, H4, 4'', 2H), 8.16 (t, H5, 5'', 2H), 7.98 (d, tolyl-H2, 6, 2H), 7.57 (d, tolyl-H3,
5, 2H), 2.50 (s, tolyl-CH3, 3H). 13C NMR (150.9 MHz, D2O): δ = 158.6 (C2, 2''); 157.6
(C2', 6'), 152.5 (C4'), 151.3 (C6, 6''), 145,7 (C4, 4''), 144.3 (tolyl-C4), 132.3 (tolyl-C1),
131.1 (tolyl-C3, 5), 130.7 (C5, 5''), 128.9 (tolyl-C2, 6), 128.4 (C3, 3''), 124.6 (C3', 5'),
21.2(tolyl-CH3).
Elemental analysis: C22H20ClN6O2Pt, Calc. C 41.88%, H 3.19%, N 13.32%, Found:
C 41.98%, H 3.54%, N 13.36%.
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5.3 Results
5.3.1 Pt 4-nitropyridine complexes
5.3.1.1 X-ray crystallography
The solid state structures of trans-[PtCl4(NH3)(4-NO2-Py)]·H2O (28 · H2O) and
trans-[Pt(N3)2(NH3)(4-NO2-Py)] (30) were determined by single crystal X-ray
crystallography, Figure 5.2. X-ray data are listed in Table 5.1. The geometry of
28 · H2O is octahedral and the Pt-Cl and Pt-N bond lengths do not differ
significantly from those of published tetrachlorido PtIV complexes.23, 33 The
asymmetric unit contains a Pt complex and a molecule of water. In the crystal, two
symmetry-related complexes are bridged by two waters, hydrogen bonded to the
coordinated ammonia. This tetrameric unit lies on an inversion centre as illustrated
in Figure 5.3.
In the structure of 30, there are three crystallographically independent complexes in
the asymmetric unit. One complex lies on a general position (Pt1, as shown in Figure
S2b) and two on special positions (Pt2 and Pt3) on a two-fold axis. The Pt atom in
this structure adopts a square-planar geometry, and the Pt–N bond lengths and angles
are similar to those of published PtII diazido compounds.34 The nitrogens in N3
groups are essentially linear, with the N–N–N angle between 173° and 175°, which
again agrees very well with the angles in previous published structures. One of the
coordinated 4-nitropyridines (N301 – O309 in Pt3 complex) was disordered about
the two fold axis. Initially attempts were made to restrain the ring on the axis but this
led to an unstable refinement. The pyridine was refined using 1-2 and 1-4 distance
restraints to keep it as an idealised six-membered ring. The nitro group was also
refined with distance restraints and the whole pyridine ligand refined as disordered
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about the two fold axis at 50% occupancy (Figure 5.4). The thermal parameters of
the disordered pyridine were also restrained with SIMU restraints. The hydrogens on
the coordinated ammonias (N116, N210 and N313) could not be located so were
placed at calculated positions and refined with a riding model. Interestingly, in two
of the complexes 30 (Pt1 and Pt2), the nitro groups are not within the pyridine plane
but are twisted out of the plane with dihedral angle of 18° and 23° for N107 and
N205, respectively. However, in the structure of 28 · H2O, this torsion is only 2°,
which indicates that the nitro groups are essentially in the plane of pyridine. Previous
reports showed that in the structure of free 4-nitropyridine ligand, the nitro group is
coplanar with the pyridine ring plane.35, 36 However, in the corresponding metal
complexes, the angle of twist varies.36, 37 It is reasonable to attribute the reason for
the twist of nitro group to a crystal packing effect.
Table 5.1 Crystal structure data for the Pt complexes trans-[PtCl4(NH3)(4-NO2-
Py)] · H2O (28 ··H2O) and trans-[Pt(N3)2(NH3)(4-NO2-Py)] (30)
28 ··H2O 30
Empirical formula C5H9Cl4N3O3Pt C10H14N18O4Pt2
Formula weight 496.04 840.57
Crystal description Block Block
Crystal colour Yellow Yellow
Crystal system Triclinic Monoclinic
Space group P-1 C2/c
a (Å) 6.8498(2) 13.5983(2)
b (Å) 9.4307(4) 27.6494(8)
c (Å) 11.0158(5) 11.3576(4)
α (°) 107.784(4) 90
β (°) 95.782(3) 94.651(2)
γ (°) 106.259(3) 90
Volume (Å3) 636.85(4) 4256.2(2)
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Z 2 8
Measurement temp.(K) 100(2) 100(2)
lambda 0.71073 A 0.71073 A
Dcalcd (Mg/m3) 2.587 2.624
F (000) 460 3104
μcalcd (mm-1) 11.849 13.196
θ Range (°) <29.38 <29.95 
Reflections collected 11284 20852
Independent reflections 3160 5485
Goodness-of-fit F2 1.058 1.071
Conventional R1 0.0166 0.0231
wR2 0.0386 0.0509
Figure 5.2 X-ray crystal structure of complexes (a) trans-[PtCl4(NH3)(4-NO2-
Py)]·H2O (28 · H2O) and (b) trans-[Pt(N3)2(NH3)(4-NO2-Py)] (30, Pt1 complex)
with ORTEP ellipsoids set at 50% probability (100 K).
Figure 5.3 A water-bridged tetrameric unit that lies on an inversion centre in the
solid state structure of 28 · H2O. The H-bonds are indicated by dash lines.
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Figure 5.4 The disorder of the 4-nitopyridine ligand in one of the molecules (Pt3
complex) in the solid state structure of trans-[Pt(N3)2(NH3)(4-NO2-Py)] 30 showing
the two orientations of the 4-nitropyridine ligand about the 2-fold axis. There is a
50:50 occupancy of the two orientations, one drawn with solid lines and one with
dashed lines.
5.3.1.2 195Pt NMR characterization
The 195Pt NMR spectra for complexes 28 – 31 were assigned in accordance with
published data.11, 23, 24, 38, 39 (Figure 5.5). The 195Pt chemical shifts of complexes 28,
29, 30 and 31 are −354.3 ppm, −2023.2 ppm, −2135.9 ppm and 857.7 ppm, 
respectively, which are consistent with corresponding trans-{PtIVCl4N2}, trans-
{PtIICl2N2}, {PtIIN4}, trans-{PtIVN4O2} species.
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Figure 5.5 195Pt NMR (129.4 MHz, 298 K) spectra of complexes (a) trans-
[PtCl4(NH3)(4-NO2-Py)] (28); (b) trans-[PtCl2(NH3)(4-NO2-Py)] (29); (c) trans-
[Pt(N3)2(NH3)(4-NO2-Py)] (30); (d) trans, trans, trans-[Pt(N3)2(OH)2(NH3)(4-NO2-
Py)] (31).
5.3.1.3 Photodecomposition study
In the UV-Vis spectrum of complex 31 trans,trans,trans-[Pt(N3)2(OH)2(NH3)(4-
NO2-Py)] in aqueous solution (Figure 5.6a), there is an absorbance maximum at 287
nm (ε287=18200 L mol-1 cm-1 in H2O), which is assigned to a ligand (azide)-to-metal
(PtIV) charge-transfer (LMCT) transition. The absorption intensity at > 400 nm is
very small and no absorption was observed above 540 nm. When the sample was
irradiated at 365 nm, the major absorption band decreased in intensity, indicating the
cleavage of the PtIV-azide bonds (Figure 5.6a). For the purpose of investigating the
relationship between the wavelength of irradiation and photodecomposition of 31 in
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aqueous solution, an “action spectrum” was determined.12, 40 The action spectrum
recorded the rate of photodecomposition of the molecule upon the exposure to light
of wavelength 365 to 540 nm. The pseudo quantum yield (Φ) (ratio of the number of
photo reactions to the number of incident photons) was determined (Figure 5.6b,
Table 5.2 and Table 5.3). The pseudo quantum yield Φ for photolysis of complex 31
upon irradiation from 365 nm to 520 nm correlated closely with the extinction
coefficient at that wavelength. At irradiation wavelengths > 540 nm (including 600
nm, 633 nm, 660 nm and 700 nm), the extent of photolysis was too small to detect
under the experimental conditions used.
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Figure 5.6 (a) UV-Vis spectra for 31 in H2O upon irradiation at 365 nm. (b) Pseudo
quantum yield Φ (red, circles) of action spectrum (wavelength-dependent
photodecomposition) for 31, in comparison with extinction coefficient ε (blue, 
squares). The data points are the average of two experiments.
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Table 5.2 Pseudo quantum yields for photodecomposition of complex 31 at different
wavelengths.
Wavelength
λ (nm) 
Reaction
rate dA/dt
(×10–3)
Reaction
rate dc/dt
(×10–9)
Incident photons
(×10–9 einstein/s)
Pseudo
quantum yield
Φ (×10–3)
365 4.8 4.49 0.540 4.99
400 2.5 2.34 0.795 1.77
420 1.9 1.78 0.955 1.12
440 1.45 1.36 1.01 0.804
460 1.1 1.03 1.35 0.459
480 0.6 0.56 1.35 0.249
500 0.3 0.28 1.87 0.090
520 0.01 0.094 4.23 0.013
Table 5.3 Extinction coefficients of 31 at different wavelengths from a 3.12 mM
aqueous solution (298 K). (The extinction coefficient is low at λ > 400 nm so higher 
concentrations allow a more accurate measurement).
Wavelength
(nm)
Absorption
Extinction Coefficient
ε (M-1 cm-1)
365 1.7601 564.1
400 0.5906 189.3
420 0.3833 122.8
440 0.2305 73.87
460 0.1031 33.05
480 0.03935 12.61
500 0.01628 5.219
520 0.00977 3.133
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5.3.1.4 Action spectrum for trans, trans, trans-[Pt(N3)2(OH)2(Py)2] (24)
The wavelength-dependent photodecomposition action spectrum for trans, trans,
trans-[Pt(N3)2(OH)2(Py)2] (24) was also measured using the same method as
described above. Complex 24 has been reported to be a very potent photoactivatable
anticancer compound.12 The purpose of this experiment is to compare the difference
between the UV-Vis absorption spectrum and the rate of photodecomposition at the
corresponding wavelengths. The result shows that the difference is negligible.
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Figure 5.7 Pseudo quantum yield Φ (red, triangles) of action spectrum (wavelength-
dependent photodecomposition) for 24, in comparison with extinction coefficient ε 
(blue, squares). The data points are the average of two experiments.12
5.3.2 Pt 2,2'-bipyridine complexes
5.3.2.1 X-ray crystallography
The crystal structure of complex cis, trans-[Pt(N3)2(OH)2(Bpy)] (32) was obtained as
shown in Figure 5.8, and the data are listed in Table 5.4. The crystal system is
orthorhombic and the space group is Pbcn. The asymmetric unit contained only half
of the complex (half a Pt, half a Bpy, one OH and one azido). The Pt atom adopts
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octahedral geometry and lies on a two-fold axis that relates the two azides and two
hydroxides and runs through the phenyl-phenyl bond. There is a π – π stacking
interaction between two Bpy ligands related by an inversion centre, so mean planes
through the interacting π systems are parallel (Figure 5.9). The π – π stacking
interaction adopts “face-to-face” geometry and the centroid-centroid distance
between two pyridine planes is 3.70 Å, which suggests it a medium-strong
interaction. There are several intra- and inter-molecular short contacts as shown in
Figure 5.10. The inter-molecular H-bonds (2.18 Å) are of medium strength.
Table 5.4 Crystal structure data for complex cis, trans-[Pt(N3)2(OH)2(Bpy)] (32)
32
Empirical formula C10H10N8O2Pt
Formula weight 469.35
Crystal description Block
Crystal colour Yellow
Crystal system Orthorhombic
Space group Pbcn
a (Å) 13.4268(3)
b (Å) 9.5430(2)
c (Å) 9.9701(2)
α (°) 90
β (°) 90
γ (°) 90
Volume (Å3) 1277.49(5)
Z 4
Measurement temp.(K) 100(2)
lambda 0.71073 A
Dcalcd (Mg/m3) 2.440
F (000) 880
μcalcd (mm-1) 11.004
θ Range (°) <32.59 
Reflections collected 15261
Independent reflections 2239
Goodness-of-fit F2 0.920
Conventional R1 0.0141
wR2 0.0345
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Figure 5.8 X-ray crystallographic structure of cis, trans-[Pt(N3)2(OH)2(Bpy)] (32)
with ellipsoids set at 50% probability. (100 K)
Figure 5.9 The “face-to-face” π – π stacking interactions in structure of complex 32
between two parallel Bpy ligands related by an inversion centre (centroid-centroid
distance, 3.699 Å).
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Figure 5.10 Intra- and inter-molecular H-bonds network formed by azido and
hydroxido ligands in the structure of complex 32 which determines the orientation of
the azido ligands.
5.3.2.2 HPLC purification test
Before the cytotoxicity test are carried out, it is important to ensure the purity of
products > 95%. HPLC is a practical method to examine the purity of products. The
HPLC purity of cis, trans-[Pt(N3)2(OH)2(Bpy)] (32) was determined. All the other
compounds in this work were also studied by similar methods. The HPLC
chromatogram for complex 32 is shown in Figure 5.11. The detecting wavelength
was set up at 254nm, so most of the organic and inorganic compounds could be
detected. The percentage of each species was measured by the integration of each
peak, (assume the ε254 for all species are similar) which was automatically calculated
by the workstation. A blank sample was also run for comparison.
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Figure 5.11 HPLC chromatogram for complex cis, trans-[Pt(N3)2(OH)2(Bpy)] (32)
based on peak areas. Purity is > 95%. HPLC conditions: HP1100 series. Column:
Polymer Laboratories, PLRP-S, 250×4.6 mm, 100 Å, 5 μm. Flow rate, 1.00 ml/min. 
Wavelength: 254 nm. Mobile phases A, H2O, 0.1% TFA; B, MeOH, 0.1% TFA.
Insertion is the gradient of mobile phases used.
5.3.2.3 Photoactivation
UV-Vis spectroscopy is a quick and sensitive method to examine the
photodecomposition of PtIV diazidodihydroxido complexes upon irradiation with
various light sources. The aim of this chapter is discover PtIV complexes that can be
activated with longer wavelengths. Therefore, the photoactivation of complex cis,
trans-[Pt(N3)2(OH)2(Bpy)] (32) was carried out upon irradiation with UVA (λmax =
365 nm, 5.0 mW/cm2), light of 450 nm (50 mW/cm2) and 517 nm (25 mW/cm2) in
water at 298 K.
As shown in Figure 5.12 (black curves), in the absence of light, the solution of
complex 32 in water has three major absorption bands at 251, 303 and 315 nm. The
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absorbance at wavelengths longer than 460 nm is close to zero. The intensity of
major absorption bands decreased upon irradiation with UVA or at 450 nm, which is
due to the photolysis of 32. A lower dose of UVA irradiation induced the
decomposition of complexes faster than a higher dose of 450 nm light, which is
consistent with their extinction coefficients at these wavelengths. Interestingly, a
small absorption band around 370 nm increased during the experiment, but it did not
accelerate the rate of photodecomposition at this band. The photodecomposition of
complex 32 upon irradiation at 517 nm was not observed, which is likely due to its
extinction coefficient at this wavelength being close to zero.
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Figure 5.12 Photoactivation of complex cis, trans-[Pt(N3)2(OH)2(Bpy)] (32) in H2O
upon irradiation with UVA (0, 1, 2, 3, 5, 15, 60 min), 450 nm (0, 10, 15, 30, 60, 120
min ) and 517 nm (0, 5, 30, 60 min) (298 K).
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5.3.3 Pt terpyridine complexes
5.3.3.1 HPLC purification
Difficulty was encountered in the synthesis of trans-[Pt(N3)(OH)2(Tpy)]+ species.
Pure product could not be easily obtained (see section 5.4.1.3 for discussion), hence
semi-preparative HPLC separation was used to purify this product.
First, LC-MS was carried out to analyse all the species in the product. The
chromatogram and assignment of the species are summarized in Figure 5.13 and
Table 5.5. The peak at retention time 4.95 min is the desired product and was
collected by semi-preparative HPLC. After the fraction was collected, HCl was
added to adjust the pH to ca. 0 and the solution was then lyophilized twice to remove
TFA (pKa = 0.23) and all solvents. An 19F NMR spectrum was recorded to examine
if the residual TFA was all removed.
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Figure 5.13 Typical HPLC chromatogram for 36 raw product. Semi-preparative
HPLC was used to purify the product. The peak at retention time of 4.95 min was
collected. HPLC conditions: HP1100 series. Column: Agilent ZORBAX Eclipse
XDB-C18, 9.4 × 250 mm, 5 μm. Flow rate, 2 ml/min. Detection wavelength: 254 nm. 
Mobile phase A, H2O with 0.1% TFA; B, MeOH with 0.1% TFA. The gradient used
is the same as shown in Figure 5.11.
Chapter 5 — Tuning the Wavelength of Activation
242
Table 5.5 LC-MS data for the unpurified product complex 36.
r.t.
m/z
(with Pt isotopes)
Assignment
3.67 479.0 Pt[(OH)3(Tpy)]+
3.89
445.0 Pt[(OH)(Tpy)]+
463.0 Pt[Cl(Tpy)]+
495.0 Pt[(OH)2(OOH)(Tpy)]+
4.95 504.0 Pt[(N3)(OH)2(Tpy)]+
18.77 470.0 Pt[(N3)(Tpy)]+
After purification, HPLC analysis was carried to determine the purity of the final
product. The chromatogram is shown in Figure 5.14. Compared to Figure 5.13, the
major product of complex 36 was successfully isolated.
0 5 10 15 20
4.92
Time/min
Figure 5.14 Product of complex 36 after HPLC purification. The purity was >95%.
The same HPLC method was used as that in Figure 5.13.
5.3.3.2 Photolysis of Pt-Tpy complexes
Trans-[Pt(N3)(OH)2(Tpy)]Cl (36) is photoactivatable. UV-Vis spectroscopy was
used to follow the photodecomposition. Figure 5.15a – c show the UV-Vis spectra
recorded for 36 in H2O upon irradiation with UVA, light of 450 nm and 517 nm.
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Before irradiation with light, the solution of complex 36 in water has three major
absorption bands at 273, 339 and 355 nm (black curves in Figure 5.15a – c). The
absorbance over 400 nm is small, but the low absorption extends up to ca. 530 nm.
The intensity of major absorption bands decreased upon irradiation with the three
light sources above, which is due to the photolysis of 36. Further research is needed
to explore the detail mechanism of the photoreaction. It was not a surprise to observe
that a lower dose of UVA irradiation induced the decomposition of complexes faster
than a much higher dose of 450 nm or 517 nm; hence this is consistent with their
different extinction coefficients at these wavelengths.
The three major absorption bands of complex 36 at 273, 339 and 355 nm vanished
upon irradiation with UVA, and four new peaks emerged at 249, 279, 328 and 341
nm. Interestingly, the shape of the UV-Vis spectrum after 30 min irradiation with
UVA (Figure 5.15a, violet curve) looks exactly like the UV-Vis spectrum of
complex [Pt(Tpy)Cl]Cl (33) (Figure 5.15d). Complex 33 is stable upon irradiation
with UVA. Therefore, it is suggested that the photodecomposition of complex 36
generates a PtII species of the [Pt(Tpy)Cl]+ type.
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Figure 5.15 UV-Vis spectra recorded for trans-[Pt(N3)(OH)2(Tpy)]Cl (36) in H2O
upon irradiation with (a) UVA (4.55 mW/cm2, irradiation time 0, 0.5, 1, 2, 5, 30
min), (b) at 450 nm (50 mW/cm2, irradiation time 0, 5, 15, 30, 60 min) and (c) 517
nm (50 mW/cm2, irradiation time 0, 5, 15, 30, 60, 120 min) at 298 K. (d) UV-Vis
spectrum of [PtCl(Tpy)]Cl (33) in H2O.
5.3.4 Photocytotoxicity
The photoactivated dose-dependent inhibition of cell viability (IC50 values towards
several human cell lines) for cis, trans-[Pt(N3)2(OH)2(Bpy)] (32) and trans-
[Pt(N3)(OH)2(Tpy)]Cl (36) are summarised in Table 5.6. The corresponding data for
cisplatin, trans, trans, trans-[Pt(N3)2(OH)2(MA)(Py)] (5) and trans, trans, trans-
[Pt(N3)2(OH)2(MA)(Tz)] (8) are also listed for comparison. Upon irradiation with
UVA, complex 32 is photocytotoxic towards human keratinocytes (HaCaT),
cisplatin-sensitive ovarian carcinoma cells (A2780) and an A2780 cisplatin resistant
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subline (A2780cis). Upon the irradiation with blue light, it is photocytotoxic towards
A2780, A2780cis and OE19 (oesophageal adenocarcinoma) cell lines. Also, it is
nontoxic in the absence of light. The photocytotoxic effect of this compound is more
potent than cisplatin under the experimental conditions used, but is not as potent as
complexes 5 and 8.
Complex 36 is photocytotoxic towards HaCaT, A2780, A2780cis and OE19 cell
lines. However, it is also cytotoxic to these cells even in the absent of light. Hence
further investigation of 36 was not carried out.
Table 5.6. Photocytotoxicity (IC50 valuea/μM) cis, trans-[Pt(N3)2(OH)2(Bpy)] (32)
and trans-[Pt(N3)(OH)2(Tpy)]Cl (36), in comparison with cisplatin, complexes 5 and
8.
Cell
lines
HaCaT A2780 A2780cis OE19
Light
sources
UVA Shame UVA TL03b sham UVA TL03 sham UVA TL03 sham
32 17.0 >213.1 9.2 14.8 >213.1 12.8 29.2 >213.1 NTd 26.5 NT
36 38.6 88.3 35.9 NT 66.7 39.9 NT 128.9 NTc NT NT
5 3.5 >232.9c 3.2 34.3 >232.9 5.3 14.1 >232.9 5.3 13.9 >232.9
8 2.6 >236.3 2.3 2.2 >236.3 4.4 14.0 >236.3 4.4 19.3 >236.3
Cisplatin
(26)
144.0 173.3 151.3 NT 152.0 261.0 NT 229.0 261.0 NT 229.0
a IC50 is the concentration of complex that inhibited cell growth by 50%. The lower
value indicates higher toxicity to cells. Each value is the mean of two or three
independent experiments.
b TL03 is a blue light lamp (λmax = 420 nm).
c > indicates IC50 greater than the concentration range used.
d Not tested.
e Sham: dark control.
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5.4 Discussion
5.4.1 Synthesis
5.4.1.1 Trans,trans,trans-[Pt(N3)2(OH)2(NH3)(4-Nitropyridine)] (31).
Complex 31 trans,trans,trans-[Pt(N3)2(OH)2(NH3)(4-NO2-Py)] was synthesized
following the steps described in Figure 5.16. Initially, the attempt to synthesize
trans-[PtCl2(NH3)(4-NO2-Py)] (29) according to the method developed by Kauffman
and Cowan9, 41-45 produced the corresponding tetrachlorido PtIV species: trans-
[PtCl4(NH3)(4-NO2-Py)] (28). Although the facile oxidization of PtII to PtIV in
aqueous HCl has been observed previously,23, 24, 46 the mechanism of the oxidization
is still not clear. Even when the reaction was carried out under argon, 28 was still the
only product, which appears to rule out O2 as the oxidizing agent. The electron
withdrawing group (NO2) in the pyridine ring can stabilize the PtIV product. 29 was
reduced from 28 by hydrazine,23, 24 and obtained with satisfactory purity and yield.
The geometry of the product was assumed to be trans based on similar reactions
reported in the literature24 which give trans-products. Also, in this study, the crystal
structure of trans-[Pt(N3)2(NH3)(4-NO2-Py)] (30) (discussed below) provided
support for the geometry of trans,trans,trans-[Pt(N3)2(OH)2(NH3)(4-NO2-Py)] (31)
indirectly. Complex 30 was obtained by adding silver nitrate to remove the Cl− from
29 followed by adding excess NaN3. Then hydrogen peroxide (10%) was used to
oxidize PtII to PtIV, forming 31.
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Figure 5.16 Synthetic route for trans,trans,trans-[Pt(N3)2(OH)2(NH3)(4-NO2-Py)]
(31).
5.4.1.2 The synthesis of cis, trans-[Pt (N3)2(OH)2(Bpy)] (32)
Cis, trans-[Pt(N3)2(OH)2(Bpy)] (32) was synthesized following the method
developed by Fiona S. Mackay, a former member of the Sadler group.25 In the step to
synthesize [Pt(N3)2(Bpy)], after a reaction lasting for 2 days, an orange precipitate
deposited in the DMF solution. When water was added to the mixture, the colour
turned dark green very quickly. The orange and the dark green compound were both
isolated and analysed. There was no difference between the NMR spectra (in
DMSO-d6) of those two compounds. It is postulated that they are the same complex,
but different solvent effects make them show different colours. Adding water to the
mixture precipitated more product from DMF, so the yield was improved by ca. 20%
– 30%.
In the step to synthesize cis, trans-[Pt(N3)2(OH)2(Bpy)] (32), reaction in 30% H2O2
for a longer time did not give a clear yellow solution. Some starting material
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remained very difficult to oxidize. The oxidation was complete after the reaction
mixture was kept on the rotary evaporator for 1 – 2 hours, during which time the
reaction mixture was heated to 323 K and the H2O2 was concentrated.
5.4.1.3 The synthesis of trans-[Pt(N3)(OH)2(Tpy)]Cl (36)
The route for the synthesis of Pt-terpyridine complexes is shown in Figure 5.17. The
idea of this work was to design and synthesize trans-[PtIV(N3)(OH)2(Tpy)] type of
complexes and to investigate their cytotoxicity in the presence/absence of irradiation
with visible light.
Figure 5.17 Synthetic route for the complex trans-[Pt(N3)(OH)2(Tpy)]+.
The synthesis of [PtCl(Tpy)]Cl (33) has been reported and a recent review is
available.17 Upon heating a mixture of K2[PtCl4] and Tpy, an insoluble red Magnus-
type double salt [Pt(Tpy)Cl]2[PtCl4] was formed along with an orange solution of
[Pt(Tpy)Cl]Cl. The yield of the desired product can be increased to 65% by
prolonged heating (1 ~ 4 days), but additional heating may result in decomposition to
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Pt(0).27 Several other methods can give better yields. Annibale and coworkers31, 47
reported the rapid (15 min) and nearly quantitative formation of [Pt(Tpy)Cl]+ from
the reaction of [Pt(COD)Cl2] (COD=1,5-cyclooctadiene) with Tpy in water. The
complex [Pt(COD)Cl2] can be prepared from K2[PtCl4] and COD in 95% yield.30
Another efficient preparation method is by heating cis/trans-[PtCl2(SMe2)2] with
Tpy in warm MeOH/H2O for 30 ~ 40 min.31, 48 1H-NMR chemical shifts of
[Pt(Tpy)X]+ type of complexes are dependent on solvent, ionic strength,
concentration and temperature (See Section 5.4.2 for discussion).
[Pt(N3)(Tpy)]+ can be easily obtained by adding 2 mol equiv NaN3 to an aqueous
solution of [PtCl(Tpy)]+. N3− can directly substitute the Cl− on PtII. Either excess
NaN3 or 2 mol equiv of NH4PF6 can precipitate the [Pt(N3)(Tpy)]+ cation, resulting
in [Pt(N3)(Tpy)]N3 and [Pt(N3)(Tpy)]PF6 respectively. Many anions, such as CN−,
SCN−, NO2−, N3−, S2O32−, −OSO2CF3 and various thiols, NH3, pyridines, ketones and
acetylides can substitute the Cl− in [PtCl(Tpy)]+, forming the respective [PtX(Tpy)]+
complexes.17
Repeat attempts to oxidise [Pt(N3)(Tpy)]PF6 with H2O2 always gave a mixture of
products. Altering the reaction time from 0.5 h to 2 h and concentration of H2O2
from 1% to 30% did not improve much the yield of the main product.
Recrystallization was not successful for this compound either. Therefore, semi-
preparative HPLC purification was used the isolate the desired product (see Section
5.3.3.1).
5.4.1.4 The synthesis of trans-[Pt(N3)(OH)2(TTpy)]Cl (40)
Since the direct synthesis of [PtCl(Tpy)]Cl · 2H2O in this work gave poor yields (30%
~ 60%), an improved method was used to make Pt-TTpy (4'-(4-Methylphenyl)-
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2,2':6',2''-terpyridine) complexes. Pt[Cl2(COD)] is an intermediate in the synthesis of
cis-platinum complexes.27, 48 In this work, a satisfactory yield was obtained with
Pt[Cl2(COD)] as the intermediate for Pt-TTpy complexes.
Complex [PtCl(TTpy)]Cl (38) is only sparingly soluble in H2O, so the substitution of
Pt coordinated Cl− with N3− was not applicable in water. This reaction proceeded
well in DMF, producing [Pt(N3)(TTpy)]N3 (39).
The oxidation of 39 did not work well at 327 K. The product seemed to be unstable
at this temperature. So rotary evaporation at 327 K should not be used to remove the
solvent for this reaction. After a series of optimization experiments, reacting with 30%
H2O2 at 313 K overnight was found to be the best way to obtain an acceptable yield
of product of trans-[Pt(N3)(OH)2(TTpy)]+, and the solvent was removed by
lyophilisation. The product was then purified by semi-preparative HPLC separation,
giving trans-[Pt(N3)(OH)2(TTpy)]Cl (40) as the final product.
5.4.2 Stacking of Pt-Tpy complex by NMR studies
The 1H NMR chemical shift of terpyridineplatinum complexes varies depending on
the experimental conditions (e.g. solvent, pH, concentration, and ionic strength,
temperature). This is due to the stacking of [PtX(Tpy)]+ cations, which is more
favoured in concentrated than dilute aqueous solutions.17, 49 17, 49The effect of
stacking on the 1H NMR resonances was investigated for complexes
[PtCl(Tpy)]Cl · 2H2O (33) and [Pt(N3)(Tpy)](N3) (34), as shown in Figure 5.18 and
Figure 5.19. It is evident that the chemical shift varies with ionic strength. In non-
aqueous solvents, stacking can be minimized. This result is not new, so further
investigation was not processed.
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Figure 5.18 1H-NMR of [Pt(Cl)(tpy)]Cl (33) (10 mM) in (a) D2O, (b) 30 mM NaCl
in D2O, (c) 150 mM NaCl in D2O.
Figure 5.19 1H-NMR analysis for [Pt(Tpy)(N3)](N3) (34). (a) [Pt(Tpy)(N3)](N3)
(7.16 mM) in D2O. (b) [Pt(Tpy)(N3)]N3 + NaN3 (0 – 151 mM) in D2O. The
concentration of NaN3 over 151 mM lead to the precipitation of 34.
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5.4.3 Photoactivation wavelength and photocytotoxicity
The aim of this Chapter was to design new PtIV complexes with longer activation
wavelengths, ideally within the therapeutic window. A series of pyridine-type
ligands, e.g., 4-nitropyridine, 2,2'-bipyridine, and terpyridines, were introduced into
new PtIV complexes. The action spectrum was measured for complex trans, trans,
trans-[Pt(N3)2(OH)2(NH3)(4-NO2-Py)] (31). The result suggested that this compound
can be activated by light of wavelength as long as 520 nm. The action spectrum
complex 31 and trans, trans, trans-[Pt(N3)2(OH)2(Py)2] (24) indicated that there is a
correlation between the intensity of UV-Vis absorption and the rate of
photodecomposition. Therefore, action spectra were not measured for other
compounds. If the extinction coefficient of a PtIV diazidodihydroxido complex at a
certain wavelength is zero, it cannot be activated at this wavelength. The extinction
coefficients of cis, trans-[Pt(N3)2(OH)2(Bpy)] (32) and trans-[Pt(N3)(OH)2(Tpy)]Cl
(36) indicate that they cannot be activated by light over 460 and 530 nm,
respectively. These results were consistent with their photolysis irradiated with UVA
or light of 450 nm and 517 nm.
Complex 32 is non-toxic in the dark but toxic to cancer cells upon irradiation with
light. However, the photocytotoxicity of this compound is not as high as complexes
5 and 8 (Chapter 3). Complex 36 can be activated with green light, but it is toxic
even in the dark. These disadvantages limit their application as anticancer prodrugs.
5.5 Conclusion
In this Chapter, a series of new photoactivatable PtIV anticancer complexes were
developed and their photoactivation property and toxicity to cancer cells were
examined. Two compounds were found to be photoactivated by green light.
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However, their photocytotoxicity to cancer cells is not useful. Therefore, further
effort is still needed to develop new photoactivatable PtIV complexes with good
anticancer activity which can be activated by light of 500 – 600 nm or even longer
wavelength.
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6.1 Introduction
Two-photon absorption was originally predicted in 1931 by Maria Göppert-Mayer in
her doctoral dissertation. 1 It was theoretically demonstrated that two photons being
almost simultaneously (ca. 10−16 s) absorbed by an atom or molecule produces a
transition equivalent to the absorption of the single photon of twice the energy
(Figure 6.1).2 In other word, two-photon absorption (TPA) of longer wavelength
light can initiate the same photophysical or photochemical processes as one-photon
absorption (OPA) of shorter wavelength (λeffective ≥ 1/2 λincident). For example, lower-
energy photons (e.g. 700 nm) can promote transitions of higher-energy (e.g. 350
nm).2, 3 Therefore, two-photon activation provides an alternative mechanism for
photoactivation.
Figure 6.1 Energy level diagram showing that the absorption of two photons from
the red region (700 nm) can excite an atom of molecule to the same state as one
photon from the violet region (350 nm).
Conventional one-photon absorption is dependent linearly on the light intensity. By
contrast, TPA has a quadratic dependence on the light intensity, as it depends on two
photons interacting with a molecule almost simultaneously. TPA probabilities are
En
E0
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hv
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extremely small, so it was not until 30 years after Göppert-Mayer’s paper was
published that the first experimental evidence was obtained using a ruby laser. 4
After the 1990s, the application of sub-picosecond lasers (e.g., the Ti:sapphire laser),
which generate a very high instantaneous photon density, greatly facilitated the
investigation of TPA.2 TPA probabilities are extremely small, so it is necessary to
focus the light beam to increase the local intensity at the focus point. Away from the
focus point, TPA probabilities drop down rapidly.
Two-photon absorption cross section (δ) is an important property of a molecule
undergoing TPA.2, 5 It is not absolutely related to molecule dimensions, rather the
strength of the optical transitions and selection rules are important. TPA cross-
sections can be simply imagined as a relative capture area, or as the extinction
coefficient of one-photon absorption. TPA cross sections for most compounds are
very small numbers in SI units, so they are usually reported in Göppert-Mayer units
(1 GM ≡ 10−50 cm4 s photons−1 molecule−1).2 A large number of organic molecules
and complexes with large TPA cross sections have been designed and synthesized. 3,
5-7 Anderson and coworkers2 have summarized the general features for
chromophores with large TPA cross-section:
 Long, π-conjugated chains with enforced coplanarity;  
 Donor and acceptor groups at the centre and ends of the molecule;
 A strong OPA transition close to the TPA wavelength;
 Narrow one- and two-photon absorption bands.
The theory of TPA can also be applied to the absorption of three or more photons.8
Research on multi-photon excitation is a rapidly expanding area due to the recent
availability of commercial pulsed femtosecond lasers. Wide applications has been
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developed, such as three-dimensional data-storage,9, 10 fluorescence microscopy,11, 12
microfabrication,13 optical power limiting,14 up-converted lasing15 and photodynamic
therapy (PDT).7, 16-18 Recently, the first demonstration of in vivo photodynamic
therapy using a TPA photosensitizer was reported.19
In general, the depth of penetration of light is inversely proportional to the
wavelength within the spectrum of visible and near infrared (see Chapter 1).17, 20, 21
It is obvious that TPA has the advantage of accessing longer wavelength for
photoactivation.22, 23 The LMCT bands (N3 to PtIV) of the photoactivatable PtIV azido
complexes used in this work are centred in the UV region (300 nm). The wavelength
of activation restricts their clinic application to tumours in suface tissue. If the TPA
is applied to the photoactivatable platinum(IV) anticancer complexes, this
disadvantage can be overcome.
In this Chapter, according to the rules for chromophores with large TPA cross
sections, a ligand with a large π-conjugation system and strong electron donor, 4-[2-
(4-methoxyphenyl)ethynyl]pyridine (MOPEP), was rationally designed and used in a
new two-photon-activatable platinum complex. As a starting point, cis-
[PtCl2(MOPEP)2] was synthesized and characterized. The OPA and TPA properties
of this compound were examined as well.
6.2 Experimental
6.2.1 Materials, methods and instrument
All materials were used as obtained from commercial sources unless otherwise stated.
DMF-d7 was obtained from Cambridge Isotope Laboratories, Inc. 4-Bromopyridine
Chapter 6 — Two-photon Excitation
261
hydrochloride, 1-ethynyl-4-methoxy benzene, bis(triphenylphosphine)palladium(II)
chloride, and tetrabutylammonium fluoride trihydrate were from Sigma-Aldrich.
NMR spectra were recorded on Bruker DPX-400 (1H, 400.03 MHz), Bruker DPX-
300 (1H, 300.0 MHz; 13C, 75.5 MHz;) or Bruker AVIII-600 (1H, 600.13 MHz; 13C,
150.9MHz; 195Pt, 129.4 MHz) spectrometers. Specific parameters, along with other
general parameters for acquisition are found in Chapter 2.
Elemental analysis was performed by the Warwick Analytical Service.
Electronic absorption spectra (UV-Vis) were recorded on a Varian Cary 300 UV-Vis
spectrophotometer in a 1-cm path-length quartz cuvette. All spectra were referenced
to neat solvent and data were processed with OriginLab Origin 7.0.
Positive/negative ion electrospray mass spectrometry (ESI-MS) was performed on a
Bruker Esquire 2000 mass spectrometer coupled with an Agilent 1100 HPLC
(without column) as an automatic sample delivery system. Samples were prepared in
80% acetonitrile/20% water.
One-photon absorption decomposition of Pt complexes were carried out at 298 K by
using a LZC-ICH2 photoreactor (Luzchem Research Inc.) equipped with a
temperature controller and 8 UVA lamps (Hitachi, λmax = 365 nm) or 16 Visible light
lamps (Sylvania cool white, λ ~ 400 – 700 nm, λmax = 580 nm) with no other sources
of light filtration.
HPLC conditions: HP1100 series. Column: Agilent ZORBAX Eclipse XDB-C18
column, 5 μm, 4.6 × 250 mm. Flow rate, 1.0 ml/min. Detection wavelength: 315 nm. 
Mobile phase A, H2O, 0.1% FA; B, MeOH, 0.1% FA. A linear gradient from 5% to
80% B over 15 min and maintained at 80% B for 5 min was applied.
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Melting points and thermo decomposition were determined on a Sanyo Gallenkamp
Melting Point Meter.
The two-photon experiments were carried out with the assistance of Dr Gareth M.
Roberts and Mr S. E. Greenough, Mr Will H. Powell and Prof Vasillios G. Stavros
from the University of Warwick. The experimental setup is found in Figure 6.2.
Femtosecond (fs) laser pulses were derived from a commercial Ti:Sapphire oscillator
and regenerative amplifier system (Spectra-Physics, Tsunami and Spitfire XP,
respectively).24 And an optical parametric amplifier (OPA) (Light Conversion,
TOPAS model 4/800/f) which generates tuneable pump pulses (325 – 400 nm, ~5
µJ/pulse or 600 – 700 nm, ~20 µJ/pulse). The size of the output beam is 6 mm. A 75
cm lens was used to focus the beam and the diameter of the focus was 0.11 mm (for
700 nm as an example). Diameter of the focus is: Df = 4λf / πDb, where λ is 
wavelength; f is focal distance; Db is diameter of the beam. The power density of
each pulse at focus is 2.2 × 1012 W/cm2. The intensity of the pulse is: I = E / tA,
where E is the energy of each pulse; t is the duration of the pulse; A is the area of the
beam.
Figure 6.2 Instrument setup for TPA experiments.
Lens
Cuvette
on the focus
fs laser
Magnetic stirrer
and stir bar
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6.2.2 Synthesis and characterisation
6.2.2.1 4-[2-(4-methoxyphenyl)ethynyl]pyridine (MOPEP, 41)
4-[2-(4-Methoxyphenyl)ethynyl]pyridine (MOPEP) was synthesized according to a
published method.25 4-Bromopyridine hydrochloride (0.194 g, 1 mmol), 1-ethynyl-4-
methoxy benzene (0.158 g, 1.2 mmol), PdCl2(PPh3)2 (21 mg, 0.03 mmol), and
tetrabutylammonium fluoride trihydrate (0.784 g, 3 mmol) were stirred at 353 K for
1 h under N2 until complete consumption of starting material as monitored by TLC.
After the mixture was washed with water, extracted with diethyl ether, and
evaporated, the light yellow residue was purified by recrystallization in petroleum
ether. The spectroscopic data are consistent with those reported.25
Yield: 0.16 g (84.6%).
1H NMR (300 MHz, CDCl3) δ = 8.58 (d, 2H), 7.50 (d, 2H), 7.36 (d, 2H), 6.91 (d,
2H), 3.84 (s, 3H); 13C NMR (75.5 MHz, CDCl3) δ = 160.3, 149.6, 133.4, 131.8,
125.3, 114.1, 94.2, 85.6, 55.3.
ESI-MS: (m/z) [M + H+], calc., 210.1; found, 210.1.
Elemental analysis: C14H11NO, Cal. C 80.36%, H 5.30%, N 6.69%; Found: C
79.94%, H 5.31%, N 6.36%
6.2.2.2 Cis-[PtCl2(MOPEP)2] (42)
K2[PtCl4] (415 mg, 1.0 mmol) was dissolved in H2O (1 ml) and MOPEP (437 mg,
2.1 mmol) in THF 2 ml was added. The mixture was stirred at room temperature
overnight. A yellow-orange solid precipitated and was collected by filtration and
washed with ice cold water, ethanol, and diethyl ether, then dried under vacuum.
This product was crystalized in DMF at ambient temperature over several months,
but the quality was not good enough for X-ray crystallography.
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Yield: 401 mg (58 %).
1H NMR (300 MHz, CDCl3) δ = 8.68 (d, 2H), 7.58 (d, 2H), 7.31 (d, 2H), 6.90 (d,
2H), 3.84 (s, 3H). 195Pt NMR (DMF-d7, 129.4 MHz) δ = −1980. 
ESI-MS: (m/z) [M+Na+], calc., 707.1; found, 707.1.
Elemental analysis: C28H22Cl2N2O2Pt, Cal. C 49.13%, H 3.24%, N 4.09%; Found: C
48.85%, H 3.31%, N 3.89%
6.3 Results
6.3.1 Synthesis and characterization
Complex cis-[PtCl2(MOPEP)2] (42) was synthesized according to a reported method
for cis-PtII dichlorido complexes with pyridine type ligands (Figure 6.3).26 When a
slight excess of the pyridine type ligand was added to an aqueous solution of K2PtCl4
(Pt : ligand ratio 1 : 2.1) with stirring, the complex cis-[Pt(Py)2Cl2] precipitated.
Figure 6.3 Synthetic reaction for complex cis-[PtCl2(MOPEP)2] (42).
There are two classic methods to determine the trans or cis geometry of PtII
dichlorido complexes, Kurnakov test27 and far infrared spectroscopy.28 Because of
the poor solubility of complex 42, a mixed solvent (H2O-acetone) was used in the
Kurnakov test,27 but the result was equivocal. Herein, a 195Pt NMR method was
subsequently used to verify the cis geometry of complex 42. 195Pt NMR chemical
shifts of PtII diamine/imine dichlorido complexes are closely related to the nature of
the amine/imine ligands and geometry of complexes. On the one hand, the lower pKa
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of the protonated pyridine type ligands, the smaller the electron donation effect in the
L–M σ bond. The electron density on the Pt nucleus is thus reduced, resulting in a 
deshielding of the 195Pt NMR resonance.29 If the reported δ(195Pt) values of the cis-
[Pt(Ypy)2Cl2] (Ypy = substituted pyridine ligands) complexes are plotted against the
pKa of the protonated ligands, there seems to be a trend that the higher pKa often
leads to a resonance in higher field (lower chemical shift) (Figure 6.4).30-32 On the
other hand, the δ(195Pt) of the cis isomer is generally 50 ppm lower than the trans
isomer. The pKa of the MOPEP ligand is 4.8033 and the δ(195Pt) was determined to be
−1980 ppm in this work. Therefore, according to the trend in Figure 6.4, it is
reasonable to assign this complex as having cis geometry.
4.5 5.0 5.5 6.0 6.5 7.0
-2050
-2025
-2000
-1975
-1950
-1925
-1900 cis
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42
19
5 P
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m
)
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Figure 6.4 Plot of the δ(195Pt) of some reported [Pt(Ypy)2Cl2] (Ypy = substituted
pyridine ligands) complexes against the pKa of the protonated ligands.29 Green
circles, trans isomers; red squares, cis isomers; blue triangles, complex 42. Isomers
with a specific Ypy ligand are connected with orange lines.
6.3.2 Absorption spectrum and stability
The absorption spectra of cis-[PtCl2(MOPEP)2] (42) and MOPEP (41) in acetonitrile
(MeCN) are shown in Figure 6.5. Compound 41 has two major absorption bands at
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λ = 297 and 310 nm. These bands are assigned as n → π* and π → π* transitions. 
Compound 42 has a major absorption band at λ = 344 nm, which corresponds to the 
intra-ligand charge transfer band. The coordination to Pt lowers the electron density
of pyridine moiety in the ligand, which hence facilitates the charge transfer.
Therefore, the absorption wavelength of the band for 42 was red-shifted compared to
free ligand 41. In MeCN, it has no absorbance over 500 nm and it is hence stable in
the dark or upon irradiation with light λ > 500 nm, as judged by UV-Vis 
spectroscopy. This compound was also stable in MeCN when heated to 343 – 353 K.
(MeCN b.p., 355 K) The melting point of crystalline complex 42 was measured, but
only decomposition was observed over 473 K.
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Figure 6.5 UV-Vis pectra of MOPEP (41) and cis-[PtCl2(MOPEP)2] (42) in MeCN
at 298 K. For compound 41 ε297nm = 32445 M-1 cm-1, 42 ε344nm = 40420 M-1 cm-1.
6.3.3 OPA decomposition
Complex cis-[PtCl2(MOPEP)2] (42) is light sensitive. UV-Vis spectroscopy was
used to follow the photodecomposition in MeCN. Upon irradiation with UVA or a
broad-band white light, the intensity of the major absorption band (λ = 344 nm) in 
the UV-Vis spectrum decreased, as shown in Figure 6.6 and Figure 6.7. After
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irradiation with UVA for 5 min (Figure 6.6, green curve) or white light for 30 min
(Figure 6.7, magenta curve), the absorbance at λ = 344 nm disappeared, indicating 
the complete consumption of starting material. Also, two strong absorption bands at
ca. 300 nm emerged in the UV-Vis spectra which are exactly the same shape as that
of the ligand MOPEP (Figure 6.5). Therefore, it is suggested that the
photodecomposition of complex 42 generates the free ligand MOPEP. The
mechanism of the photodecomposition may also involve solvent substitution, in
which MeCN replaces one or two of the MOPEP ligands in complex 42. When
irradiation with UVA was stopped after 1 or 10 min, no recovery of complex 42 was
observed after 12 hours in the dark, as followed by UV-Vis spectrophotometry.
The rate of photodecomposition upon irradiation with UVA is much faster than that
with white light, despite the lower power of UVA. This is reasonable as only the
light below 500 nm (especially below 400 nm) is effective.
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Figure 6.6 Photoactivation of cis-[PtCl2(MOPEP)2] (42) upon irradiation with UVA
(λmax = 365 nm, 3.5 mW/cm2, irradiation time 0, 1, 5, 15, 30, 60, 120 min) in MeCN
at 298 K.
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Figure 6.7 Photoactivation of cis-[PtCl2(MOPEP)2] (42) with white light (λ ~ 400 – 
700 nm, 12 mW/cm2, irradiation time 0, 1, 3, 10, 30, 60, 120 min) in MeCN at 298 K.
Upon longer period of irradiation in both experiments (over 5 min by UVA and 30
min by white light), the major absorption bands that corresponding to the ligand
decreased, which suggests decomposition of the ligand. The decomposition of the
ligand MOPEP upon irradiation with UVA was confirmed by a control experiment
(Figure 6.8). A sample of MOPEP in MeCN was irradiated with UVA for 30 min
and the major absorption band decreased in a similar manor as that in Figure 6.6
after 5 min.
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Figure 6.8 Photodecomposition of MOPEP (41) with UVA (λmax = 365 nm, 3.5
mW/cm2, irradiation time 0, 30 min) in MeCN. (20 mM, 298 K)
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The photodecomposition of complex cis-[PtCl2(MOPEP)2] (42) in MeCN was
examined by 1H NMR (Figure 6.9). Complex 42 was dissolved in MeCN-d3 for 20
μM. Before irradiation with light, the resonances of Pt coordinated ligand was 
observed, e.g., δ (Ha) = 8.63, δ (Hc) = 7.55. After irradiation with UVA for only 5
min, the signals of coordinated ligand were completely lost, and a set of resonances
corresponding to the free ligand were observed, e.g., δ (Ha’) = 8.57, δ (Hc’) = 7.53.
The shifts of the other signals were very tiny, and the spectrum in Figure 6.9B is
consistent with the NMR spectrum of a genuine sample of the ligand.
Figure 6.9 1H NMR spectra of cis-[PtCl2(MOPEP)2] (42) (20 μM, MeCN-d3) before
(A) and after (B) irradiation with UVA for 5 min.
The photodecomposition of complex cis-[PtCl2(MOPEP)2] (42) in MeCN was also
examined by HPLC and LC-ESI-MS analysis. Figure 6.10A and B shows the HPLC
chromatograms of the photolysis of 42 and control samples of intact ligand MOPEP
41 and 42. The detection wavelength was 315 nm. The retention time (RT) for 41 is
7.007.508.008.509.0 8.5 8.0 .5 .0 6.5
δ (1H) / ppm
Complex 42 (20 μM, MeCN-d3)
A no irradiation
B UVA nm 5 min
Residue
CHCl3
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Residue
CHCl3
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22.3 min and for 42 24.3 min. These peaks were further confirmed by LC-ESI-MS
analysis. When a solution of 42 in MeCN was irradiated with UVA for 1 min
(Figure 6.10C) a peak for ligand 42 was observed. Also, there was another small
peak with RT 23.3 min, which can be reasonably assigned as cis-
[PtCl2(MOPEP)(MeCN)]. When the irradiation with UVA was extended to 10 min
and 60 min, only the peak corresponding to the ligand 41 was found and this peak
diminished in intensity at longer times. These results confirm the conclusion from
the UV-Vis study that complex 42 can rapidly lose the ligand 41 upon irradiation
with UVA for only one minute, and ligand 41 decompose upon prolonged irradiation
with UVA.
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Figure 6.10 HPLC analysis of (A) MOPEP (41) (RT = 22.3 min); (B) cis-
[PtCl2(MOPEP)2] (42) (RT = 24.3 min) and the photolysis of 42 in MeCN upon
irradiation with UVA (3.5 mW/cm2) for (C) 1 min, (D) 10 min, (E) 60 min; and
upon irradiation with a focused 640 nm fs laser light (F) 15 min, (G) 45 min.
Detection wavelength: 315 nm.
A MOPEP (41)
22.3
C 42 + UVA 1 min
24.3
D 42 + UVA 10 min
B cis-[PtCl2(MOPEP)2] (42)
E 42 + UVA 60 min
23.3
0 10 20 30
time/min
F 42 + fs laser 640 nm 15 min
G 42 + fs laser 640 nm 45 min
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6.3.4 TPA decomposition
When the solution of complex cis-[PtCl2(MOPEP)2] (42) was irradiated with a
focused femto-second (fs) laser at the wavelength 600, 650 and 700 nm, a decrease
in the intensity of the major absorption band (λ = 344 nm) was again observed. The 
reaction mixture was analysed by ESI-MS and the signal of the ligand MOPEP (m/z
= 210.1 for [M + H]+) was observed. HPLC was carried out to analyse the
photoproduct of two-photon activation (2PA). Figure 6.10F and G are the
chromatograms of complex 42 in MeCN upon irradiation with fs laser at 640 nm for
15 and 45 min. Compared to the other chromatograms in Figure 6.10, it is obvious
that free MOPEP ligand and a small amount of cis-[PtCl2(MOPEP)(MeCN)] were
produced during the 2PA and the starting material was all consumed after 45 min. It
is safe to conclude that the photoreaction initiated by two-photon excitation was the
same as it was by UVA.
The time-dependent decrease of absorbance at 344 nm is summarized in Figure 6.11.
Although the powers of the three wavelengths were slightly different, it was still
reasonable to conclude that TPA activation at 650 nm was faster than that at 700 or
600 nm.
Several control experiments were carried out (Figure 6.12). Irradiation with
unfocused fs laser pulses at 700 nm could hardly activate the photodecomposition of
complex 42. But irradiation with unfocused fs laser at 325, 350 and 400 nm easily
activated OPA photodecomposition. The activation efficiencies are consistent with
their OPA absorption at the corresponding wavelengths. These control experiments
confirmed that when the power density of red light is very high, the
photodecomposition of complex 42 could be initiated.
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Figure 6.11 Time-dependent decrease of absorbance at 344 nm for complex 42 by
two-photon absorption. Power of the laser at these wavelengths: 600 nm, 16 μJ/pulse; 
650 nm, 21 μJ/pulse; 700 nm, 21 μJ/pulse.  
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Figure 6.12 Control experiments for time-dependent decrease of absorbance at 344
nm for complex 42. Irradiation with fs laser pulses at 700 nm (unfocused beam) and
325, 350, 400 nm (focused beam).
6.4 Discussion
Platinum(IV) diazidodihydroxido complexes have been reported to be photosensitive
and related studies has been carried out in this work. Also, PtIV
dichloridodihydroxido or tetrachlorido complexes are also reported to be sensitive to
light.34, 35 However, the photo-induced disassociation/substitution can occur with the
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Cl, OH or N3 ligands. Evidence from literature reports36 and this work suggests that
Pt-pyridine bonds are very stable on Pt upon irradiation with UVA. However, there
are a few reports of the photodissociation of pyridine from PtII upon irradiation at
254 nm37 and pyridine derivatives from PtII upon irradiation with UVA38 or broad
band UV light.39 A time-dependent DFT calculation suggested that for complex
[(en)Pt(PyH)2]2+, the absorption band at 305 nm can be ascribed to a HOMO-LUMO
transition. The LUMO is dominated by antibonding dx2−y2 orbital, so the excitation of
this charge-transfer transition should weaken the PtII-Py coordination bond.38 As the
output of the UVA lamp is between 320 – 400 nm, the photolabilization of PtII-Py
bond was not observed in this work. However, in this chapter, the derived pyridine
ligand MOPEP is a chromophore with a larger π-conjugation system (Figure 6.13)
and is also a strong electron donor. Therefore, lower energy is needed to excite the
MOPEP-PtII charge-transfer transition, and hence light of longer wavelengths could
weaken the PtII-MOPEP bond.
The photo-decomposition of complex 42 is likely to take place in two steps: the two
MOPEP ligands can bereleased one by one rapidly upon irradiation with UVA
(Figure 6.13).
Figure 6.13 Proposed photoreaction of complex cis-[PtCl2(MOPEP)2] (42).
To the best knowledge of the author, this work is the first report of the two-photon
excitation induced disassociation of a pyridine type ligand, 4-[2-(4-
methoxyphenyl)ethynyl] pyridine (MOPEP), from the corresponding PtII complex
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cis-[PtCl2(MOPEP)2] (42). The TPA decomposition initiated by irradiation of fs
laser light at 650 nm is faster than that at 700 and 600 nm. This result implies that
there could be a TPA maximum between 700 and 600 nm, although a full two-
photon absorption spectrum of complex 42 has not yet been determined. The
absorption maximum for OPA is at 344 nm (Figure 6.5). Usually, the TPA
maximum is more or less consistent with the corresponding OPA peak at λex ≈ 
2λOPA.3, 6, 40 For complex 42, the wavelength-dependent photodecomposition
efficiency of two-photon excitation almost coincides their one-photon absorbance at
half of the corresponding wavelength.
6.5 Conclusion
To conclude, a new two-photon-activatable platinum(II) complexes has been
designed, synthesized and characterized. Its one-photon and two-photon absorption
properties and photochemistry were examined. It was discovered that this complex is
sensitive to one photon excitation below 500 nm and the pyridine-type ligand
MOPEP undergo a quickly solvent MeCN substitution from Pt upon irradiation. The
same photoreaction can be triggered upon irradiation with fs-pulsed laser between
600 – 700 nm. This interesting property can be applied to design new
photoactivatable anticancer complexes.
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7.1 Conclusions
This thesis is concerned with the development of a series of novel photoactivatable
PtIV diazidodihydroxido complexes so as to achive higher photocytotoxicity, lower
cross-resistance and longer wavelength of activation. The photodecomposition
pathways of selected complexes were studied in detail. MS spectrometry, HPLC,
multinuclear NMR, UV-Vis, EPR and fluorescence spectroscopy were used
extensively to probe the photoreactions of Pt complexes as well as with some
biomolecules and identify their photoproducts.
A series of PtIV diazidodihydroxido complexes with trans azido, trans hydroxido
groups and mixed trans aliphatic/aromatic amines, were designed, synthesized and
characterized and their activities as photoactivatable anticancer prodrugs were
determined. It was discovered that trans, trans, trans-[Pt(N3)2(OH)2(MA)(Py)] (5)
and trans, trans, trans-[Pt(N3)2(OH)2(MA)(Tz)] (8) are potently cytotoxic towards
human ovarian carcinoma cells (A2780), A2780cis (cisplatin resistant subline of
A2780), OE19 (oesophageal adenocarcinoma) and HaCaT (human keratinocytes)
upon irradiation with UVA. Remarkably, they also showed potent cytotoxic effects
towards A2780cis, the cisplatin-resistant ovarian cancer A2780 cell subline. Also,
the photocytotoxicity towards the A2780, A2780cis, OE19 and HaCaT cell lines
were similar upon irradiation with blue light (λmax = 420 nm) compared to that upon
irradiation with UVA. Last but not least, these complexes are highly inert in the
absence of light and almost no dark toxicity was observed. These results suggest that
they are promising candidates for use in the cancer photochemotherapy.
In order to explore the photocytotoxic effect of Pt-diazidodihydroxido complexes
from the chemistry point of view, the photochemistry of the mixed amines
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methylamine (MA)/pyridine (Py) complex trans, trans, trans-
[Pt(N3)2(OH)2(MA)(Py)] (5) was investigated in detail. Various analytical methods,
such as 1H NMR, 14N NMR, UV-Vis, EPR and fluorescence spectroscopy were used
to track the hydroxido groups, azido groups and the other ligands. The
photodecomposition pathways involving the azido ligands and the hydroxido ligands
were elucidated. Evidence for the release of free azide anions N3−, azidyl radicals
N3•, nitrogen gas N2 and formation of nitrene intermediates {Pt-N} were observed. It
was of importance to discover that singlet oxygen (1O2) is generated from
photoreactions in the absence of an exogenous source of oxygen, whereas hydrogen
peroxide (H2O2) and hydroxyl radical intermediates did not seem to be formed.
These photoreactions may contribute to the photocytotoxicity of the complexes.
The photoinduced efficieny of binding of trans, trans, trans-[Pt(N3)2(OH)2(MA)(Py)]
(5) and the thiazole (Tz) complex trans, trans, trans-[Pt(N3)2(OH)2(MA)(Tz)] (8) to
5'-GMP and a DNA oligonucleotide was also analysed. Mono-functional and bi-
functional Pt adduct were captured by LC-MS and high-resolution MS. It was
discovered for the first time that the oxidation of 5'-GMP can occur during the
photoreaction of complex 5 upon irradiation with light (especially UVA). Singlet
oxygen and nitrene intermediates generated from this photoreaction are likely to be
the cause of the oxidative damage to guanine. These features contribute to the high
photocytoxicity of this class of compounds. Also, the formation of singlet oxygen
does not need an exogenous source of O2 and hence the Pt-diazidodihydroxido
complexes have a potentially novel mechanism of photochemotherapeutic activity.
For the purpose of activating complexes with longer wavelength, two series of new
photoactivatable PtIV anticancer complexes were synthesized and their
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photoactivation and toxicity to cancer cells were investigated. 4-Nnitropyridine, 2,2'-
bipyridine, and terpyridines were used as ligands in novel Pt (di)azido complexes for
one-photon excitation. Two complexes trans, trans, trans-[Pt(N3)2(OH)2(NH3)(4-
NO2-Py)] (31) and trans-[Pt(N3)(OH)2(Tpy)]Cl (36) were found to be photoactivated
by green light. However, the photocytotoxicity of the complexes measured so far
towards cancer cells are not satisfied. Complex cis, trans-[Pt(N3)2(OH)2(Bpy)] (32)
is non-toxic in the absence of irradiation but the photocytotoxicity is at 10 μM scale, 
not as good as complexes 5 and 8. Complex trans-[Pt(N3)(OH)2(Tpy)]Cl (36) is also
toxic in the dark and the difference between dark toxicity and photo toxicity is not
satisfied. Further effort is still needed to develop new photoactivatable PtIV
complexes with good anticancer activities and can be activated by light of
wavelength 500 – 600 nm or even longer.
A new two-photon-activatable PtII complex, cis-[PtCl2(MOPEP)2](42), has also been
designed, synthesized and characterized. Its one-photon and two-photon absorption
properties and photochemistry were determined with continuous wave light sources
and fs-pulses laser light, respectively. It was observed that this complex is sensitive
to one-photon excitation below 500 nm and the pyridine type ligand MOPEP
underwent rapid solvent (acetonitrile) substitution upon irradiation. The same
photoreaction was also triggered by irradiation with fs-pulses laser light between
wavelength 600 – 700 nm. This interesting property could be applied to the design of
novel photoactivatable anticancer complexes.
7.2 Future work
First, the reason for the unprecedented potent photocytotoxicity and the
circumvention of cisplatin cross-resistance of PtIV diazidodihydroxido complexes
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trans, trans, trans-[Pt(N3)2(OH)2(MA)(Py)] (5) and trans, trans, trans-
[Pt(N3)2(OH)2(MA)(Tz)] (8) from the biological point of view is still not clear. The
different aliphatic amine and heterocyclic imine groups also change the
hydrophilicity/lipophilicity of the complexes and the shape of the molecules which
could influence their cellular uptake and accumulation.1, 2 The mono-functional and
bi-functional DNA adducts found in cell-free media may also present as lesions in
the cancer cells. This may lead to DNA distortions including bending, kinking and
unwinding,3 and inhibit the enzyme-driven transcription4 and repair. Also, singlet
oxygen5-8 and the nitrene intermediate may also cause oxidative damage to the
DNA.9-13 Further experiments need to be carried out to investigate this process.
Second, the mechanism of singlet oxygen generation in the photochemical reaction
of PtIV diazidodihydroxido complexes needs to be investigated and the source of
oxygen determined. The release of singlet oxygen could be confirmed in two other
ways, EPR spectroscopy using 2,2,6,6-tetramethyl-4-piperidone (TEMP)14 as a 1O2
trap or the direct detection of the phosphorescence of 1O2 at 1270 nm (monomol
emission) and 630/710 nm (dimol emission) using an extremely sensitive detector.15,
16 A good strategy to follow the source of oxygen is to perform the reaction in H218O
(water-18O). The released oxygen gas could be captured and analyse directly in GC-
MS17 or using an oxygen trap,18 such as Ir(PEt3)3Cl, and then analysing by ESI-MS
spectrometry. From the isotope composition of the released oxygen, it could be
possible to determine the source of oxygen: the Pt complex and/or the solvent H2O.
Another method to track the pathway of OH groups in the photoreaction of Pt
complexes is time-resolved infra-red (TR-IR) studies. TR-IR could shed further light
on the breaking of Pt-O bond and generation of short-lived intermediates at
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picosecond timescale. However, solvent should be carefully selected as H2O has a
broadband absorption for OH stretching in IR.
Third, the photocytotoxicities of a few PtIV diazidodihydroxyl complexes, such as
trans, trans, trans-[Pt(N3)2(OH)2(NH3)(4-nitropyridine)] (31) and trans-
[Pt(N3)(OH)2(TTpy)]Cl (40), still need to be determined. The photoreactions of PtIV
mono-azido complexes, such as trans-[Pt(N3)(OH)2(Tpy)]Cl (36), are of great
interest. It was generally believed that two azido groups should release as •N3
radicals together19 and avoid formation of an unstable PtIII product. However, in this
work, it was discovered that one azido group disassociated from Pt without affecting
the other and the PtIV was still reduced to PtII, so the second electron must be from
the other groups, such as the OH ligand.20-22
Fourth, a two-photon absorption spectrum of complex cis-[PtCl2(MOPEP)2] (42)
will be recorded. The dissociation of pyridine ligands from Pt has been applied in the
development of interesting molecule devices, such as catenations.23 The
photolabilization of the PtII-Py bond can also be used in designing photoactivatable
anticancer drugs. A receptor-specific pyridine derivative could be designed so as to
make new Pt complexes that could be selectively accumulated in the tumour cells or
tissues. Thereafter, the complexes could be activated by two-photon excitation with
Near-IR laser light. These complexes could also be made water-soluble without
compromising the two-photon activity.24
Fifth, various types of novel PtIV anticancer prodrugs could be developed with a
broad range of features. The Pt complex could be coupled with cancer cell targeting
peptides, such as RGD,25 NGR,26 LHRH27 and IFLLWQR28 peptides or encapsulated
in polymeric carriers, such as ethylene glycol nanoparticles29, 30 to increase the
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accumulation of drug and reduce the side effects. Ligands with larger π-conjugation 
systems, such as dipyridoquinoxaline and dipyridophenazine could be used in
making new PtIV diazido complexes. These ligands are not only good chromophores
for red or near IR light absorption, but also are efficient photosensitizers.31-34 Taking
advantage of these features, absorption of light in the therapeutic window as well as
potent PDT could be obtained.
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Appendices
Appendix 1 Table of compounds referred.
Compound Name Structure
Cis-[PtI2(MA)2] (1)
Cis-[PtCl2(MA)2] (2)
Trans-[Pt(Cl)2(MA)(py)] (3)
Trans-[Pt(N3)2(MA)(py)] (4)
Trans, trans, trans-
[Pt(N3)2(OH)2(MA)(py)] (5)
Pt
NH2CH3
N3
N3
OH
OH
N
Trans, trans, trans-
[Pt(15N3)2(OH)2(MA)(py)] (5*)
Trans-[Pt(MA)(Py)(5'-GMP)2 − 2H] (5a)
(SP-4-4)-[Pt(N3)(MA)(Py)(5'-GMP) − H] 
(5b)
Pt
NH2CH3
Cl
Cl
N
Pt
NH2CH3
N3
N3
N
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Trans-[Pt(MA)(Py)(H2O)2](BF4)2 (5g)
Trans-[Pt(Cl)2(MA)(tz)] (6)
Trans-[Pt(N3)2(MA)(tz)] (7)
Trans, trans, trans-
[Pt(N3)2(OH)2(MA)(tz)] (8)
Trans-[Pt(MA)(Tz)(5'-GMP)2 − 2H] (8a)
(SP-4-4)-[Pt(N3)(MA)(Tz)(5'-GMP) − H] 
(8b)
Cis-[PtI2(DMA)2] (9)
Cis-[PtCl2(DMA)2] (10)
Trans-[Pt(Cl)2(DMA)(tz)] (11)
Pt
NH2CH3
Cl
Cl
N
S
Pt
NH2CH3
N3
N3
N
S
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Trans-[Pt(N3)2(DMA)(tz)] (12)
Trans, trans, trans-
[Pt(N3)2(OH)2(DMA)(tz)] (13)
Trans-[Pt(Cl)2(DMA)(py)] (14)
Trans-[Pt(N3)2(DMA)(py)] (15)
Trans, trans, trans-
[Pt(N3)2(OH)2(DMA)(py)] (16)
Cis-[PtCl2(IPA)2] (17)
Trans-[Pt(Cl)2(IPA)(tz)] (18) Pt
H2
N
Cl
Cl
N
S
Trans-[Pt(Cl)2(IPA)(py)] (19)
Trans-[Pt(N3)2(IPA)(py)] (20)
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Trans, trans, trans-
[Pt(N3)2(OH)2(IPA)(py)] (21)
Trans, trans, trans-
[Pt(N3)2(OH)2(NH3)(Py)] (22)
Trans, trans, trans-
[Pt(N3)2(OH)2(NH3)(Tz)] (23)
Trans, trans, trans-[Pt(N3)2(OH)2(Py)2]
(24)
Cis-[PtI2(NH3)2] (25)
Cis-[PtCl2(NH3)2] (26)
4-Nitropyridine (4-NO2-Py, 27)
Trans-[Pt(Cl)4(NH3)(4-py-NO2)] (28) N NO2PtH3N
Cl
Cl Cl
Cl
Trans-[Pt(Cl)2(NH3)(4-py-NO2)] (29) N NO2PtH3N
Cl
Cl
Trans-[Pt(N3)2(NH3)(4-py-NO2)] (30) N NO2PtH3N
N3
N3
Appendix 1 — Table of compounds referred
292
Trans, trans, trans-
[Pt(N3)2(OH)2(NH3)(4-py-NO2)] (31)
N NO2PtH3N
N3
N3
HO
OH
Cis, trans-[Pt(N3)2(OH)2(bpy)] (32)
[Pt(Cl)(Tpy)]Cl · 2H2O (33) N
NN Pt
Cl
Cl
[Pt(N3)(Tpy)]PF6 (34)
[Pt(N3)(Tpy)]N3 (35)
Trans-[Pt(N3)(OH)2(Tpy)]Cl (36)
[PtCl2(COD)] (37)
[PtCl(TTpy)]Cl (38) N
N
N
Pt Cl Cl
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[Pt(N3)(TTpy)]N3 (39)
Trans-[Pt(N3)(OH)2(TTpy)]Cl (40)
4-[2-(4-methoxyphenyl)ethynyl]pyridine
(MOPEP, 41)
Cis-[PtCl2(MOPEP)2] (42)
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Appendix 2 Output spectra of light sources.
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Figure A.1 Output spectrum of Hitachi UVA lamps.
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Figure A.2 Output spectrum of Hitachi visible lamp.
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Figure A.3 Output spectrum of Luzchem LZC-420 lamps.
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Figure A.4 Output spectrum of ACULED® VHL™ 450 nm LEDs.
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Figure A.5 Output spectrum of High-Power 38 LED bulb/GU10 Green LEDs.
